<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>5.805e-08</TD><TD>-16.66</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1782</TD><TD>17</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,EFNB2,FGF9,SLK,STXBP6,GRHL3,CLSTN2,VIM,NR2F1,MSX2,CAMK2D,NEBL,CSMD3,NR2F2,ITGB4,MMP16,PRPS1</TD></TR>
<TR><TD>1.072e-07</TD><TD>-16.05</TD><TD>tissue development</TD><TD>biological process</TD><TD>GO:0009888</TD><TD>1601</TD><TD>16</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,CAMK2D,MSX2,NEBL,WNT16,NR2F2,CD44,ITGB4,PDLIM5</TD></TR>
<TR><TD>1.213e-07</TD><TD>-15.93</TD><TD>BENPORATH_EED_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_EED_TARGETS</TD><TD>1009</TD><TD>13</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX2,MSX1,PDE10A,STXBP6,CLSTN2,SLCO5A1,CSMD3,ZIC2,WNT16,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>1.530e-07</TD><TD>-15.69</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>MSigDB lists</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>531</TD><TD>10</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CAMK2D,S100A10,PPARG,STXBP6,VIM,NR2F2,CD44,PRPS1,PKIB</TD></TR>
<TR><TD>1.594e-07</TD><TD>-15.65</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>1033</TD><TD>13</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX2,MSX1,PDE10A,STXBP6,GRHL3,SLCO5A1,ZIC2,VIM,SORCS2,PDLIM5,PDE3A,PKIB</TD></TR>
<TR><TD>2.624e-07</TD><TD>-15.15</TD><TD>organ development</TD><TD>biological process</TD><TD>GO:0048513</TD><TD>2766</TD><TD>20</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ZIC2,NR2F1,MSX2,CAMK2D,NEBL,WNT16,ITGB4,NR2F2,CD44,PDLIM5,PRPS1,MMP16,NT5E</TD></TR>
<TR><TD>3.594e-07</TD><TD>-14.84</TD><TD>V$SRF_Q4</TD><TD>MSigDB lists</TD><TD>V$SRF_Q4</TD><TD>213</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NR2F2,PPARG,PDLIM5,TANK,NR2F1,GRHL3</TD></TR>
<TR><TD>4.583e-07</TD><TD>-14.60</TD><TD>positive regulation of biological process</TD><TD>biological process</TD><TD>GO:0048518</TD><TD>5310</TD><TD>27</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VSNL1,CLSTN2,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,S100A10,UNC13A,TANK,WNT16,CD44,NR2F2,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>5.830e-07</TD><TD>-14.36</TD><TD>nail development</TD><TD>biological process</TD><TD>GO:0035878</TD><TD>8</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>6.514e-07</TD><TD>-14.24</TD><TD>circulatory system development</TD><TD>biological process</TD><TD>GO:0072359</TD><TD>774</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,FGF9,CAMK2D,MSX1,NEBL,PPARG,WNT16,NR2F2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>6.514e-07</TD><TD>-14.24</TD><TD>cardiovascular system development</TD><TD>biological process</TD><TD>GO:0072358</TD><TD>774</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,FGF9,CAMK2D,MSX1,NEBL,PPARG,WNT16,NR2F2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>8.291e-07</TD><TD>-14.00</TD><TD>regulation of developmental process</TD><TD>biological process</TD><TD>GO:0050793</TD><TD>2113</TD><TD>17</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,PPARG,GRHL3,CLSTN2,VIM,ZIC2,ANGPTL4,PDE3A,RHOU,MSX2,S100A10,UNC13A,PDLIM5</TD></TR>
<TR><TD>1.171e-06</TD><TD>-13.66</TD><TD>system development</TD><TD>biological process</TD><TD>GO:0048731</TD><TD>4011</TD><TD>23</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.655e-06</TD><TD>-13.31</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>1059</TD><TD>12</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,FGF9,SLC40A1,MSX1,STXBP6,PDE10A,GRHL3,CLSTN2,SLCO5A1,CSMD3,WNT16,NR2F2</TD></TR>
<TR><TD>2.801e-06</TD><TD>-12.79</TD><TD>P53_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>P53_DN.V1_UP</TD><TD>184</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,ITGB4,NEBL,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.209e-06</TD><TD>-12.65</TD><TD>regulation of multicellular organismal development</TD><TD>biological process</TD><TD>GO:2000026</TD><TD>1553</TD><TD>14</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,LAMA4,MSX2,TNIK,FGF9,MSX1,PPARG,UNC13A,GRHL3,CLSTN2,VIM,ZIC2,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>4.151e-06</TD><TD>-12.39</TD><TD>anatomical structure development</TD><TD>biological process</TD><TD>GO:0048856</TD><TD>4662</TD><TD>24</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>5.982e-06</TD><TD>-12.03</TD><TD>regulation of multicellular organismal process</TD><TD>biological process</TD><TD>GO:0051239</TD><TD>2431</TD><TD>17</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,PPARG,GRHL3,CLSTN2,VIM,ZIC2,ANGPTL4,PDE3A,CAMK2D,MSX2,UNC13A,NR2F2,PDLIM5</TD></TR>
<TR><TD>6.125e-06</TD><TD>-12.00</TD><TD>anatomical structure formation involved in morphogenesis</TD><TD>biological process</TD><TD>GO:0048646</TD><TD>974</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX2,MSX1,NEBL,GRHL3,ZIC2,WNT16,ITGB4,ANGPTL4</TD></TR>
<TR><TD>6.433e-06</TD><TD>-11.95</TD><TD>epithelium development</TD><TD>biological process</TD><TD>GO:0060429</TD><TD>979</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,SLC40A1,MSX1,PPARG,GRHL3,ZIC2,VIM,WNT16,NR2F2,CD44</TD></TR>
<TR><TD>6.495e-06</TD><TD>-11.94</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>329</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,NR2F2,PPARG,PDLIM5,PDE10A,TANK,NR2F1</TD></TR>
<TR><TD>8.509e-06</TD><TD>-11.67</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>MSigDB lists</TD><TD>SABATES_COLORECTAL_ADENOMA_UP</TD><TD>128</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,MSX1,CD44,GRHL3,VSNL1</TD></TR>
<TR><TD>1.034e-05</TD><TD>-11.48</TD><TD>V$SRF_Q6</TD><TD>MSigDB lists</TD><TD>V$SRF_Q6</TD><TD>231</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,MSX1,NR2F2,PPARG,PDLIM5,NR2F1</TD></TR>
<TR><TD>1.353e-05</TD><TD>-11.21</TD><TD>nervous system development</TD><TD>biological process</TD><TD>GO:0007399</TD><TD>2292</TD><TD>16</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,NR2F1,CAMK2D,UNC13A,WNT16,NR2F2,PDLIM5,PRPS1,NT5E</TD></TR>
<TR><TD>1.429e-05</TD><TD>-11.16</TD><TD>multicellular organismal development</TD><TD>biological process</TD><TD>GO:0007275</TD><TD>4594</TD><TD>23</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>1.445e-05</TD><TD>-11.14</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>245</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,CD44,NEBL,S100A10,NR2F2,MMP16</TD></TR>
<TR><TD>1.476e-05</TD><TD>-11.12</TD><TD>embryonic nail plate morphogenesis</TD><TD>biological process</TD><TD>GO:0035880</TD><TD>3</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.476e-05</TD><TD>-11.12</TD><TD>positive regulation of mesenchymal cell apoptotic process</TD><TD>biological process</TD><TD>GO:2001055</TD><TD>3</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.636e-05</TD><TD>-11.02</TD><TD>organ morphogenesis</TD><TD>biological process</TD><TD>GO:0009887</TD><TD>876</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,SLC40A1,MSX2,MSX1,GRHL3,WNT16,CD44,ITGB4,MMP16</TD></TR>
<TR><TD>1.801e-05</TD><TD>-10.92</TD><TD>cardiac epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0060317</TD><TD>23</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>1.929e-05</TD><TD>-10.86</TD><TD>anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0009653</TD><TD>2356</TD><TD>16</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,SLC40A1,MSX1,GRHL3,ZIC2,ANGPTL4,CAMK2D,MSX2,NEBL,WNT16,NR2F2,CD44,ITGB4,MMP16</TD></TR>
<TR><TD>2.120e-05</TD><TD>-10.76</TD><TD>MSX2 (msh homeobox 2)</TD><TD>protein interactions</TD><TD>4488</TD><TD>25</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1,PPARG</TD></TR>
<TR><TD>2.255e-05</TD><TD>-10.70</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>2204</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,SLC40A1,PPARG,PDE10A,STXBP6,TANK,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>2.255e-05</TD><TD>-10.70</TD><TD>Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>Burkitt_lymphoma</TD><TD>2204</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,SLC40A1,PPARG,PDE10A,STXBP6,TANK,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>2.376e-05</TD><TD>-10.65</TD><TD>regulation of cellular component organization</TD><TD>biological process</TD><TD>GO:0051128</TD><TD>2113</TD><TD>15</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,MSX1,S100A10,PPARG,STXBP6,UNC13A,GRHL3,CLSTN2,VIM,PDLIM5,PKIB,PDE3A</TD></TR>
<TR><TD>2.639e-05</TD><TD>-10.54</TD><TD>embryonic morphogenesis</TD><TD>biological process</TD><TD>GO:0048598</TD><TD>556</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX2,MSX1,GRHL3,ZIC2,WNT16,ITGB4,MMP16</TD></TR>
<TR><TD>2.923e-05</TD><TD>-10.44</TD><TD>tissue morphogenesis</TD><TD>biological process</TD><TD>GO:0048729</TD><TD>564</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,MSX1,GRHL3,ZIC2,WNT16,CD44,ITGB4</TD></TR>
<TR><TD>2.948e-05</TD><TD>-10.43</TD><TD>activation of meiosis</TD><TD>biological process</TD><TD>GO:0090427</TD><TD>4</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.957e-05</TD><TD>-10.43</TD><TD>purine ribonucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009154</TD><TD>27</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.306e-05</TD><TD>-10.32</TD><TD>ribonucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009261</TD><TD>28</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.347e-05</TD><TD>-10.30</TD><TD>NSD1 (nuclear receptor binding SET domain protein 1)</TD><TD>protein interactions</TD><TD>64324</TD><TD>29</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.573e-05</TD><TD>-10.24</TD><TD>single-organism developmental process</TD><TD>biological process</TD><TD>GO:0044767</TD><TD>5226</TD><TD>24</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>3.670e-05</TD><TD>-10.21</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>980</TD><TD>10</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,SLC40A1,MSX1,STXBP6,CLSTN2,CSMD3,SLCO5A1,WNT16,NR2F2,CD44</TD></TR>
<TR><TD>3.822e-05</TD><TD>-10.17</TD><TD>limb development</TD><TD>biological process</TD><TD>GO:0060173</TD><TD>171</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>3.822e-05</TD><TD>-10.17</TD><TD>appendage development</TD><TD>biological process</TD><TD>GO:0048736</TD><TD>171</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>4.085e-05</TD><TD>-10.11</TD><TD>regulation of meiotic nuclear division</TD><TD>biological process</TD><TD>GO:0040020</TD><TD>30</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>4.411e-05</TD><TD>-10.03</TD><TD>COUP_TF</TD><TD>interpro domains</TD><TD>IPR003068</TD><TD>5</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>4.688e-05</TD><TD>-9.97</TD><TD>follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>follicular_lymphoma</TD><TD>1269</TD><TD>11</TD><TD>17775</TD><TD>38</TD>
<TD>TNIK,PDE10A,C1orf226,CSMD3,RNF43,CD44,SORCS2,ITGB4,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>4.739e-05</TD><TD>-9.96</TD><TD>developmental process</TD><TD>biological process</TD><TD>GO:0032502</TD><TD>5307</TD><TD>24</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,UNC13A,WNT16,ITGB4,NR2F2,CD44,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>4.758e-05</TD><TD>-9.95</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>616</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX1,STXBP6,CSMD3,SLCO5A1,CLSTN2,WNT16,NR2F2</TD></TR>
<TR><TD>4.816e-05</TD><TD>-9.94</TD><TD>heart development</TD><TD>biological process</TD><TD>GO:0007507</TD><TD>440</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,WNT16,NEBL,PPARG,PDLIM5</TD></TR>
<TR><TD>4.907e-05</TD><TD>-9.92</TD><TD>BMP signaling pathway involved in heart development</TD><TD>biological process</TD><TD>GO:0061312</TD><TD>5</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.319e-05</TD><TD>-9.84</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>MSigDB lists</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>309</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLC40A1,CAMK2D,VIM,S100A10,NT5E</TD></TR>
<TR><TD>5.421e-05</TD><TD>-9.82</TD><TD>RAF_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>RAF_UP.V1_UP</TD><TD>188</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,CD44,PPARG,PRPS1,ANGPTL4</TD></TR>
<TR><TD>5.944e-05</TD><TD>-9.73</TD><TD>positive regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048522</TD><TD>4598</TD><TD>22</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VSNL1,CLSTN2,ZIC2,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,S100A10,UNC13A,WNT16,CD44,NR2F2,PKIB</TD></TR>
<TR><TD>6.105e-05</TD><TD>-9.70</TD><TD>LOPEZ_TRANSLATION_VIA_FN1_SIGNALING</TD><TD>MSigDB lists</TD><TD>LOPEZ_TRANSLATION_VIA_FN1_SIGNALING</TD><TD>35</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,MMP16,PDE3A</TD></TR>
<TR><TD>7.013e-05</TD><TD>-9.57</TD><TD>positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0090100</TD><TD>99</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1</TD></TR>
<TR><TD>8.030e-05</TD><TD>-9.43</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>487</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,MSX2,S100A10,PPARG,PDLIM5,MMP16,GRHL3</TD></TR>
<TR><TD>8.552e-05</TD><TD>-9.37</TD><TD>V$SRF_Q5_01</TD><TD>MSigDB lists</TD><TD>V$SRF_Q5_01</TD><TD>207</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PPARG,PDLIM5,TANK,NR2F1</TD></TR>
<TR><TD>9.362e-05</TD><TD>-9.28</TD><TD>TSENG_IRS1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>TSENG_IRS1_TARGETS_UP</TD><TD>109</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,RHOU,EFNB2,NR2F1</TD></TR>
<TR><TD>9.854e-05</TD><TD>-9.23</TD><TD>MODULE_455</TD><TD>MSigDB lists</TD><TD>MODULE_455</TD><TD>41</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,PKIB,UNC13A</TD></TR>
<TR><TD>9.990e-05</TD><TD>-9.21</TD><TD>NCOR2 (nuclear receptor corepressor 2)</TD><TD>protein interactions</TD><TD>9612</TD><TD>112</TD><TD>4</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.023e-04</TD><TD>-9.19</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>215</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NEBL,PDLIM5,MMP16,PDE10A</TD></TR>
<TR><TD>1.028e-04</TD><TD>-9.18</TD><TD>physiological muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003298</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.028e-04</TD><TD>-9.18</TD><TD>physiological cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003301</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.028e-04</TD><TD>-9.18</TD><TD>cell growth involved in cardiac muscle cell development</TD><TD>biological process</TD><TD>GO:0061049</TD><TD>7</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.054e-04</TD><TD>-9.16</TD><TD>COUPTNFACTOR</TD><TD>prints domains</TD><TD>PR01282</TD><TD>5</TD><TD>2</TD><TD>4759</TD><TD>16</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.054e-04</TD><TD>-9.16</TD><TD>regulation of meiotic cell cycle</TD><TD>biological process</TD><TD>GO:0051445</TD><TD>41</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>1.065e-04</TD><TD>-9.15</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>691</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,NEBL,RNF43,NR2F2,CD44,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.075e-04</TD><TD>-9.14</TD><TD>proteinaceous extracellular matrix</TD><TD>cellular component</TD><TD>GO:0005578</TD><TD>357</TD><TD>6</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4,FGF9,WNT16,ITGB4,MMP16,ANGPTL4</TD></TR>
<TR><TD>1.127e-04</TD><TD>-9.09</TD><TD>cell differentiation</TD><TD>biological process</TD><TD>GO:0030154</TD><TD>3353</TD><TD>18</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,CAMK2D,MSX2,NEBL,UNC13A,WNT16,NR2F2,ITGB4,PDLIM5</TD></TR>
<TR><TD>1.208e-04</TD><TD>-9.02</TD><TD>positive regulation of developmental process</TD><TD>biological process</TD><TD>GO:0051094</TD><TD>1108</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,FGF9,S100A10,PPARG,UNC13A,CLSTN2,ZIC2,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.217e-04</TD><TD>-9.01</TD><TD>purine nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0006195</TD><TD>43</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.232e-04</TD><TD>-9.00</TD><TD>SANSOM_APC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SANSOM_APC_TARGETS_UP</TD><TD>117</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,SLC40A1,MSX1,CD44</TD></TR>
<TR><TD>1.275e-04</TD><TD>-8.97</TD><TD>signal transduction</TD><TD>biological process</TD><TD>GO:0007165</TD><TD>4816</TD><TD>22</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>1.276e-04</TD><TD>-8.97</TD><TD>Znf_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001628</TD><TD>46</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.356e-04</TD><TD>-8.91</TD><TD>GRIP1 (glutamate receptor interacting protein 1)</TD><TD>protein interactions</TD><TD>23426</TD><TD>46</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2,PPARG,NR2F1</TD></TR>
<TR><TD>1.361e-04</TD><TD>-8.90</TD><TD>Nuclear_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001723</TD><TD>47</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.450e-04</TD><TD>-8.84</TD><TD>Nucl_hrmn_rcpt_lig-bd</TD><TD>interpro domains</TD><TD>IPR000536</TD><TD>48</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.468e-04</TD><TD>-8.83</TD><TD>regulation of biological process</TD><TD>biological process</TD><TD>GO:0050789</TD><TD>10636</TD><TD>34</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VSNL1,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,MSX2,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.562e-04</TD><TD>-8.76</TD><TD>zf-C4</TD><TD>pfam domains</TD><TD>PF00105</TD><TD>46</TD><TD>3</TD><TD>16629</TD><TD>38</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.589e-04</TD><TD>-8.75</TD><TD>cardiac muscle cell development</TD><TD>biological process</TD><TD>GO:0055013</TD><TD>47</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.683e-04</TD><TD>-8.69</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>49</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CD44,PRPS1</TD></TR>
<TR><TD>1.683e-04</TD><TD>-8.69</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>49</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,MSX1,NR2F2</TD></TR>
<TR><TD>1.757e-04</TD><TD>-8.65</TD><TD>positive regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032927</TD><TD>9</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,FGF9</TD></TR>
<TR><TD>1.774e-04</TD><TD>-8.64</TD><TD>Hormone_recep</TD><TD>pfam domains</TD><TD>PF00104</TD><TD>48</TD><TD>3</TD><TD>16629</TD><TD>38</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.784e-04</TD><TD>-8.63</TD><TD>transcription factor activity, direct ligand regulated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0098531</TD><TD>49</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.784e-04</TD><TD>-8.63</TD><TD>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0004879</TD><TD>49</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.800e-04</TD><TD>-8.62</TD><TD>purine-containing compound catabolic process</TD><TD>biological process</TD><TD>GO:0072523</TD><TD>49</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.800e-04</TD><TD>-8.62</TD><TD>cardiac cell development</TD><TD>biological process</TD><TD>GO:0055006</TD><TD>49</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.849e-04</TD><TD>-8.60</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>130</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,TNIK,S100A10,PDLIM5</TD></TR>
<TR><TD>1.873e-04</TD><TD>-8.58</TD><TD>embryo development</TD><TD>biological process</TD><TD>GO:0009790</TD><TD>943</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,GRHL3,ZIC2,WNT16,NR2F2,ITGB4,MMP16</TD></TR>
<TR><TD>1.896e-04</TD><TD>-8.57</TD><TD>MODULE_325</TD><TD>MSigDB lists</TD><TD>MODULE_325</TD><TD>51</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,MSX2,MMP16</TD></TR>
<TR><TD>1.961e-04</TD><TD>-8.54</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>132</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CD44,NR2F2,SLK</TD></TR>
<TR><TD>1.969e-04</TD><TD>-8.53</TD><TD>positive regulation of metabolic process</TD><TD>biological process</TD><TD>GO:0009893</TD><TD>3495</TD><TD>18</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,ZIC2,NR2F1,CAMK2D,S100A10,WNT16,NR2F2,CD44,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>2.044e-04</TD><TD>-8.50</TD><TD>Wnt signaling pathway</TD><TD>biological process</TD><TD>GO:0016055</TD><TD>244</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,RNF43,WNT16,CD44,GRHL3</TD></TR>
<TR><TD>2.060e-04</TD><TD>-8.49</TD><TD>DLX5 (distal-less homeobox 5)</TD><TD>protein interactions</TD><TD>1749</TD><TD>10</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.143e-04</TD><TD>-8.45</TD><TD>single-multicellular organism process</TD><TD>biological process</TD><TD>GO:0044707</TD><TD>6192</TD><TD>25</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,NR2F1,PDE3A,MSX2,CAMK2D,NEBL,PDE10A,UNC13A,WNT16,ITGB4,CD44,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>2.158e-04</TD><TD>-8.44</TD><TD>TGGNNNNNNKCCAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGGNNNNNNKCCAR_UNKNOWN</TD><TD>399</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,VIM,STXBP6,TANK,NR2F1,GRHL3</TD></TR>
<TR><TD>2.193e-04</TD><TD>-8.43</TD><TD>epithelial to mesenchymal transition involved in endocardial cushion formation</TD><TD>biological process</TD><TD>GO:0003198</TD><TD>10</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.215e-04</TD><TD>-8.42</TD><TD>cellular developmental process</TD><TD>biological process</TD><TD>GO:0048869</TD><TD>3526</TD><TD>18</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,CAMK2D,MSX2,NEBL,UNC13A,WNT16,NR2F2,ITGB4,PDLIM5</TD></TR>
<TR><TD>2.245e-04</TD><TD>-8.40</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>985</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,TNIK,TANK,SORCS2,NR2F2,CD44,ANGPTL4,PKIB,NT5E</TD></TR>
<TR><TD>2.390e-04</TD><TD>-8.34</TD><TD>LEE_NEURAL_CREST_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LEE_NEURAL_CREST_STEM_CELL_UP</TD><TD>139</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,S100A10,NR2F2,NR2F1</TD></TR>
<TR><TD>2.421e-04</TD><TD>-8.33</TD><TD>Znf_NHR/GATA</TD><TD>interpro domains</TD><TD>IPR013088</TD><TD>57</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.454e-04</TD><TD>-8.31</TD><TD>regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045595</TD><TD>1454</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,TNIK,FGF9,MSX1,S100A10,PPARG,UNC13A,VIM,PDLIM5,PDE3A</TD></TR>
<TR><TD>2.480e-04</TD><TD>-8.30</TD><TD>cell development</TD><TD>biological process</TD><TD>GO:0048468</TD><TD>1717</TD><TD>12</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,TNIK,FGF9,CAMK2D,MSX1,NEBL,PPARG,VIM,WNT16,PDLIM5,PDE3A</TD></TR>
<TR><TD>2.484e-04</TD><TD>-8.30</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>1028</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>PDE10A,C1orf226,CSMD3,RNF43,CD44,SORCS2,ITGB4,MMP16,PDE3A</TD></TR>
<TR><TD>2.494e-04</TD><TD>-8.30</TD><TD>tube development</TD><TD>biological process</TD><TD>GO:0035295</TD><TD>573</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,FGF9,ZIC2,ITGB4,CD44,GRHL3</TD></TR>
<TR><TD>2.506e-04</TD><TD>-8.29</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.565.10</TD><TD>48</TD><TD>3</TD><TD>9988</TD><TD>26</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.517e-04</TD><TD>-8.29</TD><TD>steroid hormone receptor activity</TD><TD>molecular function</TD><TD>GO:0003707</TD><TD>55</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.526e-04</TD><TD>-8.28</TD><TD>V$IK1_01</TD><TD>MSigDB lists</TD><TD>V$IK1_01</TD><TD>261</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,MSX1,MMP16,PDE10A,VSNL1</TD></TR>
<TR><TD>2.666e-04</TD><TD>-8.23</TD><TD>extracellular matrix</TD><TD>cellular component</TD><TD>GO:0031012</TD><TD>422</TD><TD>6</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4,FGF9,WNT16,ITGB4,MMP16,ANGPTL4</TD></TR>
<TR><TD>2.679e-04</TD><TD>-8.22</TD><TD>epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0001837</TD><TD>56</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>2.780e-04</TD><TD>-8.19</TD><TD>VERRECCHIA_EARLY_RESPONSE_TO_TGFB1</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_EARLY_RESPONSE_TO_TGFB1</TD><TD>58</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CD44,MMP16</TD></TR>
<TR><TD>2.823e-04</TD><TD>-8.17</TD><TD>cellular response to steroid hormone stimulus</TD><TD>biological process</TD><TD>GO:0071383</TD><TD>142</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.823e-04</TD><TD>-8.17</TD><TD>steroid hormone mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0043401</TD><TD>57</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.979e-04</TD><TD>-8.12</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>3776</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,VSNL1,CLSTN2,PDE3A,CAMK2D,NEBL,UNC13A,TANK,CSMD3,SLCO5A1,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.999e-04</TD><TD>-8.11</TD><TD>NUCLEAR_REC_DBD_2</TD><TD>prosite domains</TD><TD>PS51030</TD><TD>46</TD><TD>3</TD><TD>11866</TD><TD>34</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.999e-04</TD><TD>-8.11</TD><TD>NUCLEAR_REC_DBD_1</TD><TD>prosite domains</TD><TD>PS00031</TD><TD>46</TD><TD>3</TD><TD>11866</TD><TD>34</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.073e-04</TD><TD>-8.09</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>60</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,NR2F1,NT5E</TD></TR>
<TR><TD>3.185e-04</TD><TD>-8.05</TD><TD>regulation of cell death</TD><TD>biological process</TD><TD>GO:0010941</TD><TD>1498</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,WNT16,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>3.207e-04</TD><TD>-8.05</TD><TD>positive regulation of meiotic nuclear division</TD><TD>biological process</TD><TD>GO:0045836</TD><TD>12</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.227e-04</TD><TD>-8.04</TD><TD>MARSON_FOXP3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MARSON_FOXP3_TARGETS_UP</TD><TD>61</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44,S100A10</TD></TR>
<TR><TD>3.227e-04</TD><TD>-8.04</TD><TD>MODULE_418</TD><TD>MSigDB lists</TD><TD>MODULE_418</TD><TD>61</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,PKIB,UNC13A</TD></TR>
<TR><TD>3.242e-04</TD><TD>-8.03</TD><TD>YOSHIMURA_MAPK8_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>YOSHIMURA_MAPK8_TARGETS_UP</TD><TD>1274</TD><TD>10</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,SLK,UNC13A,VSNL1,VIM,ITGB4,CD44,PDE3A,NR2F1,PKIB</TD></TR>
<TR><TD>3.309e-04</TD><TD>-8.01</TD><TD>embryonic organ development</TD><TD>biological process</TD><TD>GO:0048568</TD><TD>423</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,WNT16,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>3.378e-04</TD><TD>-7.99</TD><TD>BENPORATH_OCT4_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_OCT4_TARGETS</TD><TD>278</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ZIC2,NEBL,NR2F2,PRPS1</TD></TR>
<TR><TD>3.393e-04</TD><TD>-7.99</TD><TD>morphogenesis of an epithelium</TD><TD>biological process</TD><TD>GO:0002009</TD><TD>425</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,ZIC2,WNT16,CD44,GRHL3</TD></TR>
<TR><TD>3.417e-04</TD><TD>-7.98</TD><TD>regulation of organelle organization</TD><TD>biological process</TD><TD>GO:0033043</TD><TD>1022</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,CAMK2D,MSX1,S100A10,STXBP6,GRHL3,PDE3A,PKIB</TD></TR>
<TR><TD>3.451e-04</TD><TD>-7.97</TD><TD>nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009166</TD><TD>61</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.533e-04</TD><TD>-7.95</TD><TD>ACTB (actin, beta)</TD><TD>protein interactions</TD><TD>60</TD><TD>284</TD><TD>5</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL,PDLIM5,ANGPTL4,NT5E,VSNL1</TD></TR>
<TR><TD>3.556e-04</TD><TD>-7.94</TD><TD>BIK (BCL2-interacting killer (apoptosis-inducing))</TD><TD>protein interactions</TD><TD>638</TD><TD>13</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,TANK</TD></TR>
<TR><TD>3.589e-04</TD><TD>-7.93</TD><TD>ZnF_C4</TD><TD>smart domains</TD><TD>SM00399</TD><TD>46</TD><TD>3</TD><TD>9131</TD><TD>28</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.610e-04</TD><TD>-7.93</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>13</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.620e-04</TD><TD>-7.92</TD><TD>KEGG_PURINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_PURINE_METABOLISM</TD><TD>155</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>3.658e-04</TD><TD>-7.91</TD><TD>cartilage development</TD><TD>biological process</TD><TD>GO:0051216</TD><TD>152</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,CD44</TD></TR>
<TR><TD>3.710e-04</TD><TD>-7.90</TD><TD>PHONG_TNF_RESPONSE_VIA_P38_PARTIAL</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_VIA_P38_PARTIAL</TD><TD>156</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CD44,NR2F2,TANK</TD></TR>
<TR><TD>3.784e-04</TD><TD>-7.88</TD><TD>endocardial cushion formation</TD><TD>biological process</TD><TD>GO:0003272</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.784e-04</TD><TD>-7.88</TD><TD>regulation of transcription from RNA polymerase II promoter involved in heart development</TD><TD>biological process</TD><TD>GO:1901213</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.784e-04</TD><TD>-7.88</TD><TD>regulation of mesenchymal cell apoptotic process</TD><TD>biological process</TD><TD>GO:2001053</TD><TD>13</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.984e-04</TD><TD>-7.83</TD><TD>embryonic organ morphogenesis</TD><TD>biological process</TD><TD>GO:0048562</TD><TD>282</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,WNT16,MMP16,GRHL3</TD></TR>
<TR><TD>4.073e-04</TD><TD>-7.81</TD><TD>HOLI</TD><TD>smart domains</TD><TD>SM00430</TD><TD>48</TD><TD>3</TD><TD>9131</TD><TD>28</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.174e-04</TD><TD>-7.78</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.50.10</TD><TD>57</TD><TD>3</TD><TD>9988</TD><TD>26</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.206e-04</TD><TD>-7.77</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN</TD><TD>MSigDB lists</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>4.206e-04</TD><TD>-7.77</TD><TD>ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS</TD><TD>MSigDB lists</TD><TD>ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.206e-04</TD><TD>-7.77</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,NT5E</TD></TR>
<TR><TD>4.206e-04</TD><TD>-7.77</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>14</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.298e-04</TD><TD>-7.75</TD><TD>single organism signaling</TD><TD>biological process</TD><TD>GO:0044700</TD><TD>5196</TD><TD>22</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>4.335e-04</TD><TD>-7.74</TD><TD>STROIDFINGER</TD><TD>prints domains</TD><TD>PR00047</TD><TD>46</TD><TD>3</TD><TD>4759</TD><TD>16</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.337e-04</TD><TD>-7.74</TD><TD>signaling</TD><TD>biological process</TD><TD>GO:0023052</TD><TD>5199</TD><TD>22</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>4.355e-04</TD><TD>-7.74</TD><TD>organ growth</TD><TD>biological process</TD><TD>GO:0035265</TD><TD>66</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,PDLIM5</TD></TR>
<TR><TD>4.363e-04</TD><TD>-7.74</TD><TD>negative regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048523</TD><TD>4068</TD><TD>19</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,STXBP6,VSNL1,VIM,ZIC2,RNF43,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>4.379e-04</TD><TD>-7.73</TD><TD>membrane region</TD><TD>cellular component</TD><TD>GO:0098589</TD><TD>1097</TD><TD>9</TD><TD>17570</TD><TD>38</TD>
<TD>TNIK,SLC40A1,S100A10,UNC13A,CLSTN2,ITGB4,CD44,PDLIM5,NT5E</TD></TR>
<TR><TD>4.409e-04</TD><TD>-7.73</TD><TD>positive regulation of meiotic cell cycle</TD><TD>biological process</TD><TD>GO:0051446</TD><TD>14</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.409e-04</TD><TD>-7.73</TD><TD>cAMP catabolic process</TD><TD>biological process</TD><TD>GO:0006198</TD><TD>14</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.447e-04</TD><TD>-7.72</TD><TD>ROSS_AML_OF_FAB_M7_TYPE</TD><TD>MSigDB lists</TD><TD>ROSS_AML_OF_FAB_M7_TYPE</TD><TD>68</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,PDLIM5,STXBP6</TD></TR>
<TR><TD>4.455e-04</TD><TD>-7.72</TD><TD>multicellular organismal process</TD><TD>biological process</TD><TD>GO:0032501</TD><TD>6447</TD><TD>25</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,NEBL,PDE10A,UNC13A,WNT16,ITGB4,CD44,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>4.464e-04</TD><TD>-7.71</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>1862</TD><TD>12</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,EFNB2,FGF9,MSX1,STXBP6,PDE10A,SLCO5A1,CSMD3,RNF43,VIM,NR2F2,MMP16</TD></TR>
<TR><TD>4.476e-04</TD><TD>-7.71</TD><TD>positive regulation of signaling</TD><TD>biological process</TD><TD>GO:0023056</TD><TD>1558</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,UNC13A,VSNL1,CLSTN2,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>4.544e-04</TD><TD>-7.70</TD><TD>negative regulation of biological process</TD><TD>biological process</TD><TD>GO:0048519</TD><TD>4447</TD><TD>20</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,FGF9,MSX1,PPARG,STXBP6,VSNL1,VIM,ZIC2,RNF43,ANGPTL4,PDE3A,NR2F1,MSX2,CAMK2D,WNT16,CD44,NR2F2,PKIB,NT5E</TD></TR>
<TR><TD>4.621e-04</TD><TD>-7.68</TD><TD>STRDHORMONER</TD><TD>prints domains</TD><TD>PR00398</TD><TD>47</TD><TD>3</TD><TD>4759</TD><TD>16</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.773e-04</TD><TD>-7.65</TD><TD>DLX2 (distal-less homeobox 2)</TD><TD>protein interactions</TD><TD>1746</TD><TD>15</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.842e-04</TD><TD>-7.63</TD><TD>REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION</TD><TD>70</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>4.887e-04</TD><TD>-7.62</TD><TD>positive regulation of cell communication</TD><TD>biological process</TD><TD>GO:0010647</TD><TD>1574</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,UNC13A,VSNL1,CLSTN2,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>4.963e-04</TD><TD>-7.61</TD><TD>nucleoside phosphate catabolic process</TD><TD>biological process</TD><TD>GO:1901292</TD><TD>69</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>5.048e-04</TD><TD>-7.59</TD><TD>PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2</TD><TD>MSigDB lists</TD><TD>PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2</TD><TD>71</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,ANGPTL4,NT5E</TD></TR>
<TR><TD>5.080e-04</TD><TD>-7.59</TD><TD>craniofacial suture morphogenesis</TD><TD>biological process</TD><TD>GO:0097094</TD><TD>15</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MMP16</TD></TR>
<TR><TD>5.080e-04</TD><TD>-7.59</TD><TD>AMP metabolic process</TD><TD>biological process</TD><TD>GO:0046033</TD><TD>15</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>5.090e-04</TD><TD>-7.58</TD><TD>regulation of molecular function</TD><TD>biological process</TD><TD>GO:0065009</TD><TD>2753</TD><TD>15</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,S100A10,PPARG,SLK,GRHL3,ZIC2,CD44,NR2F2,ANGPTL4,MMP16,PKIB</TD></TR>
<TR><TD>5.134e-04</TD><TD>-7.57</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>MSigDB lists</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>170</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,FGF9,MMP16,PDE10A</TD></TR>
<TR><TD>5.160e-04</TD><TD>-7.57</TD><TD>generation of neurons</TD><TD>biological process</TD><TD>GO:0048699</TD><TD>1584</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,PPARG,UNC13A,VIM,WNT16,NR2F2,PDLIM5,NR2F1</TD></TR>
<TR><TD>5.260e-04</TD><TD>-7.55</TD><TD>SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP</TD><TD>MSigDB lists</TD><TD>SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP</TD><TD>72</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,PDLIM5,NR2F1</TD></TR>
<TR><TD>5.361e-04</TD><TD>-7.53</TD><TD>central nervous system development</TD><TD>biological process</TD><TD>GO:0007417</TD><TD>859</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,GRHL3,ZIC2,VIM,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>5.448e-04</TD><TD>-7.52</TD><TD>BCL11B (B-cell CLL/lymphoma 11B (zinc finger protein))</TD><TD>protein interactions</TD><TD>64919</TD><TD>16</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>5.528e-04</TD><TD>-7.50</TD><TD>epithelial tube morphogenesis</TD><TD>biological process</TD><TD>GO:0060562</TD><TD>303</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,ZIC2,CD44,GRHL3</TD></TR>
<TR><TD>5.531e-04</TD><TD>-7.50</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>16</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>5.651e-04</TD><TD>-7.48</TD><TD>cell communication</TD><TD>biological process</TD><TD>GO:0007154</TD><TD>5288</TD><TD>22</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,NR2F1,PDE3A,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,SORCS2,NR2F2,CD44</TD></TR>
<TR><TD>5.907e-04</TD><TD>-7.43</TD><TD>Nuclear Receptors</TD><TD>WikiPathways</TD><TD>WP170</TD><TD>38</TD><TD>3</TD><TD>4455</TD><TD>20</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>5.948e-04</TD><TD>-7.43</TD><TD>biological regulation</TD><TD>biological process</TD><TD>GO:0065007</TD><TD>11168</TD><TD>34</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VSNL1,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,MSX2,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>5.952e-04</TD><TD>-7.43</TD><TD>plasma membrane region</TD><TD>cellular component</TD><TD>GO:0098590</TD><TD>906</TD><TD>8</TD><TD>17570</TD><TD>38</TD>
<TD>TNIK,SLC40A1,UNC13A,CLSTN2,CD44,ITGB4,PDLIM5,NT5E</TD></TR>
<TR><TD>6.059e-04</TD><TD>-7.41</TD><TD>positive regulation of macromolecule metabolic process</TD><TD>biological process</TD><TD>GO:0010604</TD><TD>2797</TD><TD>15</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,TNIK,CAMK2D,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,ZIC2,WNT16,CD44,NR2F2,PKIB,NR2F1</TD></TR>
<TR><TD>6.089e-04</TD><TD>-7.40</TD><TD>vif (p23)</TD><TD>protein interactions</TD><TD>155459</TD><TD>320</TD><TD>5</TD><TD>16036</TD><TD>35</TD>
<TD>RHOU,VIM,CD44,PPARG,NT5E</TD></TR>
<TR><TD>6.094e-04</TD><TD>-7.40</TD><TD>carbohydrate derivative catabolic process</TD><TD>biological process</TD><TD>GO:1901136</TD><TD>174</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CD44,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>6.101e-04</TD><TD>-7.40</TD><TD>positive regulation of multicellular organismal process</TD><TD>biological process</TD><TD>GO:0051240</TD><TD>1353</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,PPARG,UNC13A,CLSTN2,ZIC2,ANGPTL4,PDE3A</TD></TR>
<TR><TD>6.233e-04</TD><TD>-7.38</TD><TD>WU_CELL_MIGRATION</TD><TD>MSigDB lists</TD><TD>WU_CELL_MIGRATION</TD><TD>179</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,VIM,ITGB4,NR2F2</TD></TR>
<TR><TD>6.260e-04</TD><TD>-7.38</TD><TD>LE_SKI_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>LE_SKI_TARGETS_UP</TD><TD>17</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>6.260e-04</TD><TD>-7.38</TD><TD>MATTHEWS_AP1_TARGETS</TD><TD>MSigDB lists</TD><TD>MATTHEWS_AP1_TARGETS</TD><TD>17</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>6.337e-04</TD><TD>-7.36</TD><TD>odontogenesis of dentin-containing tooth</TD><TD>biological process</TD><TD>GO:0042475</TD><TD>75</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>6.443e-04</TD><TD>-7.35</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>490</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ZIC2,NR2F2,PPARG,PDE10A,TANK</TD></TR>
<TR><TD>6.561e-04</TD><TD>-7.33</TD><TD>signal transduction involved in regulation of gene expression</TD><TD>biological process</TD><TD>GO:0023019</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>6.561e-04</TD><TD>-7.33</TD><TD>amelogenesis</TD><TD>biological process</TD><TD>GO:0097186</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ITGB4</TD></TR>
<TR><TD>6.561e-04</TD><TD>-7.33</TD><TD>cyclic nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009214</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>6.561e-04</TD><TD>-7.33</TD><TD>negative regulation of transcription regulatory region DNA binding</TD><TD>biological process</TD><TD>GO:2000678</TD><TD>17</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>6.740e-04</TD><TD>-7.30</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>2007</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,SLC40A1,NEBL,CLSTN2,SLCO5A1,CSMD3,ZIC2,SORCS2,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>6.801e-04</TD><TD>-7.29</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>2009</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,SLC40A1,NEBL,CLSTN2,SLCO5A1,CSMD3,ZIC2,SORCS2,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>6.805e-04</TD><TD>-7.29</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>MSigDB lists</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>1950</TD><TD>12</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,FGF9,SLC40A1,MSX2,MSX1,STXBP6,CLSTN2,ZIC2,RNF43,ITGB4,NR2F2,NR2F1</TD></TR>
<TR><TD>6.844e-04</TD><TD>-7.29</TD><TD>cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0055007</TD><TD>77</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>6.912e-04</TD><TD>-7.28</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>184</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLCO5A1,CD44,PDE10A</TD></TR>
<TR><TD>6.912e-04</TD><TD>-7.28</TD><TD>ERB2_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>ERB2_UP.V1_UP</TD><TD>184</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ITGB4,PRPS1,ANGPTL4</TD></TR>
<TR><TD>7.033e-04</TD><TD>-7.26</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN</TD><TD>MSigDB lists</TD><TD>HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN</TD><TD>18</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>7.158e-04</TD><TD>-7.24</TD><TD>LEE_TARGETS_OF_PTCH1_AND_SUFU_DN</TD><TD>MSigDB lists</TD><TD>LEE_TARGETS_OF_PTCH1_AND_SUFU_DN</TD><TD>80</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,CAMK2D,VSNL1</TD></TR>
<TR><TD>7.214e-04</TD><TD>-7.23</TD><TD>PATIL_LIVER_CANCER</TD><TD>MSigDB lists</TD><TD>PATIL_LIVER_CANCER</TD><TD>698</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,RNF43,VIM,ZIC2,S100A10,PPARG,STXBP6</TD></TR>
<TR><TD>7.232e-04</TD><TD>-7.23</TD><TD>ZYX (zyxin)</TD><TD>protein interactions</TD><TD>7791</TD><TD>81</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,NEBL,PDLIM5</TD></TR>
<TR><TD>7.265e-04</TD><TD>-7.23</TD><TD>cellular response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0071495</TD><TD>1133</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,PPARG,NR2F2,CD44,PDE3A,NR2F1</TD></TR>
<TR><TD>7.371e-04</TD><TD>-7.21</TD><TD>endocardial cushion morphogenesis</TD><TD>biological process</TD><TD>GO:0003203</TD><TD>18</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>7.731e-04</TD><TD>-7.17</TD><TD>TLE2 (transducin-like enhancer of split 2)</TD><TD>protein interactions</TD><TD>7089</TD><TD>19</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>7.844e-04</TD><TD>-7.15</TD><TD>neurogenesis</TD><TD>biological process</TD><TD>GO:0022008</TD><TD>1664</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,PPARG,UNC13A,VIM,WNT16,NR2F2,PDLIM5,NR2F1</TD></TR>
<TR><TD>7.849e-04</TD><TD>-7.15</TD><TD>REACTOME_CGMP_EFFECTS</TD><TD>MSigDB lists</TD><TD>REACTOME_CGMP_EFFECTS</TD><TD>19</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>7.849e-04</TD><TD>-7.15</TD><TD>HU_ANGIOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>HU_ANGIOGENESIS_UP</TD><TD>19</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,ITGB4</TD></TR>
<TR><TD>8.018e-04</TD><TD>-7.13</TD><TD>regulation of anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0022603</TD><TD>913</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,TNIK,MSX1,S100A10,UNC13A,GRHL3,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>8.158e-04</TD><TD>-7.11</TD><TD>regulation of apoptotic process</TD><TD>biological process</TD><TD>GO:0042981</TD><TD>1404</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>8.175e-04</TD><TD>-7.11</TD><TD>regulation of cellular process</TD><TD>biological process</TD><TD>GO:0050794</TD><TD>10106</TD><TD>32</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,LAMA4,FGF9,SLC40A1,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,MSX2,SORCS2,NR2F2,ITGB4,PDLIM5,PKIB</TD></TR>
<TR><TD>8.226e-04</TD><TD>-7.10</TD><TD>regulation of transcription involved in cell fate commitment</TD><TD>biological process</TD><TD>GO:0060850</TD><TD>19</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>8.226e-04</TD><TD>-7.10</TD><TD>cell surface receptor signaling pathway involved in heart development</TD><TD>biological process</TD><TD>GO:0061311</TD><TD>19</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>8.252e-04</TD><TD>-7.10</TD><TD>KEGG_ECM_RECEPTOR_INTERACTION</TD><TD>MSigDB lists</TD><TD>KEGG_ECM_RECEPTOR_INTERACTION</TD><TD>84</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>8.470e-04</TD><TD>-7.07</TD><TD>mesenchyme development</TD><TD>biological process</TD><TD>GO:0060485</TD><TD>190</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,WNT16</TD></TR>
<TR><TD>8.519e-04</TD><TD>-7.07</TD><TD>regulation of signaling</TD><TD>biological process</TD><TD>GO:0023051</TD><TD>2886</TD><TD>15</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,FGF9,MSX1,PPARG,PDE10A,UNC13A,VSNL1,CLSTN2,ZIC2,RNF43,WNT16,CD44</TD></TR>
<TR><TD>8.541e-04</TD><TD>-7.07</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>MSigDB lists</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>85</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,RNF43,PPARG</TD></TR>
<TR><TD>8.585e-04</TD><TD>-7.06</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>MSigDB lists</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>195</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,MSX1,CD44,NT5E</TD></TR>
<TR><TD>8.585e-04</TD><TD>-7.06</TD><TD>HALLMARK_ADIPOGENESIS</TD><TD>MSigDB lists</TD><TD>HALLMARK_ADIPOGENESIS</TD><TD>195</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PPARG,ANGPTL4,TANK</TD></TR>
<TR><TD>8.622e-04</TD><TD>-7.06</TD><TD>regulation of programmed cell death</TD><TD>biological process</TD><TD>GO:0043067</TD><TD>1414</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,TNIK,CAMK2D,MSX1,PPARG,SLK,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>8.709e-04</TD><TD>-7.05</TD><TD>WOTTON_RUNX_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>WOTTON_RUNX_TARGETS_UP</TD><TD>20</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,ANGPTL4</TD></TR>
<TR><TD>8.917e-04</TD><TD>-7.02</TD><TD>HALLMARK_GLYCOLYSIS</TD><TD>MSigDB lists</TD><TD>HALLMARK_GLYCOLYSIS</TD><TD>197</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PRPS1,ANGPTL4,NT5E</TD></TR>
<TR><TD>8.942e-04</TD><TD>-7.02</TD><TD>regulation of nervous system development</TD><TD>biological process</TD><TD>GO:0051960</TD><TD>709</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>CLSTN2,VIM,TNIK,PPARG,PDLIM5,UNC13A,GRHL3</TD></TR>
<TR><TD>9.066e-04</TD><TD>-7.01</TD><TD>PDEase_catalytic_dom</TD><TD>interpro domains</TD><TD>IPR002073</TD><TD>21</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>9.066e-04</TD><TD>-7.01</TD><TD>PDEase_CS</TD><TD>interpro domains</TD><TD>IPR023174</TD><TD>21</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>9.259e-04</TD><TD>-6.98</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>MSigDB lists</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>199</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLC40A1,NR2F2,PDLIM5</TD></TR>
<TR><TD>9.442e-04</TD><TD>-6.97</TD><TD>bone morphogenesis</TD><TD>biological process</TD><TD>GO:0060349</TD><TD>86</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>9.667e-04</TD><TD>-6.94</TD><TD>tube morphogenesis</TD><TD>biological process</TD><TD>GO:0035239</TD><TD>343</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,ZIC2,CD44,GRHL3</TD></TR>
<TR><TD>9.788e-04</TD><TD>-6.93</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>202</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,CAMK2D,CD44,NR2F2</TD></TR>
<TR><TD>9.788e-04</TD><TD>-6.93</TD><TD>V$AHR_Q5</TD><TD>MSigDB lists</TD><TD>V$AHR_Q5</TD><TD>202</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,CAMK2D,ZIC2,NR2F2</TD></TR>
<TR><TD>9.875e-04</TD><TD>-6.92</TD><TD>connective tissue development</TD><TD>biological process</TD><TD>GO:0061448</TD><TD>198</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,CD44</TD></TR>
<TR><TD>9.969e-04</TD><TD>-6.91</TD><TD>MODULE_12</TD><TD>MSigDB lists</TD><TD>MODULE_12</TD><TD>353</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NEBL,PDLIM5,NR2F1,VSNL1</TD></TR>
<TR><TD>1.001e-03</TD><TD>-6.91</TD><TD>central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-thalamus-glioma-oligoastrocytoma_Grade_III</TD><TD>22</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>PDE10A,GRHL3</TD></TR>
<TR><TD>1.006e-03</TD><TD>-6.90</TD><TD>regulation of cell communication</TD><TD>biological process</TD><TD>GO:0010646</TD><TD>2931</TD><TD>15</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,FGF9,MSX1,PPARG,PDE10A,UNC13A,VSNL1,CLSTN2,ZIC2,RNF43,WNT16,CD44</TD></TR>
<TR><TD>1.007e-03</TD><TD>-6.90</TD><TD>lymph vessel development</TD><TD>biological process</TD><TD>GO:0001945</TD><TD>21</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,NR2F2</TD></TR>
<TR><TD>1.014e-03</TD><TD>-6.89</TD><TD>ATF2 (activating transcription factor 2)</TD><TD>protein interactions</TD><TD>1386</TD><TD>206</TD><TD>4</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,ITGB4,CD44,S100A10</TD></TR>
<TR><TD>1.015e-03</TD><TD>-6.89</TD><TD>V$SRF_C</TD><TD>MSigDB lists</TD><TD>V$SRF_C</TD><TD>204</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PDLIM5,TANK,NR2F1</TD></TR>
<TR><TD>1.034e-03</TD><TD>-6.87</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>205</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,PKIB,NR2F1,VSNL1</TD></TR>
<TR><TD>1.039e-03</TD><TD>-6.87</TD><TD>PDEase_I</TD><TD>pfam domains</TD><TD>PF00233</TD><TD>21</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.041e-03</TD><TD>-6.87</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>91</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,SORCS2,PDE10A</TD></TR>
<TR><TD>1.092e-03</TD><TD>-6.82</TD><TD>basement membrane</TD><TD>cellular component</TD><TD>GO:0005604</TD><TD>94</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4,FGF9,ITGB4</TD></TR>
<TR><TD>1.107e-03</TD><TD>-6.81</TD><TD>regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010869</TD><TD>22</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>1.107e-03</TD><TD>-6.81</TD><TD>regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902253</TD><TD>22</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>1.120e-03</TD><TD>-6.79</TD><TD>cGMP effects</TD><TD>REACTOME pathways</TD><TD>R-HSA-418457</TD><TD>18</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.155e-03</TD><TD>-6.76</TD><TD>V$MEF2_04</TD><TD>MSigDB lists</TD><TD>V$MEF2_04</TD><TD>23</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,NR2F1</TD></TR>
<TR><TD>1.161e-03</TD><TD>-6.76</TD><TD>TAATTA_V$CHX10_01</TD><TD>MSigDB lists</TD><TD>TAATTA_V$CHX10_01</TD><TD>757</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,SLCO5A1,MSX2,MSX1,NEBL,NR2F1,GRHL3</TD></TR>
<TR><TD>1.187e-03</TD><TD>-6.74</TD><TD>HD/PDEase_dom</TD><TD>interpro domains</TD><TD>IPR003607</TD><TD>24</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.191e-03</TD><TD>-6.73</TD><TD>V$CHX10_01</TD><TD>MSigDB lists</TD><TD>V$CHX10_01</TD><TD>213</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NEBL,NR2F1,VSNL1</TD></TR>
<TR><TD>1.210e-03</TD><TD>-6.72</TD><TD>cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0003300</TD><TD>23</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.210e-03</TD><TD>-6.72</TD><TD>trabecula formation</TD><TD>biological process</TD><TD>GO:0060343</TD><TD>23</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>1.222e-03</TD><TD>-6.71</TD><TD>hormone-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0009755</TD><TD>94</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.251e-03</TD><TD>-6.68</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>14911</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.260e-03</TD><TD>-6.68</TD><TD>cellular response to organic cyclic compound</TD><TD>biological process</TD><TD>GO:0071407</TD><TD>364</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1,PDE3A</TD></TR>
<TR><TD>1.260e-03</TD><TD>-6.68</TD><TD>single-organism cellular process</TD><TD>biological process</TD><TD>GO:0044763</TD><TD>11471</TD><TD>34</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,RNF43,ZIC2,PDE3A,NEBL,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,MSX2,SLCO5A1,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16</TD></TR>
<TR><TD>1.278e-03</TD><TD>-6.66</TD><TD>Transcriptional regulation of white adipocyte differentiation</TD><TD>REACTOME pathways</TD><TD>R-HSA-381340</TD><TD>78</TD><TD>3</TD><TD>8202</TD><TD>23</TD>
<TD>NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.310e-03</TD><TD>-6.64</TD><TD>3',5'-cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004114</TD><TD>24</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.310e-03</TD><TD>-6.64</TD><TD>cAMP binding</TD><TD>molecular function</TD><TD>GO:0030552</TD><TD>24</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.318e-03</TD><TD>-6.63</TD><TD>striated muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014897</TD><TD>24</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.318e-03</TD><TD>-6.63</TD><TD>cardiac muscle tissue growth</TD><TD>biological process</TD><TD>GO:0055017</TD><TD>24</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.327e-03</TD><TD>-6.62</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.1300.10</TD><TD>21</TD><TD>2</TD><TD>9988</TD><TD>26</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.328e-03</TD><TD>-6.62</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>MSigDB lists</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>99</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,CD44,PDE10A</TD></TR>
<TR><TD>1.345e-03</TD><TD>-6.61</TD><TD>MSX1 (msh homeobox 1)</TD><TD>protein interactions</TD><TD>4487</TD><TD>25</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.345e-03</TD><TD>-6.61</TD><TD>PLA2G4A (phospholipase A2, group IVA (cytosolic, calcium-dependent))</TD><TD>protein interactions</TD><TD>5321</TD><TD>25</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>1.362e-03</TD><TD>-6.60</TD><TD>regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0090092</TD><TD>216</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1</TD></TR>
<TR><TD>1.365e-03</TD><TD>-6.60</TD><TD>cerebellum</TD><TD>COSMIC cancer mutations</TD><TD>cerebellum</TD><TD>801</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2,PDE10A</TD></TR>
<TR><TD>1.366e-03</TD><TD>-6.60</TD><TD>REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE</TD><TD>MSigDB lists</TD><TD>REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE</TD><TD>25</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.367e-03</TD><TD>-6.60</TD><TD>HOELZEL_NF1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_DN</TD><TD>100</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,MMP16,NR2F1</TD></TR>
<TR><TD>1.367e-03</TD><TD>-6.60</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>379</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,PDE10A,STXBP6,NR2F1,VSNL1</TD></TR>
<TR><TD>1.378e-03</TD><TD>-6.59</TD><TD>cardiocyte differentiation</TD><TD>biological process</TD><TD>GO:0035051</TD><TD>98</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.421e-03</TD><TD>-6.56</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,CAMK2D,FGF9,NEBL,VSNL1,CLSTN2,CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>1.421e-03</TD><TD>-6.56</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,CAMK2D,FGF9,NEBL,VSNL1,CLSTN2,CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>1.422e-03</TD><TD>-6.56</TD><TD>cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004112</TD><TD>25</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.431e-03</TD><TD>-6.55</TD><TD>positive regulation of cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0055025</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>1.431e-03</TD><TD>-6.55</TD><TD>heart growth</TD><TD>biological process</TD><TD>GO:0060419</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.431e-03</TD><TD>-6.55</TD><TD>regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032925</TD><TD>25</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,FGF9</TD></TR>
<TR><TD>1.455e-03</TD><TD>-6.53</TD><TD>ARHGEF1 (Rho guanine nucleotide exchange factor 1)</TD><TD>protein interactions</TD><TD>9138</TD><TD>26</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CD44,SLK</TD></TR>
<TR><TD>1.455e-03</TD><TD>-6.53</TD><TD>MPPED1 (metallophosphoesterase domain containing 1)</TD><TD>protein interactions</TD><TD>758</TD><TD>26</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.477e-03</TD><TD>-6.52</TD><TD>XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR</TD><TD>MSigDB lists</TD><TD>XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR</TD><TD>26</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,ANGPTL4</TD></TR>
<TR><TD>1.482e-03</TD><TD>-6.51</TD><TD>V$EVI1_04</TD><TD>MSigDB lists</TD><TD>V$EVI1_04</TD><TD>226</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,SLC40A1,NR2F2,NR2F1</TD></TR>
<TR><TD>1.486e-03</TD><TD>-6.51</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>790</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,VIM,CAMK2D,NEBL,PDE10A,SLK,NT5E</TD></TR>
<TR><TD>1.548e-03</TD><TD>-6.47</TD><TD>muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014896</TD><TD>26</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.584e-03</TD><TD>-6.45</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>2863</TD><TD>14</TD><TD>17775</TD><TD>38</TD>
<TD>NEBL,STXBP6,UNC13A,CLSTN2,SLCO5A1,CSMD3,ZIC2,CD44,SORCS2,PDLIM5,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>1.589e-03</TD><TD>-6.44</TD><TD>odontogenesis</TD><TD>biological process</TD><TD>GO:0042476</TD><TD>103</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,ITGB4</TD></TR>
<TR><TD>1.593e-03</TD><TD>-6.44</TD><TD>WATANABE_COLON_CANCER_MSI_VS_MSS_UP</TD><TD>MSigDB lists</TD><TD>WATANABE_COLON_CANCER_MSI_VS_MSS_UP</TD><TD>27</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,PDE10A</TD></TR>
<TR><TD>1.595e-03</TD><TD>-6.44</TD><TD>cell-substrate junction</TD><TD>cellular component</TD><TD>GO:0030055</TD><TD>399</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,ITGB4,CD44</TD></TR>
<TR><TD>1.617e-03</TD><TD>-6.43</TD><TD>PDEASE_I</TD><TD>prosite domains</TD><TD>PS00126</TD><TD>21</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.618e-03</TD><TD>-6.43</TD><TD>PIAS1 (protein inhibitor of activated STAT 1)</TD><TD>protein interactions</TD><TD>8554</TD><TD>107</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1,NR2F2,PPARG</TD></TR>
<TR><TD>1.638e-03</TD><TD>-6.41</TD><TD>human chr6q14-q21</TD><TD>chromosome location</TD><TD>human chr6q14-q21</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.660e-03</TD><TD>-6.40</TD><TD>actinin binding</TD><TD>molecular function</TD><TD>GO:0042805</TD><TD>27</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>1.688e-03</TD><TD>-6.38</TD><TD>RNF13 (ring finger protein 13)</TD><TD>protein interactions</TD><TD>11342</TD><TD>28</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.713e-03</TD><TD>-6.37</TD><TD>regulation of cell development</TD><TD>biological process</TD><TD>GO:0060284</TD><TD>793</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,TNIK,S100A10,PPARG,PDLIM5,UNC13A,PDE3A</TD></TR>
<TR><TD>1.714e-03</TD><TD>-6.37</TD><TD>TSENG_ADIPOGENIC_POTENTIAL_UP</TD><TD>MSigDB lists</TD><TD>TSENG_ADIPOGENIC_POTENTIAL_UP</TD><TD>28</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,EFNB2</TD></TR>
<TR><TD>1.766e-03</TD><TD>-6.34</TD><TD>ovary-other-neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>ovary-other-neoplasm</TD><TD>13367</TD><TD>36</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.795e-03</TD><TD>-6.32</TD><TD>regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043516</TD><TD>28</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>1.798e-03</TD><TD>-6.32</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>4353</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,VSNL1,CLSTN2,PDE3A,CAMK2D,NEBL,UNC13A,TANK,CSMD3,SLCO5A1,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>1.836e-03</TD><TD>-6.30</TD><TD>Laminin interactions</TD><TD>REACTOME pathways</TD><TD>R-HSA-3000157</TD><TD>23</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>1.870e-03</TD><TD>-6.28</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>407</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,SLCO5A1,MSX1,NR2F1,C1orf226</TD></TR>
<TR><TD>1.890e-03</TD><TD>-6.27</TD><TD>SP1 (Sp1 transcription factor)</TD><TD>protein interactions</TD><TD>6667</TD><TD>244</TD><TD>4</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,MSX1,PPARG,NR2F1</TD></TR>
<TR><TD>1.903e-03</TD><TD>-6.26</TD><TD>V$PBX1_01</TD><TD>MSigDB lists</TD><TD>V$PBX1_01</TD><TD>242</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,CAMK2D,ZIC2,SLK</TD></TR>
<TR><TD>1.926e-03</TD><TD>-6.25</TD><TD>embryonic hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035116</TD><TD>29</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.926e-03</TD><TD>-6.25</TD><TD>endocardial cushion development</TD><TD>biological process</TD><TD>GO:0003197</TD><TD>29</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.932e-03</TD><TD>-6.25</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>MSigDB lists</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>243</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,NR2F2,NR2F1,VSNL1</TD></TR>
<TR><TD>1.956e-03</TD><TD>-6.24</TD><TD>chordate embryonic development</TD><TD>biological process</TD><TD>GO:0043009</TD><TD>595</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,ZIC2,MSX1,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>1.961e-03</TD><TD>-6.23</TD><TD>V$AREB6_03</TD><TD>MSigDB lists</TD><TD>V$AREB6_03</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ITGB4,MMP16,GRHL3</TD></TR>
<TR><TD>1.961e-03</TD><TD>-6.23</TD><TD>V$PAX2_02</TD><TD>MSigDB lists</TD><TD>V$PAX2_02</TD><TD>244</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,FGF9,PPARG,NR2F1</TD></TR>
<TR><TD>1.967e-03</TD><TD>-6.23</TD><TD>RODRIGUES_NTN1_AND_DCC_TARGETS</TD><TD>MSigDB lists</TD><TD>RODRIGUES_NTN1_AND_DCC_TARGETS</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,CAMK2D</TD></TR>
<TR><TD>1.967e-03</TD><TD>-6.23</TD><TD>TING_SILENCED_BY_DICER</TD><TD>MSigDB lists</TD><TD>TING_SILENCED_BY_DICER</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,VIM</TD></TR>
<TR><TD>1.989e-03</TD><TD>-6.22</TD><TD>PHB2 (prohibitin 2)</TD><TD>protein interactions</TD><TD>11331</TD><TD>115</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.994e-03</TD><TD>-6.22</TD><TD>Purine metabolism</TD><TD>KEGG pathways</TD><TD>hsa00230</TD><TD>174</TD><TD>4</TD><TD>6908</TD><TD>22</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>1.994e-03</TD><TD>-6.22</TD><TD>Purine metabolism</TD><TD>KEGG pathways</TD><TD>ko00230</TD><TD>174</TD><TD>4</TD><TD>6908</TD><TD>22</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>2.000e-03</TD><TD>-6.21</TD><TD>Nitric oxide stimulates guanylate cyclase</TD><TD>REACTOME pathways</TD><TD>R-HSA-392154</TD><TD>24</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.011e-03</TD><TD>-6.21</TD><TD>plasma membrane part</TD><TD>cellular component</TD><TD>GO:0044459</TD><TD>2566</TD><TD>13</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,TNIK,SLC40A1,S100A10,UNC13A,CLSTN2,SLCO5A1,RNF43,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>2.015e-03</TD><TD>-6.21</TD><TD>CUI_TCF21_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>CUI_TCF21_TARGETS_2_UP</TD><TD>414</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,RHOU,LAMA4,NR2F2,MMP16</TD></TR>
<TR><TD>2.022e-03</TD><TD>-6.20</TD><TD>negative regulation of molecular function</TD><TD>biological process</TD><TD>GO:0044092</TD><TD>1054</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,PPARG,NR2F2,CD44,ANGPTL4,PKIB</TD></TR>
<TR><TD>2.046e-03</TD><TD>-6.19</TD><TD>positive regulation of cellular component organization</TD><TD>biological process</TD><TD>GO:0051130</TD><TD>1056</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,MSX1,S100A10,PPARG,UNC13A,CLSTN2,PKIB</TD></TR>
<TR><TD>2.058e-03</TD><TD>-6.19</TD><TD>embryo development ending in birth or egg hatching</TD><TD>biological process</TD><TD>GO:0009792</TD><TD>601</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,ZIC2,MSX1,NR2F2,MMP16,GRHL3</TD></TR>
<TR><TD>2.068e-03</TD><TD>-6.18</TD><TD>BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein))</TD><TD>protein interactions</TD><TD>53335</TD><TD>31</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.080e-03</TD><TD>-6.18</TD><TD>V$CREL_01</TD><TD>MSigDB lists</TD><TD>V$CREL_01</TD><TD>248</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,MSX1,S100A10,NR2F2</TD></TR>
<TR><TD>2.109e-03</TD><TD>-6.16</TD><TD>synaptic membrane</TD><TD>cellular component</TD><TD>GO:0097060</TD><TD>253</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>CLSTN2,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>2.113e-03</TD><TD>-6.16</TD><TD>RNA polymerase II transcription factor activity, sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000981</TD><TD>606</TD><TD>6</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,MSX1,NR2F2,PPARG,NR2F1,GRHL3</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>5'-Nucleotdase_C</TD><TD>interpro domains</TD><TD>IPR008334</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>DUF4628</TD><TD>interpro domains</TD><TD>IPR027851</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>C1orf226</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>S100-A10</TD><TD>interpro domains</TD><TD>IPR028476</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>FGF9</TD><TD>interpro domains</TD><TD>IPR028251</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>UVR_dom</TD><TD>interpro domains</TD><TD>IPR001943</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLK</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>Ferroportin-1</TD><TD>interpro domains</TD><TD>IPR009716</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>CD44_antigen</TD><TD>interpro domains</TD><TD>IPR001231</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>5'-Nucleotdase_CS</TD><TD>interpro domains</TD><TD>IPR006146</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>PPARgamma_N</TD><TD>interpro domains</TD><TD>IPR022590</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>Wnt16</TD><TD>interpro domains</TD><TD>IPR013304</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>ANGPTL4</TD><TD>interpro domains</TD><TD>IPR028793</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>Integrin_bsu-4</TD><TD>interpro domains</TD><TD>IPR012013</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>5_nucleotidase/apyrase</TD><TD>interpro domains</TD><TD>IPR006179</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>MMP16</TD><TD>interpro domains</TD><TD>IPR028697</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>1Cnucl_rcpt_G</TD><TD>interpro domains</TD><TD>IPR003077</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.146e-03</TD><TD>-6.14</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>MSigDB lists</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>420</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,VIM,NEBL,PDLIM5,SLK</TD></TR>
<TR><TD>2.173e-03</TD><TD>-6.13</TD><TD>V$AFP1_Q6</TD><TD>MSigDB lists</TD><TD>V$AFP1_Q6</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,TANK,NR2F1,GRHL3</TD></TR>
<TR><TD>2.173e-03</TD><TD>-6.13</TD><TD>V$OCT1_Q6</TD><TD>MSigDB lists</TD><TD>V$OCT1_Q6</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,NR2F1,GRHL3,VSNL1</TD></TR>
<TR><TD>2.178e-03</TD><TD>-6.13</TD><TD>ear morphogenesis</TD><TD>biological process</TD><TD>GO:0042471</TD><TD>115</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,GRHL3</TD></TR>
<TR><TD>2.183e-03</TD><TD>-6.13</TD><TD>G (attachment glycoprotein)</TD><TD>protein interactions</TD><TD>920955</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.183e-03</TD><TD>-6.13</TD><TD>ACTB (actin, beta)</TD><TD>protein interactions</TD><TD>396526</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VSNL1</TD></TR>
<TR><TD>2.183e-03</TD><TD>-6.13</TD><TD>ANKRD35 (ankyrin repeat domain 35)</TD><TD>protein interactions</TD><TD>148741</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.183e-03</TD><TD>-6.13</TD><TD>daf-12 (Nuclear hormone receptor family member daf-12)</TD><TD>protein interactions</TD><TD>181263</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.183e-03</TD><TD>-6.13</TD><TD>Ephb1 (Eph receptor B1)</TD><TD>protein interactions</TD><TD>24338</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.190e-03</TD><TD>-6.12</TD><TD>cellular response to stimulus</TD><TD>biological process</TD><TD>GO:0051716</TD><TD>6201</TD><TD>23</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,CD44,SORCS2,NR2F2</TD></TR>
<TR><TD>2.233e-03</TD><TD>-6.10</TD><TD>organophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0046434</TD><TD>116</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>2.237e-03</TD><TD>-6.10</TD><TD>V$AML_Q6</TD><TD>MSigDB lists</TD><TD>V$AML_Q6</TD><TD>253</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,VIM,RNF43,GRHL3</TD></TR>
<TR><TD>2.244e-03</TD><TD>-6.10</TD><TD>iron channel activity</TD><TD>molecular function</TD><TD>GO:0097689</TD><TD>1</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>radial pattern formation</TD><TD>biological process</TD><TD>GO:0009956</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>iron cation export</TD><TD>biological process</TD><TD>GO:1903414</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>spleen trabecula formation</TD><TD>biological process</TD><TD>GO:0060345</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>adenosine biosynthetic process</TD><TD>biological process</TD><TD>GO:0046086</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>cardiac muscle thin filament assembly</TD><TD>biological process</TD><TD>GO:0071691</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>negative regulation of pancreatic stellate cell proliferation</TD><TD>biological process</TD><TD>GO:2000230</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>ferrous iron export</TD><TD>biological process</TD><TD>GO:1903988</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>low-density lipoprotein particle receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0045713</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.250e-03</TD><TD>-6.10</TD><TD>response to metformin</TD><TD>biological process</TD><TD>GO:1901558</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>DUF4628</TD><TD>pfam domains</TD><TD>PF15429</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>C1orf226</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>5_nucleotid_C</TD><TD>pfam domains</TD><TD>PF02872</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>PPARgamma_N</TD><TD>pfam domains</TD><TD>PF12577</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>FPN1</TD><TD>pfam domains</TD><TD>PF06963</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.291e-03</TD><TD>-6.08</TD><TD>sensory organ morphogenesis</TD><TD>biological process</TD><TD>GO:0090596</TD><TD>249</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,WNT16,GRHL3</TD></TR>
<TR><TD>2.315e-03</TD><TD>-6.07</TD><TD>mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>mantle_cell_lymphoma</TD><TD>2976</TD><TD>14</TD><TD>17775</TD><TD>38</TD>
<TD>NEBL,STXBP6,UNC13A,CLSTN2,SLCO5A1,CSMD3,ZIC2,CD44,SORCS2,PDLIM5,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>2.343e-03</TD><TD>-6.06</TD><TD>regulation of transcription regulatory region DNA binding</TD><TD>biological process</TD><TD>GO:2000677</TD><TD>32</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.343e-03</TD><TD>-6.06</TD><TD>positive regulation of BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030513</TD><TD>32</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.344e-03</TD><TD>-6.06</TD><TD>striated muscle cell development</TD><TD>biological process</TD><TD>GO:0055002</TD><TD>118</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>2.358e-03</TD><TD>-6.05</TD><TD>RODRIGUES_DCC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_DCC_TARGETS_DN</TD><TD>121</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,TANK,NR2F1</TD></TR>
<TR><TD>2.401e-03</TD><TD>-6.03</TD><TD>HDc</TD><TD>smart domains</TD><TD>SM00471</TD><TD>24</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.460e-03</TD><TD>-6.01</TD><TD>pattern specification process</TD><TD>biological process</TD><TD>GO:0007389</TD><TD>424</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,NR2F2,NR2F1,GRHL3</TD></TR>
<TR><TD>2.469e-03</TD><TD>-6.00</TD><TD>KRAS.600_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.600_UP.V1_UP</TD><TD>260</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,SLCO5A1,FGF9,ANGPTL4</TD></TR>
<TR><TD>2.469e-03</TD><TD>-6.00</TD><TD>V$ER_Q6</TD><TD>MSigDB lists</TD><TD>V$ER_Q6</TD><TD>260</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NR2F2,NR2F1</TD></TR>
<TR><TD>2.485e-03</TD><TD>-6.00</TD><TD>NR2F2 (nuclear receptor subfamily 2, group F, member 2)</TD><TD>protein interactions</TD><TD>7026</TD><TD>34</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NT5E</TD></TR>
<TR><TD>2.499e-03</TD><TD>-5.99</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>hsa04512</TD><TD>87</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>2.499e-03</TD><TD>-5.99</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>ko04512</TD><TD>87</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>LAMA4,ITGB4,CD44</TD></TR>
<TR><TD>2.504e-03</TD><TD>-5.99</TD><TD>V$COREBINDINGFACTOR_Q6</TD><TD>MSigDB lists</TD><TD>V$COREBINDINGFACTOR_Q6</TD><TD>261</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,VIM,RNF43,PPARG</TD></TR>
<TR><TD>2.517e-03</TD><TD>-5.98</TD><TD>mesenchymal cell development</TD><TD>biological process</TD><TD>GO:0014031</TD><TD>121</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>2.539e-03</TD><TD>-5.98</TD><TD>positive regulation of cellular metabolic process</TD><TD>biological process</TD><TD>GO:0031325</TD><TD>2864</TD><TD>14</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,TNIK,CAMK2D,FGF9,MSX1,PPARG,SLK,GRHL3,ZIC2,WNT16,CD44,NR2F2,PKIB,NR2F1</TD></TR>
<TR><TD>2.587e-03</TD><TD>-5.96</TD><TD>extracellular matrix component</TD><TD>cellular component</TD><TD>GO:0044420</TD><TD>127</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4,FGF9,ITGB4</TD></TR>
<TR><TD>2.603e-03</TD><TD>-5.95</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.780.10</TD><TD>1</TD><TD>1</TD><TD>9988</TD><TD>26</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.642e-03</TD><TD>-5.94</TD><TD>regulation of telomerase activity</TD><TD>biological process</TD><TD>GO:0051972</TD><TD>34</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PKIB</TD></TR>
<TR><TD>2.642e-03</TD><TD>-5.94</TD><TD>embryonic forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035115</TD><TD>34</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.671e-03</TD><TD>-5.93</TD><TD>SPECIFIC_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>SPECIFIC_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>35</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.671e-03</TD><TD>-5.93</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC</TD><TD>MSigDB lists</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC</TD><TD>35</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,MMP16</TD></TR>
<TR><TD>2.675e-03</TD><TD>-5.92</TD><TD>regulation of response to stimulus</TD><TD>biological process</TD><TD>GO:0048583</TD><TD>3566</TD><TD>16</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,MSX1,PPARG,VSNL1,RNF43,ZIC2,RHOU,CAMK2D,MSX2,PDE10A,TANK,WNT16,CD44,NT5E</TD></TR>
<TR><TD>2.703e-03</TD><TD>-5.91</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN</TD><TD>443</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ZIC2,CD44,NR2F1,NT5E</TD></TR>
<TR><TD>2.705e-03</TD><TD>-5.91</TD><TD>GAL_LEUKEMIC_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>GAL_LEUKEMIC_STEM_CELL_UP</TD><TD>127</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,ITGB4,PDLIM5</TD></TR>
<TR><TD>2.718e-03</TD><TD>-5.91</TD><TD>SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12</TD><TD>MSigDB lists</TD><TD>SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12</TD><TD>267</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ITGB4,NEBL,STXBP6</TD></TR>
<TR><TD>2.756e-03</TD><TD>-5.89</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>445</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,VIM,NR2F1,NT5E,VSNL1</TD></TR>
<TR><TD>2.760e-03</TD><TD>-5.89</TD><TD>stem cell development</TD><TD>biological process</TD><TD>GO:0048864</TD><TD>125</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>2.798e-03</TD><TD>-5.88</TD><TD>cAMP metabolic process</TD><TD>biological process</TD><TD>GO:0046058</TD><TD>35</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.798e-03</TD><TD>-5.88</TD><TD>mesenchyme morphogenesis</TD><TD>biological process</TD><TD>GO:0072132</TD><TD>35</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.823e-03</TD><TD>-5.87</TD><TD>cellular response to metal ion</TD><TD>biological process</TD><TD>GO:0071248</TD><TD>126</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,CAMK2D,PPARG</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>HUANG_FOXA2_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HUANG_FOXA2_TARGETS_DN</TD><TD>36</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>2.859e-03</TD><TD>-5.86</TD><TD>actin filament-based process</TD><TD>biological process</TD><TD>GO:0030029</TD><TD>439</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,VIM,TNIK,CAMK2D,NEBL</TD></TR>
<TR><TD>2.865e-03</TD><TD>-5.86</TD><TD>5_NUCLEOTIDASE_1</TD><TD>prosite domains</TD><TD>PS00785</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.865e-03</TD><TD>-5.86</TD><TD>5_NUCLEOTIDASE_2</TD><TD>prosite domains</TD><TD>PS00786</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.865e-03</TD><TD>-5.86</TD><TD>UVR</TD><TD>prosite domains</TD><TD>PS50151</TD><TD>1</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>SLK</TD></TR>
<TR><TD>2.887e-03</TD><TD>-5.85</TD><TD>embryonic limb morphogenesis</TD><TD>biological process</TD><TD>GO:0030326</TD><TD>127</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX2,MSX1</TD></TR>
<TR><TD>2.887e-03</TD><TD>-5.85</TD><TD>embryonic appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035113</TD><TD>127</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX2,MSX1</TD></TR>
<TR><TD>2.890e-03</TD><TD>-5.85</TD><TD>RODWELL_AGING_KIDNEY_DN</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_DN</TD><TD>130</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,SLK,C1orf226</TD></TR>
<TR><TD>2.895e-03</TD><TD>-5.84</TD><TD>cell surface receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0007166</TD><TD>2257</TD><TD>12</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,TNIK,CAMK2D,FGF9,MSX1,GRHL3,RNF43,VIM,WNT16,ITGB4,CD44</TD></TR>
<TR><TD>2.908e-03</TD><TD>-5.84</TD><TD>striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0014706</TD><TD>266</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,NR2F2,PDLIM5</TD></TR>
<TR><TD>2.933e-03</TD><TD>-5.83</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>678</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2</TD></TR>
<TR><TD>2.941e-03</TD><TD>-5.83</TD><TD>frizzled binding</TD><TD>molecular function</TD><TD>GO:0005109</TD><TD>36</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>RNF43,WNT16</TD></TR>
<TR><TD>2.952e-03</TD><TD>-5.83</TD><TD>positive regulation of cell division</TD><TD>biological process</TD><TD>GO:0051781</TD><TD>128</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1</TD></TR>
<TR><TD>2.955e-03</TD><TD>-5.82</TD><TD>SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>SHH_subtype</TD><TD>679</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,SLCO5A1,CSMD3,CAMK2D,NEBL,SORCS2</TD></TR>
<TR><TD>3.017e-03</TD><TD>-5.80</TD><TD>KRAS.LUNG.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.LUNG.BREAST_UP.V1_UP</TD><TD>132</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>3.022e-03</TD><TD>-5.80</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP</TD><TD>MSigDB lists</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP</TD><TD>275</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,SLC40A1,CD44,SLK</TD></TR>
<TR><TD>3.093e-03</TD><TD>-5.78</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7542</TD><TD>25</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,PPARG,STXBP6,GRHL3,VSNL1,CLSTN2,RNF43,PDE3A,RHOU,CAMK2D,NEBL,PDE10A,UNC13A,TANK,SLCO5A1,CSMD3,CD44,SORCS2,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>3.105e-03</TD><TD>-5.77</TD><TD>cyclic nucleotide binding</TD><TD>molecular function</TD><TD>GO:0030551</TD><TD>37</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.116e-03</TD><TD>-5.77</TD><TD>brain development</TD><TD>biological process</TD><TD>GO:0007420</TD><TD>653</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,ZIC2,MSX1,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>3.123e-03</TD><TD>-5.77</TD><TD>trabecula morphogenesis</TD><TD>biological process</TD><TD>GO:0061383</TD><TD>37</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>3.131e-03</TD><TD>-5.77</TD><TD>ovary-carcinoma-clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-clear_cell_carcinoma</TD><TD>687</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,RNF43,TNIK,CAMK2D,NR2F2,TANK</TD></TR>
<TR><TD>3.148e-03</TD><TD>-5.76</TD><TD>KRAS.300_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.300_UP.V1_UP</TD><TD>134</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,FGF9,ANGPTL4</TD></TR>
<TR><TD>3.148e-03</TD><TD>-5.76</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>134</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,NR2F2,NR2F1</TD></TR>
<TR><TD>3.152e-03</TD><TD>-5.76</TD><TD>muscle cell development</TD><TD>biological process</TD><TD>GO:0055001</TD><TD>131</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>3.202e-03</TD><TD>-5.74</TD><TD>LRIF1 (ligand dependent nuclear receptor interacting factor 1)</TD><TD>protein interactions</TD><TD>55791</TD><TD>136</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4,VIM,PPARG</TD></TR>
<TR><TD>3.202e-03</TD><TD>-5.74</TD><TD>regulation of catalytic activity</TD><TD>biological process</TD><TD>GO:0050790</TD><TD>2284</TD><TD>12</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,CD44,NR2F2,ANGPTL4,MMP16,PKIB</TD></TR>
<TR><TD>3.223e-03</TD><TD>-5.74</TD><TD>clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell_carcinoma</TD><TD>691</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,RNF43,TNIK,CAMK2D,NR2F2,TANK</TD></TR>
<TR><TD>3.239e-03</TD><TD>-5.73</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>462</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,MSX1,ITGB4,NT5E,VSNL1</TD></TR>
<TR><TD>3.274e-03</TD><TD>-5.72</TD><TD>human chr8q23.3</TD><TD>chromosome location</TD><TD>human chr8q23.3</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>CSMD3</TD></TR>
<TR><TD>3.274e-03</TD><TD>-5.72</TD><TD>human chr1q42.11-q42.3</TD><TD>chromosome location</TD><TD>human chr1q42.11-q42.3</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>RHOU</TD></TR>
<TR><TD>3.274e-03</TD><TD>-5.72</TD><TD>human chr5p14.1</TD><TD>chromosome location</TD><TD>human chr5p14.1</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>LINC01021</TD></TR>
<TR><TD>3.292e-03</TD><TD>-5.72</TD><TD>hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035137</TD><TD>38</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.303e-03</TD><TD>-5.71</TD><TD>muscle structure development</TD><TD>biological process</TD><TD>GO:0061061</TD><TD>454</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,MSX1,NEBL,NR2F2,PDLIM5</TD></TR>
<TR><TD>3.308e-03</TD><TD>-5.71</TD><TD>GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP</TD><TD>39</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,PDE10A</TD></TR>
<TR><TD>3.308e-03</TD><TD>-5.71</TD><TD>TOMLINS_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>TOMLINS_PROSTATE_CANCER_DN</TD><TD>39</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>3.322e-03</TD><TD>-5.71</TD><TD>positive regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010628</TD><TD>1690</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,ZIC2,WNT16,NR2F2,CD44</TD></TR>
<TR><TD>3.325e-03</TD><TD>-5.71</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4013</TD><TD>17</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,S100A10,PDE10A,TANK,UNC13A,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>3.359e-03</TD><TD>-5.70</TD><TD>mesenchymal cell differentiation</TD><TD>biological process</TD><TD>GO:0048762</TD><TD>134</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>3.362e-03</TD><TD>-5.70</TD><TD>CD44</TD><TD>prints domains</TD><TD>PR00658</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>CD44</TD></TR>
<TR><TD>3.362e-03</TD><TD>-5.70</TD><TD>PROXISOMPAGR</TD><TD>prints domains</TD><TD>PR01291</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.362e-03</TD><TD>-5.70</TD><TD>WNT16PROTEIN</TD><TD>prints domains</TD><TD>PR01895</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.362e-03</TD><TD>-5.70</TD><TD>APYRASEFAMLY</TD><TD>prints domains</TD><TD>PR01607</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.373e-03</TD><TD>-5.69</TD><TD>negative regulation of cell death</TD><TD>biological process</TD><TD>GO:0060548</TD><TD>894</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,WNT16,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>3.420e-03</TD><TD>-5.68</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>138</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SORCS2,PPARG,NT5E</TD></TR>
<TR><TD>3.474e-03</TD><TD>-5.66</TD><TD>CTTTAAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTTTAAR_UNKNOWN</TD><TD>918</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX2,ZIC2,NR2F2,PDE10A,STXBP6,VSNL1</TD></TR>
<TR><TD>3.476e-03</TD><TD>-5.66</TD><TD>ion binding</TD><TD>molecular function</TD><TD>GO:0043167</TD><TD>5991</TD><TD>22</TD><TD>16491</TD><TD>37</TD>
<TD>TNIK,FGF9,PPARG,STXBP6,SLK,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,CAMK2D,S100A10,PDE10A,UNC13A,TANK,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>3.478e-03</TD><TD>-5.66</TD><TD>PHOSPHORIC_DIESTER_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>PHOSPHORIC_DIESTER_HYDROLASE_ACTIVITY</TD><TD>40</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.495e-03</TD><TD>-5.66</TD><TD>muscle tissue development</TD><TD>biological process</TD><TD>GO:0060537</TD><TD>280</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,NR2F2,PDLIM5</TD></TR>
<TR><TD>3.517e-03</TD><TD>-5.65</TD><TD>ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>MSigDB lists</TD><TD>ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>471</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CAMK2D,PDLIM5,SLK,ANGPTL4</TD></TR>
<TR><TD>3.561e-03</TD><TD>-5.64</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_DN</TD><TD>140</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,SLK,C1orf226</TD></TR>
<TR><TD>3.597e-03</TD><TD>-5.63</TD><TD>TNPO2 (transportin 2)</TD><TD>protein interactions</TD><TD>30000</TD><TD>41</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D,NT5E</TD></TR>
<TR><TD>3.651e-03</TD><TD>-5.61</TD><TD>MIKKELSEN_ES_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_ES_HCP_WITH_H3K27ME3</TD><TD>41</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>3.706e-03</TD><TD>-5.60</TD><TD>GCCNNNWTAAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GCCNNNWTAAR_UNKNOWN</TD><TD>142</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,CAMK2D,MSX1</TD></TR>
<TR><TD>3.706e-03</TD><TD>-5.60</TD><TD>HALLMARK_UV_RESPONSE_DN</TD><TD>MSigDB lists</TD><TD>HALLMARK_UV_RESPONSE_DN</TD><TD>142</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,PDLIM5,MMP16</TD></TR>
<TR><TD>3.761e-03</TD><TD>-5.58</TD><TD>ERBB2 (erb-b2 receptor tyrosine kinase 2)</TD><TD>protein interactions</TD><TD>2064</TD><TD>144</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4,CD44,MMP16</TD></TR>
<TR><TD>3.772e-03</TD><TD>-5.58</TD><TD>TRIP4 (thyroid hormone receptor interactor 4)</TD><TD>protein interactions</TD><TD>9325</TD><TD>42</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>3.772e-03</TD><TD>-5.58</TD><TD>DST (dystonin)</TD><TD>protein interactions</TD><TD>667</TD><TD>42</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK,ITGB4</TD></TR>
<TR><TD>3.824e-03</TD><TD>-5.57</TD><TD>purine nucleobase metabolic process</TD><TD>biological process</TD><TD>GO:0006144</TD><TD>41</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.864e-03</TD><TD>-5.56</TD><TD>skeletal system development</TD><TD>biological process</TD><TD>GO:0001501</TD><TD>471</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,CD44,MMP16</TD></TR>
<TR><TD>3.905e-03</TD><TD>-5.55</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>11219</TD><TD>32</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,C1orf226,CLSTN2,RNF43,PDE3A,NEBL,S100A10,PDE10A,UNC13A,WNT16,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,CAMK2D,MSX2,CSMD3,SLCO5A1,ITGB4,NR2F2,SORCS2,PDLIM5,MMP16</TD></TR>
<TR><TD>3.930e-03</TD><TD>-5.54</TD><TD>BROWNE_HCMV_INFECTION_24HR_DN</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_24HR_DN</TD><TD>145</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,S100A10,CD44</TD></TR>
<TR><TD>4.002e-03</TD><TD>-5.52</TD><TD>cellular response to hormone stimulus</TD><TD>biological process</TD><TD>GO:0032870</TD><TD>687</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.006e-03</TD><TD>-5.52</TD><TD>ACCTGTTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ACCTGTTG_UNKNOWN</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,RNF43,MMP16</TD></TR>
<TR><TD>4.006e-03</TD><TD>-5.52</TD><TD>GSE13485_DAY3_VS_DAY21_YF17D_VACCINE_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE13485_DAY3_VS_DAY21_YF17D_VACCINE_PBMC_DN</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>WNT16,PPARG,PRPS1</TD></TR>
<TR><TD>4.006e-03</TD><TD>-5.52</TD><TD>PHOSPHORIC_ESTER_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>PHOSPHORIC_ESTER_HYDROLASE_ACTIVITY</TD><TD>146</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>4.009e-03</TD><TD>-5.52</TD><TD>forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035136</TD><TD>42</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.009e-03</TD><TD>-5.52</TD><TD>KRASNOSELSKAYA_ILF3_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>KRASNOSELSKAYA_ILF3_TARGETS_DN</TD><TD>43</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,NT5E</TD></TR>
<TR><TD>4.084e-03</TD><TD>-5.50</TD><TD>IGLESIAS_E2F_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>IGLESIAS_E2F_TARGETS_UP</TD><TD>147</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,S100A10,TANK</TD></TR>
<TR><TD>4.158e-03</TD><TD>-5.48</TD><TD>regulation of cell division</TD><TD>biological process</TD><TD>GO:0051302</TD><TD>294</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,PDE3A</TD></TR>
<TR><TD>4.176e-03</TD><TD>-5.48</TD><TD>head development</TD><TD>biological process</TD><TD>GO:0060322</TD><TD>693</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,FGF9,MSX1,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>4.192e-03</TD><TD>-5.47</TD><TD>cellular response to inorganic substance</TD><TD>biological process</TD><TD>GO:0071241</TD><TD>145</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,CAMK2D,PPARG</TD></TR>
<TR><TD>4.195e-03</TD><TD>-5.47</TD><TD>BURTON_ADIPOGENESIS_4</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_4</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,ANGPTL4</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>PKK</TD><TD>interpro domains</TD><TD>IPR022165</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLK</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>Sec3-PIP2_bind</TD><TD>interpro domains</TD><TD>IPR028258</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.293e-03</TD><TD>-5.45</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4106</TD><TD>17</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG,VSNL1,CLSTN2,RNF43,ZIC2,PDE3A,NR2F1,RHOU,S100A10,PDE10A,TANK,UNC13A,NR2F2,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>4.321e-03</TD><TD>-5.44</TD><TD>macrophage migration inhibitory factor receptor complex</TD><TD>cellular component</TD><TD>GO:0035692</TD><TD>2</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>CD44</TD></TR>
<TR><TD>4.356e-03</TD><TD>-5.44</TD><TD>cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0048738</TD><TD>147</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>4.356e-03</TD><TD>-5.44</TD><TD>morphogenesis of embryonic epithelium</TD><TD>biological process</TD><TD>GO:0016331</TD><TD>147</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,WNT16,GRHL3</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>ZDHHC2 (zinc finger, DHHC-type containing 2)</TD><TD>protein interactions</TD><TD>51201</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>RNF180 (ring finger protein 180)</TD><TD>protein interactions</TD><TD>285671</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>Foxo1 (forkhead box O1)</TD><TD>protein interactions</TD><TD>56458</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>DMP1 (dentin matrix acidic phosphoprotein 1)</TD><TD>protein interactions</TD><TD>1758</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>Fbxo45 (F-box protein 45)</TD><TD>protein interactions</TD><TD>268882</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>UNC13A</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>FAM171B (family with sequence similarity 171, member B)</TD><TD>protein interactions</TD><TD>165215</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>ARMCX2 (armadillo repeat containing, X-linked 2)</TD><TD>protein interactions</TD><TD>9823</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>Ncor1 (nuclear receptor co-repressor 1)</TD><TD>protein interactions</TD><TD>20185</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>GRHL1 (grainyhead-like transcription factor 1)</TD><TD>protein interactions</TD><TD>29841</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>Tbk1 (TANK-binding kinase 1)</TD><TD>protein interactions</TD><TD>56480</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>4.361e-03</TD><TD>-5.44</TD><TD>DACT2 (dishevelled-binding antagonist of beta-catenin 2)</TD><TD>protein interactions</TD><TD>168002</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.404e-03</TD><TD>-5.43</TD><TD>oesophagus-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-adenocarcinoma</TD><TD>13776</TD><TD>36</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.415e-03</TD><TD>-5.42</TD><TD>response to metal ion</TD><TD>biological process</TD><TD>GO:0010038</TD><TD>299</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,CAMK2D,PPARG,NT5E</TD></TR>
<TR><TD>4.482e-03</TD><TD>-5.41</TD><TD>cGMP-inhibited cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004119</TD><TD>2</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>urate biosynthetic process</TD><TD>biological process</TD><TD>GO:0034418</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>low-density lipoprotein receptor particle metabolic process</TD><TD>biological process</TD><TD>GO:0032799</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>regulation of cholesterol transporter activity</TD><TD>biological process</TD><TD>GO:0060694</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>divalent metal ion export</TD><TD>biological process</TD><TD>GO:0070839</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>response to diuretic</TD><TD>biological process</TD><TD>GO:0036270</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>regulation of pancreatic stellate cell proliferation</TD><TD>biological process</TD><TD>GO:2000229</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>lymphatic endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060838</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>positive regulation of Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0035022</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>AMP catabolic process</TD><TD>biological process</TD><TD>GO:0006196</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>Wnt receptor catabolic process</TD><TD>biological process</TD><TD>GO:0038018</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>cardiac muscle cell contraction</TD><TD>biological process</TD><TD>GO:0086003</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>regulation of transcription involved in lymphatic endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060849</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.496e-03</TD><TD>-5.40</TD><TD>regulation of transcription from RNA polymerase II promoter in response to iron</TD><TD>biological process</TD><TD>GO:0034395</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>4.510e-03</TD><TD>-5.40</TD><TD>CAMK2D (calcium/calmodulin-dependent protein kinase II delta)</TD><TD>protein interactions</TD><TD>817</TD><TD>46</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>4.523e-03</TD><TD>-5.40</TD><TD>appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035107</TD><TD>149</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX2,MSX1</TD></TR>
<TR><TD>4.523e-03</TD><TD>-5.40</TD><TD>limb morphogenesis</TD><TD>biological process</TD><TD>GO:0035108</TD><TD>149</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX2,MSX1</TD></TR>
<TR><TD>4.526e-03</TD><TD>-5.40</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>308</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,S100A10,PDLIM5,NT5E</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>Sec3-PIP2_bind</TD><TD>pfam domains</TD><TD>PF15277</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>PKK</TD><TD>pfam domains</TD><TD>PF12474</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SLK</TD></TR>
<TR><TD>4.577e-03</TD><TD>-5.39</TD><TD>KHETCHOUMIAN_TRIM24_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KHETCHOUMIAN_TRIM24_TARGETS_UP</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>4.577e-03</TD><TD>-5.39</TD><TD>NUTT_GBM_VS_AO_GLIOMA_UP</TD><TD>MSigDB lists</TD><TD>NUTT_GBM_VS_AO_GLIOMA_UP</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>4.577e-03</TD><TD>-5.39</TD><TD>SESTO_RESPONSE_TO_UV_C5</TD><TD>MSigDB lists</TD><TD>SESTO_RESPONSE_TO_UV_C5</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,SLK</TD></TR>
<TR><TD>4.577e-03</TD><TD>-5.39</TD><TD>PID_A6B1_A6B4_INTEGRIN_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_A6B1_A6B4_INTEGRIN_PATHWAY</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>4.589e-03</TD><TD>-5.38</TD><TD>RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN</TD><TD>722</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,VIM,SLC40A1,CD44,NR2F2,PDLIM5</TD></TR>
<TR><TD>4.590e-03</TD><TD>-5.38</TD><TD>regulation of cardiac muscle tissue development</TD><TD>biological process</TD><TD>GO:0055024</TD><TD>45</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>4.736e-03</TD><TD>-5.35</TD><TD>purine ribonucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009150</TD><TD>305</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>4.771e-03</TD><TD>-5.35</TD><TD>regulation of cell cycle</TD><TD>biological process</TD><TD>GO:0051726</TD><TD>952</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,MSX1,NR2F2,SLK,PDE3A</TD></TR>
<TR><TD>4.773e-03</TD><TD>-5.34</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>MSigDB lists</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>47</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>4.773e-03</TD><TD>-5.34</TD><TD>KRAS.50_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.50_UP.V1_UP</TD><TD>47</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ANGPTL4</TD></TR>
<TR><TD>4.821e-03</TD><TD>-5.33</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>156</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NR2F2,TANK</TD></TR>
<TR><TD>4.878e-03</TD><TD>-5.32</TD><TD>positive regulation of molecular function</TD><TD>biological process</TD><TD>GO:0044093</TD><TD>1782</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,ZIC2,MMP16,PKIB</TD></TR>
<TR><TD>4.906e-03</TD><TD>-5.32</TD><TD>human chr13q11-q12</TD><TD>chromosome location</TD><TD>human chr13q11-q12</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.935e-03</TD><TD>-5.31</TD><TD>sensory organ development</TD><TD>biological process</TD><TD>GO:0007423</TD><TD>499</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,FGF9,MSX1,WNT16,GRHL3</TD></TR>
<TR><TD>4.974e-03</TD><TD>-5.30</TD><TD>LEE_AGING_MUSCLE_DN</TD><TD>MSigDB lists</TD><TD>LEE_AGING_MUSCLE_DN</TD><TD>48</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,NR2F1</TD></TR>
<TR><TD>4.998e-03</TD><TD>-5.30</TD><TD>negative regulation of DNA binding</TD><TD>biological process</TD><TD>GO:0043392</TD><TD>47</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>5.066e-03</TD><TD>-5.29</TD><TD>cellular component morphogenesis</TD><TD>biological process</TD><TD>GO:0032989</TD><TD>1223</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,MSX2,MSX1,NEBL,WNT16</TD></TR>
<TR><TD>5.103e-03</TD><TD>-5.28</TD><TD>DPYSL2 (dihydropyrimidinase-like 2)</TD><TD>protein interactions</TD><TD>1808</TD><TD>49</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK,PDE3A</TD></TR>
<TR><TD>5.178e-03</TD><TD>-5.26</TD><TD>WANG_BARRETTS_ESOPHAGUS_UP</TD><TD>MSigDB lists</TD><TD>WANG_BARRETTS_ESOPHAGUS_UP</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NR2F2</TD></TR>
<TR><TD>5.178e-03</TD><TD>-5.26</TD><TD>EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION</TD><TD>MSigDB lists</TD><TD>EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>5.178e-03</TD><TD>-5.26</TD><TD>MODULE_485</TD><TD>MSigDB lists</TD><TD>MODULE_485</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,MSX2</TD></TR>
<TR><TD>5.208e-03</TD><TD>-5.26</TD><TD>positive regulation of muscle organ development</TD><TD>biological process</TD><TD>GO:0048636</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>5.208e-03</TD><TD>-5.26</TD><TD>actin-mediated cell contraction</TD><TD>biological process</TD><TD>GO:0070252</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>5.208e-03</TD><TD>-5.26</TD><TD>positive regulation of striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0045844</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>5.232e-03</TD><TD>-5.25</TD><TD>regulation of nuclear division</TD><TD>biological process</TD><TD>GO:0051783</TD><TD>157</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,PDE3A</TD></TR>
<TR><TD>5.237e-03</TD><TD>-5.25</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_UP</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_UP</TD><TD>321</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5,PRPS1,TANK,PDE3A</TD></TR>
<TR><TD>5.258e-03</TD><TD>-5.25</TD><TD>ANATOMICAL_STRUCTURE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>ANATOMICAL_STRUCTURE_DEVELOPMENT</TD><TD>990</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,SLC40A1,MSX2,ZIC2,MSX1,PRPS1,ANGPTL4</TD></TR>
<TR><TD>5.354e-03</TD><TD>-5.23</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>162</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,NEBL,NR2F1</TD></TR>
<TR><TD>5.354e-03</TD><TD>-5.23</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_2H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_2H_ACT_CD4_TCELL_UP</TD><TD>162</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,CAMK2D,MMP16</TD></TR>
<TR><TD>5.377e-03</TD><TD>-5.23</TD><TD>negative regulation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0000122</TD><TD>730</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>5.411e-03</TD><TD>-5.22</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>MSigDB lists</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>324</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,FGF9,WNT16,PPARG</TD></TR>
<TR><TD>5.411e-03</TD><TD>-5.22</TD><TD>movement of cell or subcellular component</TD><TD>biological process</TD><TD>GO:0006928</TD><TD>1515</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,VIM,ITGB4,NR2F2,CD44,NR2F1</TD></TR>
<TR><TD>5.422e-03</TD><TD>-5.22</TD><TD>regulation of signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:1901796</TD><TD>49</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>5.422e-03</TD><TD>-5.22</TD><TD>positive regulation of muscle tissue development</TD><TD>biological process</TD><TD>GO:1901863</TD><TD>49</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>5.446e-03</TD><TD>-5.21</TD><TD>WNT_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>WNT_UP.V1_DN</TD><TD>163</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,VIM,CD44</TD></TR>
<TR><TD>5.499e-03</TD><TD>-5.20</TD><TD>NR3C1 (nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor))</TD><TD>protein interactions</TD><TD>2908</TD><TD>165</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,NR2F2,PPARG</TD></TR>
<TR><TD>5.513e-03</TD><TD>-5.20</TD><TD>adenosine nucleotides degradation II</TD><TD>BIOCYC pathways</TD><TD>META_SALVADEHYPOX-PWY</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>5.513e-03</TD><TD>-5.20</TD><TD>urate biosynthesis/inosine 5'-phosphate degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-5695</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>5.553e-03</TD><TD>-5.19</TD><TD>positive regulation of catalytic activity</TD><TD>biological process</TD><TD>GO:0043085</TD><TD>1521</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,S100A10,PPARG,SLK,GRHL3,MMP16,PKIB</TD></TR>
<TR><TD>5.580e-03</TD><TD>-5.19</TD><TD>synapse part</TD><TD>cellular component</TD><TD>GO:0044456</TD><TD>534</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>CLSTN2,SLC40A1,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>5.599e-03</TD><TD>-5.19</TD><TD>PID_CASPASE_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_CASPASE_PATHWAY</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,SLK</TD></TR>
<TR><TD>5.599e-03</TD><TD>-5.19</TD><TD>chr6q21</TD><TD>MSigDB lists</TD><TD>chr6q21</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PKIB</TD></TR>
<TR><TD>5.608e-03</TD><TD>-5.18</TD><TD>ribonucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009259</TD><TD>320</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>5.633e-03</TD><TD>-5.18</TD><TD>GSE6269_HEALTHY_VS_STREP_AUREUS_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_HEALTHY_VS_STREP_AUREUS_INF_PBMC_DN</TD><TD>165</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,VIM,S100A10</TD></TR>
<TR><TD>5.708e-03</TD><TD>-5.17</TD><TD>bone development</TD><TD>biological process</TD><TD>GO:0060348</TD><TD>162</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>5.774e-03</TD><TD>-5.15</TD><TD>regulation of transferase activity</TD><TD>biological process</TD><TD>GO:0051338</TD><TD>986</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,PPARG,SLK,PKIB</TD></TR>
<TR><TD>5.815e-03</TD><TD>-5.15</TD><TD>V$CDPCR3_01</TD><TD>MSigDB lists</TD><TD>V$CDPCR3_01</TD><TD>52</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,PPARG</TD></TR>
<TR><TD>5.854e-03</TD><TD>-5.14</TD><TD>cellular response to growth factor stimulus</TD><TD>biological process</TD><TD>GO:0071363</TD><TD>743</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,CD44,PDE3A</TD></TR>
<TR><TD>5.860e-03</TD><TD>-5.14</TD><TD>astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astrocytoma_Grade_III</TD><TD>1611</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,MSX2,CAMK2D,UNC13A,CSMD3,SLCO5A1,CLSTN2,PDLIM5,NT5E</TD></TR>
<TR><TD>5.913e-03</TD><TD>-5.13</TD><TD>positive regulation of organelle organization</TD><TD>biological process</TD><TD>GO:0010638</TD><TD>521</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,MSX1,S100A10,PKIB</TD></TR>
<TR><TD>5.921e-03</TD><TD>-5.13</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_UP</TD><TD>168</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,S100A10,NR2F2</TD></TR>
<TR><TD>5.921e-03</TD><TD>-5.13</TD><TD>regionalization</TD><TD>biological process</TD><TD>GO:0003002</TD><TD>325</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,NR2F2,NR2F1</TD></TR>
<TR><TD>5.964e-03</TD><TD>-5.12</TD><TD>Extracellular matrix organization</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474244</TD><TD>267</TD><TD>4</TD><TD>8202</TD><TD>23</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>5.985e-03</TD><TD>-5.12</TD><TD>eye development</TD><TD>biological process</TD><TD>GO:0001654</TD><TD>326</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,FGF9,WNT16,GRHL3</TD></TR>
<TR><TD>6.007e-03</TD><TD>-5.11</TD><TD>response to wounding</TD><TD>biological process</TD><TD>GO:0009611</TD><TD>747</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ITGB4,CD44,PDE10A,PDE3A,GRHL3</TD></TR>
<TR><TD>6.050e-03</TD><TD>-5.11</TD><TD>purine nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0006163</TD><TD>327</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>6.050e-03</TD><TD>-5.11</TD><TD>Non-integrin membrane-ECM interactions</TD><TD>REACTOME pathways</TD><TD>R-HSA-3000171</TD><TD>42</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>LAMA4,ITGB4</TD></TR>
<TR><TD>6.088e-03</TD><TD>-5.10</TD><TD>endochondral bone morphogenesis</TD><TD>biological process</TD><TD>GO:0060350</TD><TD>52</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MMP16</TD></TR>
<TR><TD>6.146e-03</TD><TD>-5.09</TD><TD>NABA_SECRETED_FACTORS</TD><TD>MSigDB lists</TD><TD>NABA_SECRETED_FACTORS</TD><TD>336</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,WNT16,S100A10,ANGPTL4</TD></TR>
<TR><TD>6.152e-03</TD><TD>-5.09</TD><TD>response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0009719</TD><TD>1545</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,PPARG,NR2F2,CD44,PDE3A,NR2F1</TD></TR>
<TR><TD>6.173e-03</TD><TD>-5.09</TD><TD>ovary</TD><TD>COSMIC cancer mutations</TD><TD>ovary</TD><TD>15550</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>6.218e-03</TD><TD>-5.08</TD><TD>BENPORATH_NOS_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_NOS_TARGETS</TD><TD>171</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ZIC2,NEBL</TD></TR>
<TR><TD>6.260e-03</TD><TD>-5.07</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>792</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,SORCS2,PDLIM5,ANGPTL4,PDE3A</TD></TR>
<TR><TD>6.279e-03</TD><TD>-5.07</TD><TD>Cortical thickness(PMID:22792071)</TD><TD>GWAS genes</TD><TD>Cortical thickness(PMID:22792071)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>WNT16</TD></TR>
<TR><TD>6.279e-03</TD><TD>-5.07</TD><TD>Bone mineral density(PMID:22792071)</TD><TD>GWAS genes</TD><TD>Bone mineral density(PMID:22792071)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>WNT16</TD></TR>
<TR><TD>6.295e-03</TD><TD>-5.07</TD><TD>neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>neoplasm</TD><TD>15558</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>6.319e-03</TD><TD>-5.06</TD><TD>PTEN_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>PTEN_DN.V1_DN</TD><TD>172</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,VIM,WNT16</TD></TR>
<TR><TD>6.350e-03</TD><TD>-5.06</TD><TD>regulation of cell morphogenesis</TD><TD>biological process</TD><TD>GO:0022604</TD><TD>530</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,TNIK,S100A10,PDLIM5,UNC13A</TD></TR>
<TR><TD>6.379e-03</TD><TD>-5.05</TD><TD>ribose phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0019693</TD><TD>332</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>1Cnucl_rcpt</TD><TD>interpro domains</TD><TD>IPR003074</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>TBD</TD><TD>interpro domains</TD><TD>IPR024581</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TANK</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>cAMP_dep_PKI</TD><TD>interpro domains</TD><TD>IPR004171</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PKIB</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>PRib_PP_synth_CS</TD><TD>interpro domains</TD><TD>IPR000842</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Unc-13</TD><TD>interpro domains</TD><TD>IPR027080</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>UNC13A</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Calsyntenin</TD><TD>interpro domains</TD><TD>IPR026914</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CLSTN2</TD></TR>
<TR><TD>6.392e-03</TD><TD>-5.05</TD><TD>ANP32A (acidic nuclear phosphoprotein 32 family member A)</TD><TD>protein interactions</TD><TD>8125</TD><TD>55</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>6.400e-03</TD><TD>-5.05</TD><TD>NS-other-Krukenberg_tumour</TD><TD>COSMIC cancer mutations</TD><TD>NS-other-Krukenberg_tumour</TD><TD>3</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>6.471e-03</TD><TD>-5.04</TD><TD>CASP3 (caspase 3)</TD><TD>protein interactions</TD><TD>836</TD><TD>175</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PDE10A,SLK</TD></TR>
<TR><TD>6.523e-03</TD><TD>-5.03</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_DN</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_DN</TD><TD>174</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CD44,MMP16</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>CLCA2 (chloride channel accessory 2)</TD><TD>protein interactions</TD><TD>9635</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>RHBDL2 (rhomboid, veinlet-like 2 (Drosophila))</TD><TD>protein interactions</TD><TD>54933</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2)</TD><TD>protein interactions</TD><TD>5168</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>GRHL2 (grainyhead-like transcription factor 2)</TD><TD>protein interactions</TD><TD>79977</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>GRHL3</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>PLA2G4C (phospholipase A2, group IVC (cytosolic, calcium-independent))</TD><TD>protein interactions</TD><TD>8605</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>UPP2 (uridine phosphorylase 2)</TD><TD>protein interactions</TD><TD>151531</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>SLC6A8 (solute carrier family 6 (neurotransmitter transporter), member 8)</TD><TD>protein interactions</TD><TD>6535</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>ALOX15B (arachidonate 15-lipoxygenase, type B)</TD><TD>protein interactions</TD><TD>247</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>HAMP (hepcidin antimicrobial peptide)</TD><TD>protein interactions</TD><TD>57817</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>CYP2S1 (cytochrome P450, family 2, subfamily S, polypeptide 1)</TD><TD>protein interactions</TD><TD>29785</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>LY6D (lymphocyte antigen 6 complex, locus D)</TD><TD>protein interactions</TD><TD>8581</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PKIB</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>MAP7D2 (MAP7 domain containing 2)</TD><TD>protein interactions</TD><TD>256714</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>URGCP (upregulator of cell proliferation)</TD><TD>protein interactions</TD><TD>55665</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>6.534e-03</TD><TD>-5.03</TD><TD>CLCA1 (chloride channel accessory 1)</TD><TD>protein interactions</TD><TD>1179</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>6.571e-03</TD><TD>-5.03</TD><TD>plasma membrane</TD><TD>cellular component</TD><TD>GO:0005886</TD><TD>4806</TD><TD>18</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,TNIK,SLC40A1,STXBP6,CLSTN2,VIM,RNF43,RHOU,CAMK2D,S100A10,UNC13A,SLCO5A1,CSMD3,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>6.615e-03</TD><TD>-5.02</TD><TD>urate biosynthesis/inosine 5'-phosphate degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-5695</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>MSigDB lists</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5,ANGPTL4</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>KEGG_HEDGEHOG_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_HEDGEHOG_SIGNALING_PATHWAY</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>ferrous iron transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0015093</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004118</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A</TD></TR>
<TR><TD>6.732e-03</TD><TD>-5.00</TD><TD>response to growth factor</TD><TD>biological process</TD><TD>GO:0070848</TD><TD>765</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,CD44,PDE3A</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>ferrous iron transmembrane transport</TD><TD>biological process</TD><TD>GO:1903874</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>regulation of monocyte aggregation</TD><TD>biological process</TD><TD>GO:1900623</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>positive regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900224</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>cellular response to vitamin E</TD><TD>biological process</TD><TD>GO:0071306</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>positive regulation of monocyte aggregation</TD><TD>biological process</TD><TD>GO:1900625</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>optic cup formation involved in camera-type eye development</TD><TD>biological process</TD><TD>GO:0003408</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902255</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>monocyte aggregation</TD><TD>biological process</TD><TD>GO:0070487</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>6.737e-03</TD><TD>-5.00</TD><TD>positive regulation of catagen</TD><TD>biological process</TD><TD>GO:0051795</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>6.753e-03</TD><TD>-5.00</TD><TD>response to stimulus</TD><TD>biological process</TD><TD>GO:0050896</TD><TD>7571</TD><TD>25</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,TNIK,FGF9,MSX1,PPARG,SLK,GRHL3,VIM,RNF43,ANGPTL4,PDE3A,NR2F1,RHOU,MSX2,CAMK2D,PDE10A,TANK,UNC13A,WNT16,ITGB4,CD44,NR2F2,SORCS2,NT5E</TD></TR>
<TR><TD>6.838e-03</TD><TD>-4.99</TD><TD>E2F3_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>E2F3_UP.V1_UP</TD><TD>177</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NR2F1</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>TBD</TD><TD>pfam domains</TD><TD>PF12845</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TANK</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>PKI</TD><TD>pfam domains</TD><TD>PF02827</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PKIB</TD></TR>
<TR><TD>6.872e-03</TD><TD>-4.98</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>2630</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,CAMK2D,STXBP6,UNC13A,CLSTN2,CSMD3,SLCO5A1,VIM,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>6.877e-03</TD><TD>-4.98</TD><TD>whole membrane</TD><TD>cellular component</TD><TD>GO:0098805</TD><TD>1942</TD><TD>10</TD><TD>17570</TD><TD>38</TD>
<TD>TNIK,SLC40A1,CAMK2D,S100A10,UNC13A,CLSTN2,ITGB4,CD44,PDLIM5,NT5E</TD></TR>
<TR><TD>6.983e-03</TD><TD>-4.96</TD><TD>serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>serous_carcinoma</TD><TD>11513</TD><TD>32</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,C1orf226,CLSTN2,RNF43,PDE3A,NEBL,S100A10,PDE10A,UNC13A,WNT16,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,CAMK2D,MSX2,CSMD3,SLCO5A1,ITGB4,NR2F2,SORCS2,PDLIM5,MMP16</TD></TR>
<TR><TD>7.084e-03</TD><TD>-4.95</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>MSigDB lists</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>350</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4,S100A10,TANK</TD></TR>
<TR><TD>7.086e-03</TD><TD>-4.95</TD><TD>ZHX1 (zinc fingers and homeoboxes 1)</TD><TD>protein interactions</TD><TD>11244</TD><TD>58</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4,VIM</TD></TR>
<TR><TD>7.161e-03</TD><TD>-4.94</TD><TD>GCAAAAA,MIR-129</TD><TD>MSigDB lists</TD><TD>GCAAAAA,MIR-129</TD><TD>180</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,NEBL,PDLIM5</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>REACTOME_INTERFERON_GAMMA_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_INTERFERON_GAMMA_SIGNALING</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>SANSOM_WNT_PATHWAY_REQUIRE_MYC</TD><TD>MSigDB lists</TD><TD>SANSOM_WNT_PATHWAY_REQUIRE_MYC</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>7.271e-03</TD><TD>-4.92</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_LOW_DOSE_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_LOW_DOSE_MAC_UP</TD><TD>181</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CD44,TANK</TD></TR>
<TR><TD>7.271e-03</TD><TD>-4.92</TD><TD>TGFB_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>TGFB_UP.V1_DN</TD><TD>181</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,NR2F2,ANGPTL4</TD></TR>
<TR><TD>7.276e-03</TD><TD>-4.92</TD><TD>MARTINEZ_TP53_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MARTINEZ_TP53_TARGETS_DN</TD><TD>560</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,MSX2,S100A10,PDE3A,NR2F1</TD></TR>
<TR><TD>7.276e-03</TD><TD>-4.92</TD><TD>positive regulation of nuclear division</TD><TD>biological process</TD><TD>GO:0051785</TD><TD>57</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>7.306e-03</TD><TD>-4.92</TD><TD>other</TD><TD>COSMIC cancer mutations</TD><TD>other</TD><TD>15619</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>7.360e-03</TD><TD>-4.91</TD><TD>large_cell</TD><TD>COSMIC cancer mutations</TD><TD>large_cell</TD><TD>15622</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>7.364e-03</TD><TD>-4.91</TD><TD>organonitrogen compound catabolic process</TD><TD>biological process</TD><TD>GO:1901565</TD><TD>346</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CD44,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>7.381e-03</TD><TD>-4.91</TD><TD>E2F1_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>E2F1_UP.V1_DN</TD><TD>182</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ANGPTL4,TANK</TD></TR>
<TR><TD>7.381e-03</TD><TD>-4.91</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP</TD><TD>182</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10,TANK</TD></TR>
<TR><TD>7.431e-03</TD><TD>-4.90</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP</TD><TD>59</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,NR2F2</TD></TR>
<TR><TD>7.480e-03</TD><TD>-4.90</TD><TD>SMAD3 (SMAD family member 3)</TD><TD>protein interactions</TD><TD>4088</TD><TD>359</TD><TD>4</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,ITGB4,PPARG,TANK</TD></TR>
<TR><TD>7.493e-03</TD><TD>-4.89</TD><TD>GSE13306_LAMINA_PROPRIA_VS_SPLEEN_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE13306_LAMINA_PROPRIA_VS_SPLEEN_TREG_DN</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,ANGPTL4,NR2F1</TD></TR>
<TR><TD>7.493e-03</TD><TD>-4.89</TD><TD>LEF1_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>LEF1_UP.V1_UP</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,VIM,PRPS1</TD></TR>
<TR><TD>7.493e-03</TD><TD>-4.89</TD><TD>GSE3982_BCELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_BCELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PDE10A,PDE3A</TD></TR>
<TR><TD>7.515e-03</TD><TD>-4.89</TD><TD>striated muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051146</TD><TD>179</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>7.525e-03</TD><TD>-4.89</TD><TD>cyclic nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009187</TD><TD>58</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>7.606e-03</TD><TD>-4.88</TD><TD>GSE37416_12H_VS_24H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>MSigDB lists</TD><TD>GSE37416_12H_VS_24H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>184</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,ITGB4,CD44</TD></TR>
<TR><TD>7.644e-03</TD><TD>-4.87</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>MSigDB lists</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>1631</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,MSX1,NEBL,SLK,CD44,ITGB4,MMP16,NR2F1,PDE3A</TD></TR>
<TR><TD>7.718e-03</TD><TD>-4.86</TD><TD>adenosine nucleotides degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_SALVADEHYPOX-PWY</TD><TD>7</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>TGASTMAGC_V$NFE2_01</TD><TD>MSigDB lists</TD><TD>TGASTMAGC_V$NFE2_01</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,CD44,ANGPTL4</TD></TR>
<TR><TD>7.735e-03</TD><TD>-4.86</TD><TD>MODULE_1</TD><TD>MSigDB lists</TD><TD>MODULE_1</TD><TD>359</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,CD44,PDLIM5,NR2F1</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>GSE15324_NAIVE_VS_ACTIVATED_ELF4_KO_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE15324_NAIVE_VS_ACTIVATED_ELF4_KO_CD8_TCELL_UP</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,PDLIM5,NT5E</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,CD44,PDE10A</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,S100A10,PDE3A</TD></TR>
<TR><TD>7.880e-03</TD><TD>-4.84</TD><TD>regulation of signal transduction</TD><TD>biological process</TD><TD>GO:0009966</TD><TD>2548</TD><TD>12</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,MSX2,TNIK,CAMK2D,FGF9,MSX1,PPARG,PDE10A,ZIC2,RNF43,WNT16,CD44</TD></TR>
<TR><TD>7.950e-03</TD><TD>-4.83</TD><TD>GSE3982_MAC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PDE10A,STXBP6</TD></TR>
<TR><TD>7.950e-03</TD><TD>-4.83</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PRPS1,NR2F1</TD></TR>
<TR><TD>8.035e-03</TD><TD>-4.82</TD><TD>mammary gland epithelium development</TD><TD>biological process</TD><TD>GO:0061180</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>8.035e-03</TD><TD>-4.82</TD><TD>regulation of DNA biosynthetic process</TD><TD>biological process</TD><TD>GO:2000278</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PKIB</TD></TR>
<TR><TD>8.035e-03</TD><TD>-4.82</TD><TD>embryonic digit morphogenesis</TD><TD>biological process</TD><TD>GO:0042733</TD><TD>60</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>8.037e-03</TD><TD>-4.82</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7</TD><TD>363</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NR2F2,ANGPTL4,NT5E</TD></TR>
<TR><TD>8.067e-03</TD><TD>-4.82</TD><TD>GSE9037_WT_VS_IRAK4_KO_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE9037_WT_VS_IRAK4_KO_BMDM_UP</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,NR2F2,TANK</TD></TR>
<TR><TD>8.067e-03</TD><TD>-4.82</TD><TD>GSE2826_WT_VS_BTK_KO_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE2826_WT_VS_BTK_KO_BCELL_DN</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,MSX2,PPARG</TD></TR>
<TR><TD>8.067e-03</TD><TD>-4.82</TD><TD>GSE13306_RA_VS_UNTREATED_MEM_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE13306_RA_VS_UNTREATED_MEM_CD4_TCELL_DN</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,PRPS1,PKIB</TD></TR>
<TR><TD>8.128e-03</TD><TD>-4.81</TD><TD>positive regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045597</TD><TD>796</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,S100A10,PPARG,UNC13A,PDE3A</TD></TR>
<TR><TD>8.136e-03</TD><TD>-4.81</TD><TD>TGANTCA_V$AP1_C</TD><TD>MSigDB lists</TD><TD>TGANTCA_V$AP1_C</TD><TD>1074</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,CSMD3,FGF9,ITGB4,NEBL,S100A10,ANGPTL4</TD></TR>
<TR><TD>8.156e-03</TD><TD>-4.81</TD><TD>parathyroid-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>parathyroid-adenoma</TD><TD>194</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>MMP16,PDE3A,NT5E</TD></TR>
<TR><TD>8.164e-03</TD><TD>-4.81</TD><TD>human chr5q14</TD><TD>chromosome location</TD><TD>human chr5q14</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>NR2F1</TD></TR>
<TR><TD>8.164e-03</TD><TD>-4.81</TD><TD>human chr13q33</TD><TD>chromosome location</TD><TD>human chr13q33</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>EFNB2</TD></TR>
<TR><TD>8.179e-03</TD><TD>-4.81</TD><TD>PETROVA_PROX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_PROX1_TARGETS_DN</TD><TD>62</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,TANK</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE17721_0.5H_VS_4H_GARDIQUIMOD_BMDM_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_0.5H_VS_4H_GARDIQUIMOD_BMDM_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,CAMK2D,SLK</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>MEK_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>MEK_UP.V1_UP</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,PPARG,ANGPTL4</TD></TR>
<TR><TD>8.224e-03</TD><TD>-4.80</TD><TD>intracellular receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0030522</TD><TD>185</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>8.248e-03</TD><TD>-4.80</TD><TD>monocarboxylic acid binding</TD><TD>molecular function</TD><TD>GO:0033293</TD><TD>61</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>8.290e-03</TD><TD>-4.79</TD><TD>cell periphery</TD><TD>cellular component</TD><TD>GO:0071944</TD><TD>4907</TD><TD>18</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,SLC40A1,TNIK,STXBP6,CLSTN2,VIM,RNF43,RHOU,CAMK2D,S100A10,UNC13A,SLCO5A1,CSMD3,ITGB4,CD44,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>8.296e-03</TD><TD>-4.79</TD><TD>chondrocyte differentiation</TD><TD>biological process</TD><TD>GO:0002062</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9</TD></TR>
<TR><TD>8.296e-03</TD><TD>-4.79</TD><TD>negative regulation of cyclin-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:1904030</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>8.296e-03</TD><TD>-4.79</TD><TD>stem cell proliferation</TD><TD>biological process</TD><TD>GO:0072089</TD><TD>61</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>RNF43,MSX1</TD></TR>
<TR><TD>8.303e-03</TD><TD>-4.79</TD><TD>GSE30083_SP3_VS_SP4_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE30083_SP3_VS_SP4_THYMOCYTE_DN</TD><TD>190</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,CD44,NT5E</TD></TR>
<TR><TD>8.315e-03</TD><TD>-4.79</TD><TD>CCDC136 (coiled-coil domain containing 136)</TD><TD>protein interactions</TD><TD>64753</TD><TD>63</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>8.315e-03</TD><TD>-4.79</TD><TD>PKN1 (protein kinase N1)</TD><TD>protein interactions</TD><TD>5585</TD><TD>63</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>8.346e-03</TD><TD>-4.79</TD><TD>ANATOMICAL_STRUCTURE_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>ANATOMICAL_STRUCTURE_MORPHOGENESIS</TD><TD>367</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,SLC40A1,MSX1,ANGPTL4</TD></TR>
<TR><TD>8.390e-03</TD><TD>-4.78</TD><TD>5-Phosphoribose 1-diphosphate biosynthesis</TD><TD>REACTOME pathways</TD><TD>R-HSA-73843</TD><TD>3</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>PRPS1</TD></TR>
<TR><TD>8.423e-03</TD><TD>-4.78</TD><TD>GSE27786_NKTCELL_VS_ERYTHROBLAST_DN</TD><TD>MSigDB lists</TD><TD>GSE27786_NKTCELL_VS_ERYTHROBLAST_DN</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLK,NR2F1,VSNL1</TD></TR>
<TR><TD>8.435e-03</TD><TD>-4.78</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP</TD><TD>63</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,VSNL1</TD></TR>
<TR><TD>8.487e-03</TD><TD>-4.77</TD><TD>regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001932</TD><TD>1334</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>Ca/CaM-dep_prot_kinase-assoc</TD><TD>interpro domains</TD><TD>IPR013543</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>Pept_M10A_metallopeptidase_C</TD><TD>interpro domains</TD><TD>IPR021805</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>Nebulin_repeat</TD><TD>interpro domains</TD><TD>IPR000900</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NEBL</TD></TR>
<TR><TD>8.544e-03</TD><TD>-4.76</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLC40A1,ZIC2</TD></TR>
<TR><TD>8.544e-03</TD><TD>-4.76</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_FETAL_DN</TD><TD>MSigDB lists</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_FETAL_DN</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SORCS2,PPARG,PDLIM5</TD></TR>
<TR><TD>8.544e-03</TD><TD>-4.76</TD><TD>GSE24142_ADULT_VS_FETAL_DN3_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE24142_ADULT_VS_FETAL_DN3_THYMOCYTE_DN</TD><TD>192</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,PPARG,PDLIM5</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>PRPP_SYNTHASE</TD><TD>prosite domains</TD><TD>PS00114</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>PRPS1</TD></TR>
<TR><TD>8.624e-03</TD><TD>-4.75</TD><TD>ribose phosphate diphosphokinase complex</TD><TD>cellular component</TD><TD>GO:0002189</TD><TD>4</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>PRPS1</TD></TR>
<TR><TD>8.666e-03</TD><TD>-4.75</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DN</TD><TD>193</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,RNF43,ANGPTL4</TD></TR>
<TR><TD>8.666e-03</TD><TD>-4.75</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_0.5H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_0.5H_BMDM_UP</TD><TD>193</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PDE10A,NT5E</TD></TR>
<TR><TD>8.696e-03</TD><TD>-4.74</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP</TD><TD>64</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,NT5E</TD></TR>
<TR><TD>8.703e-03</TD><TD>-4.74</TD><TD>EPHA10 (EPH receptor A10)</TD><TD>protein interactions</TD><TD>284656</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>8.703e-03</TD><TD>-4.74</TD><TD>JAZF1 (JAZF zinc finger 1)</TD><TD>protein interactions</TD><TD>221895</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>8.703e-03</TD><TD>-4.74</TD><TD>MADCAM1 (mucosal vascular addressin cell adhesion molecule 1)</TD><TD>protein interactions</TD><TD>8174</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>8.703e-03</TD><TD>-4.74</TD><TD>SLC41A1 (solute carrier family 41 (magnesium transporter), member 1)</TD><TD>protein interactions</TD><TD>254428</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>8.719e-03</TD><TD>-4.74</TD><TD>protein autophosphorylation</TD><TD>biological process</TD><TD>GO:0046777</TD><TD>189</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE360_CTRL_VS_L_DONOVANI_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE360_CTRL_VS_L_DONOVANI_DC_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,S100A10,NR2F1</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,CD44,PKIB</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>KAECH_NAIVE_VS_DAY15_EFF_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>KAECH_NAIVE_VS_DAY15_EFF_CD8_TCELL_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10,NT5E</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE24026_PD1_LIGATION_VS_CTRL_IN_ACT_TCELL_LINE_UP</TD><TD>MSigDB lists</TD><TD>GSE24026_PD1_LIGATION_VS_CTRL_IN_ACT_TCELL_LINE_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,S100A10,NT5E</TD></TR>
<TR><TD>8.823e-03</TD><TD>-4.73</TD><TD>Nuclear Receptor transcription pathway</TD><TD>REACTOME pathways</TD><TD>R-HSA-383280</TD><TD>51</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>8.845e-03</TD><TD>-4.73</TD><TD>stem cell differentiation</TD><TD>biological process</TD><TD>GO:0048863</TD><TD>190</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>8.845e-03</TD><TD>-4.73</TD><TD>response to estrogen</TD><TD>biological process</TD><TD>GO:0043627</TD><TD>190</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG</TD></TR>
<TR><TD>8.856e-03</TD><TD>-4.73</TD><TD>regulation of neuron projection development</TD><TD>biological process</TD><TD>GO:0010975</TD><TD>365</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>8.906e-03</TD><TD>-4.72</TD><TD>MODULE_2</TD><TD>MSigDB lists</TD><TD>MODULE_2</TD><TD>374</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4,CD44,VSNL1</TD></TR>
<TR><TD>8.913e-03</TD><TD>-4.72</TD><TD>GSE28237_EARLY_VS_LATE_GC_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE28237_EARLY_VS_LATE_GC_BCELL_UP</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16,PDE10A,NR2F1</TD></TR>
<TR><TD>8.939e-03</TD><TD>-4.72</TD><TD>cellular response to lipid</TD><TD>biological process</TD><TD>GO:0071396</TD><TD>366</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>8.959e-03</TD><TD>-4.72</TD><TD>CORRE_MULTIPLE_MYELOMA_UP</TD><TD>MSigDB lists</TD><TD>CORRE_MULTIPLE_MYELOMA_UP</TD><TD>65</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,ANGPTL4</TD></TR>
<TR><TD>8.959e-03</TD><TD>-4.72</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_UP</TD><TD>65</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,TNIK</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>5-phosphoribose 1-diphosphate biosynthetic process</TD><TD>biological process</TD><TD>GO:0006015</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>regulation of nodal signaling pathway involved in determination of left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900145</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>positive regulation of hair follicle maturation</TD><TD>biological process</TD><TD>GO:0048818</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>regulation of generation of L-type calcium current</TD><TD>biological process</TD><TD>GO:1902514</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>oxidative stress-induced premature senescence</TD><TD>biological process</TD><TD>GO:0090403</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>5-phosphoribose 1-diphosphate metabolic process</TD><TD>biological process</TD><TD>GO:0046391</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>frontal suture morphogenesis</TD><TD>biological process</TD><TD>GO:0060364</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>regulation of catagen</TD><TD>biological process</TD><TD>GO:0051794</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>positive regulation of oocyte development</TD><TD>biological process</TD><TD>GO:0060282</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>8.972e-03</TD><TD>-4.71</TD><TD>regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry</TD><TD>biological process</TD><TD>GO:1900175</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>9.038e-03</TD><TD>-4.71</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_FETAL_UP</TD><TD>MSigDB lists</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_FETAL_UP</TD><TD>196</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44,PKIB</TD></TR>
<TR><TD>9.041e-03</TD><TD>-4.71</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>7606</TD><TD>24</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,FGF9,PPARG,STXBP6,VSNL1,CLSTN2,RNF43,ANGPTL4,NR2F1,PDE3A,RHOU,CAMK2D,NEBL,UNC13A,SLCO5A1,CSMD3,WNT16,CD44,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>9.055e-03</TD><TD>-4.70</TD><TD>positive regulation of response to stimulus</TD><TD>biological process</TD><TD>GO:0048584</TD><TD>1946</TD><TD>10</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,TANK,VSNL1,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>Nebulin</TD><TD>pfam domains</TD><TD>PF00880</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>NEBL</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>CaMKII_AD</TD><TD>pfam domains</TD><TD>PF08332</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>DUF3377</TD><TD>pfam domains</TD><TD>PF11857</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MMP16</TD></TR>
<TR><TD>9.164e-03</TD><TD>-4.69</TD><TD>GSE30083_SP2_VS_SP3_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE30083_SP2_VS_SP3_THYMOCYTE_UP</TD><TD>197</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,CAMK2D,NR2F2</TD></TR>
<TR><TD>9.164e-03</TD><TD>-4.69</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE24142_DN2_VS_DN3_THYMOCYTE_UP</TD><TD>197</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44,PKIB</TD></TR>
<TR><TD>9.182e-03</TD><TD>-4.69</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D</TD><TD>MSigDB lists</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D</TD><TD>835</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,NR2F2,PPARG,ANGPTL4,TANK,NR2F1</TD></TR>
<TR><TD>9.193e-03</TD><TD>-4.69</TD><TD>extracellular matrix organization</TD><TD>biological process</TD><TD>GO:0030198</TD><TD>369</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>9.226e-03</TD><TD>-4.69</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN</TD><TD>66</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,FGF9</TD></TR>
<TR><TD>9.279e-03</TD><TD>-4.68</TD><TD>extracellular structure organization</TD><TD>biological process</TD><TD>GO:0043062</TD><TD>370</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>LAMA4,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>9.291e-03</TD><TD>-4.68</TD><TD>GTATTAT,MIR-369-3P</TD><TD>MSigDB lists</TD><TD>GTATTAT,MIR-369-3P</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,NR2F2,VSNL1</TD></TR>
<TR><TD>9.291e-03</TD><TD>-4.68</TD><TD>HALLMARK_TNFA_SIGNALING_VIA_NFKB</TD><TD>MSigDB lists</TD><TD>HALLMARK_TNFA_SIGNALING_VIA_NFKB</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PDLIM5,TANK</TD></TR>
<TR><TD>9.291e-03</TD><TD>-4.68</TD><TD>GSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1,SLK,NT5E</TD></TR>
<TR><TD>9.327e-03</TD><TD>-4.67</TD><TD>SUMO2 (small ubiquitin-like modifier 2)</TD><TD>protein interactions</TD><TD>6613</TD><TD>200</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,MSX1,TANK</TD></TR>
<TR><TD>9.419e-03</TD><TD>-4.67</TD><TD>EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP</TD><TD>199</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,NEBL,PDLIM5</TD></TR>
<TR><TD>9.452e-03</TD><TD>-4.66</TD><TD>blood vessel morphogenesis</TD><TD>biological process</TD><TD>GO:0048514</TD><TD>372</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>9.452e-03</TD><TD>-4.66</TD><TD>purine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072521</TD><TD>372</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>9.492e-03</TD><TD>-4.66</TD><TD>developmental maturation</TD><TD>biological process</TD><TD>GO:0021700</TD><TD>195</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PDE3A,UNC13A</TD></TR>
<TR><TD>9.548e-03</TD><TD>-4.65</TD><TD>MODULE_342</TD><TD>MSigDB lists</TD><TD>MODULE_342</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,NEBL,STXBP6</TD></TR>
<TR><TD>9.548e-03</TD><TD>-4.65</TD><TD>V$STAT5A_04</TD><TD>MSigDB lists</TD><TD>V$STAT5A_04</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,RNF43,MSX2</TD></TR>
<TR><TD>9.548e-03</TD><TD>-4.65</TD><TD>V$TFIII_Q6</TD><TD>MSigDB lists</TD><TD>V$TFIII_Q6</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,CD44,NR2F2</TD></TR>
<TR><TD>9.656e-03</TD><TD>-4.64</TD><TD>regulation of dendrite morphogenesis</TD><TD>biological process</TD><TD>GO:0048814</TD><TD>66</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,PDLIM5</TD></TR>
<TR><TD>9.661e-03</TD><TD>-4.64</TD><TD>AAGCACA,MIR-218</TD><TD>MSigDB lists</TD><TD>AAGCACA,MIR-218</TD><TD>383</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,SLCO5A1,CSMD3,NEBL</TD></TR>
<TR><TD>9.669e-03</TD><TD>-4.64</TD><TD>negative regulation of apoptotic process</TD><TD>biological process</TD><TD>GO:0043066</TD><TD>826</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>9.678e-03</TD><TD>-4.64</TD><TD>MANALO_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>MANALO_HYPOXIA_UP</TD><TD>201</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,PPARG,ANGPTL4</TD></TR>
<TR><TD>9.729e-03</TD><TD>-4.63</TD><TD>focal adhesion</TD><TD>cellular component</TD><TD>GO:0005925</TD><TD>390</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>9.789e-03</TD><TD>-4.63</TD><TD>human chr10p12</TD><TD>chromosome location</TD><TD>human chr10p12</TD><TD>6</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>NEBL</TD></TR>
<TR><TD>9.834e-03</TD><TD>-4.62</TD><TD>regulation of protein kinase activity</TD><TD>biological process</TD><TD>GO:0045859</TD><TD>829</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,SLK,PKIB</TD></TR>
<TR><TD>9.837e-03</TD><TD>-4.62</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>2069</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>UNC13A,TANK,CSMD3,SLCO5A1,RNF43,WNT16,CD44,SORCS2,PDLIM5,NT5E</TD></TR>
<TR><TD>9.837e-03</TD><TD>-4.62</TD><TD>acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>acinar_carcinoma</TD><TD>2069</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>UNC13A,TANK,CSMD3,SLCO5A1,RNF43,WNT16,CD44,SORCS2,PDLIM5,NT5E</TD></TR>
<TR><TD>9.923e-03</TD><TD>-4.61</TD><TD>purine nucleotides degradation II (aerobic)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6353</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>9.923e-03</TD><TD>-4.61</TD><TD>purine nucleotides degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6353</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>NT5E</TD></TR>
<TR><TD>9.939e-03</TD><TD>-4.61</TD><TD>actin filament-based movement</TD><TD>biological process</TD><TD>GO:0030048</TD><TD>67</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,CAMK2D</TD></TR>
<TR><TD>1.005e-02</TD><TD>-4.60</TD><TD>KEGG_PPAR_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_PPAR_SIGNALING_PATHWAY</TD><TD>69</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.005e-02</TD><TD>-4.60</TD><TD>PROXISOMEPAR</TD><TD>prints domains</TD><TD>PR01288</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.008e-02</TD><TD>-4.60</TD><TD>carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>carcinoid-endocrine_tumour</TD><TD>8129</TD><TD>25</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,PPARG,STXBP6,VSNL1,CLSTN2,RNF43,ANGPTL4,NR2F1,PDE3A,RHOU,CAMK2D,NEBL,UNC13A,SLCO5A1,CSMD3,WNT16,CD44,ITGB4,PDLIM5,MMP16,PKIB,NT5E</TD></TR>
<TR><TD>1.016e-02</TD><TD>-4.59</TD><TD>cell-substrate adherens junction</TD><TD>cellular component</TD><TD>GO:0005924</TD><TD>395</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>negative regulation of programmed cell death</TD><TD>biological process</TD><TD>GO:0043069</TD><TD>835</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,MSX1,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>basolateral plasma membrane</TD><TD>cellular component</TD><TD>GO:0016323</TD><TD>208</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>SLC40A1,ITGB4,CD44</TD></TR>
<TR><TD>1.018e-02</TD><TD>-4.59</TD><TD>MAP2K1 (mitogen-activated protein kinase kinase 1)</TD><TD>protein interactions</TD><TD>5604</TD><TD>70</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,PDLIM5</TD></TR>
<TR><TD>1.018e-02</TD><TD>-4.59</TD><TD>STX1A (syntaxin 1A (brain))</TD><TD>protein interactions</TD><TD>6804</TD><TD>70</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,STXBP6</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>THUM_SYSTOLIC_HEART_FAILURE_UP</TD><TD>MSigDB lists</TD><TD>THUM_SYSTOLIC_HEART_FAILURE_UP</TD><TD>389</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1,TANK,VSNL1,NT5E</TD></TR>
<TR><TD>1.021e-02</TD><TD>-4.58</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>205</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,SLC40A1,MSX2</TD></TR>
<TR><TD>1.023e-02</TD><TD>-4.58</TD><TD>developmental cell growth</TD><TD>biological process</TD><TD>GO:0048588</TD><TD>68</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>1.028e-02</TD><TD>-4.58</TD><TD>positive regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043410</TD><TD>596</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44</TD></TR>
<TR><TD>1.030e-02</TD><TD>-4.58</TD><TD>Znf_LIM</TD><TD>interpro domains</TD><TD>IPR001781</TD><TD>72</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.031e-02</TD><TD>-4.58</TD><TD>ear development</TD><TD>biological process</TD><TD>GO:0043583</TD><TD>201</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1,GRHL3</TD></TR>
<TR><TD>1.031e-02</TD><TD>-4.58</TD><TD>anterior/posterior pattern specification</TD><TD>biological process</TD><TD>GO:0009952</TD><TD>201</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,NR2F2</TD></TR>
<TR><TD>1.044e-02</TD><TD>-4.56</TD><TD>regulation of cell growth</TD><TD>biological process</TD><TD>GO:0001558</TD><TD>383</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,MSX1,PPARG,UNC13A</TD></TR>
<TR><TD>1.052e-02</TD><TD>-4.55</TD><TD>nucleobase metabolic process</TD><TD>biological process</TD><TD>GO:0009112</TD><TD>69</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.052e-02</TD><TD>-4.55</TD><TD>cell junction</TD><TD>cellular component</TD><TD>GO:0030054</TD><TD>1147</TD><TD>7</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,ITGB4,CD44,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>MODULE_154</TD><TD>MSigDB lists</TD><TD>MODULE_154</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>MSigDB lists</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,ITGB4</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Munc13_dom-2</TD><TD>interpro domains</TD><TD>IPR014772</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>VPS10</TD><TD>interpro domains</TD><TD>IPR006581</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Rib-P_diPkinase</TD><TD>interpro domains</TD><TD>IPR005946</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Sortilin_C</TD><TD>interpro domains</TD><TD>IPR031777</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Sortilin_N</TD><TD>interpro domains</TD><TD>IPR031778</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Ca-dep_secretion_activator</TD><TD>interpro domains</TD><TD>IPR010439</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Munc13_subgr_dom-2</TD><TD>interpro domains</TD><TD>IPR019558</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Laminin_aI</TD><TD>interpro domains</TD><TD>IPR009254</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Pribosyltran_N</TD><TD>interpro domains</TD><TD>IPR029099</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Laminin_domII</TD><TD>interpro domains</TD><TD>IPR010307</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.066e-02</TD><TD>-4.54</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>615</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,CD44,S100A10,STXBP6,ANGPTL4</TD></TR>
<TR><TD>1.071e-02</TD><TD>-4.54</TD><TD>developmental process involved in reproduction</TD><TD>biological process</TD><TD>GO:0003006</TD><TD>602</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,CD44,NR2F2,PPARG,PDE3A</TD></TR>
<TR><TD>1.076e-02</TD><TD>-4.53</TD><TD>KIM_WT1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_UP</TD><TD>209</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PDLIM5,PDE10A</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>FGF9 (fibroblast growth factor 9)</TD><TD>protein interactions</TD><TD>2254</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>FGF9</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>XIRP2 (xin actin binding repeat containing 2)</TD><TD>protein interactions</TD><TD>129446</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>DEFB1 (defensin, beta 1)</TD><TD>protein interactions</TD><TD>1672</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>PRPS1L1 (phosphoribosyl pyrophosphate synthetase 1-like 1)</TD><TD>protein interactions</TD><TD>221823</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>BSN (bassoon presynaptic cytomatrix protein)</TD><TD>protein interactions</TD><TD>8927</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>BOD1L1 (biorientation of chromosomes in cell division 1-like 1)</TD><TD>protein interactions</TD><TD>259282</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>FABP1 (fatty acid binding protein 1, liver)</TD><TD>protein interactions</TD><TD>2168</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>ZBTB20 (zinc finger and BTB domain containing 20)</TD><TD>protein interactions</TD><TD>26137</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>HNMT (histamine N-methyltransferase)</TD><TD>protein interactions</TD><TD>3176</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>LHX2 (LIM homeobox 2)</TD><TD>protein interactions</TD><TD>9355</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>GAANYNYGACNY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GAANYNYGACNY_UNKNOWN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_DN</TD><TD>MSigDB lists</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_DN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_DN</TD><TD>MSigDB lists</TD><TD>SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_DN</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_UP</TD><TD>MSigDB lists</TD><TD>CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>1.104e-02</TD><TD>-4.51</TD><TD>locomotion</TD><TD>biological process</TD><TD>GO:0040011</TD><TD>1396</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,NR2F2,CD44,ITGB4,NR2F1</TD></TR>
<TR><TD>1.109e-02</TD><TD>-4.50</TD><TD>regulation of response to stress</TD><TD>biological process</TD><TD>GO:0080134</TD><TD>1397</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,MSX1,PPARG,TANK,WNT16,CD44,NT5E</TD></TR>
<TR><TD>1.111e-02</TD><TD>-4.50</TD><TD>organ regeneration</TD><TD>biological process</TD><TD>GO:0031100</TD><TD>71</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PRPS1</TD></TR>
<TR><TD>1.114e-02</TD><TD>-4.50</TD><TD>LIM</TD><TD>pfam domains</TD><TD>PF00412</TD><TD>70</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>sodium channel inhibitor activity</TD><TD>molecular function</TD><TD>GO:0019871</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>ribose phosphate diphosphokinase activity</TD><TD>molecular function</TD><TD>GO:0004749</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>keratin filament binding</TD><TD>molecular function</TD><TD>GO:1990254</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>arachidonic acid binding</TD><TD>molecular function</TD><TD>GO:0050544</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>MODULE_139</TD><TD>MSigDB lists</TD><TD>MODULE_139</TD><TD>73</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,NEBL</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_DN</TD><TD>MSigDB lists</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_DN</TD><TD>400</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,S100A10,PDLIM5,NT5E</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>ferrous iron transport</TD><TD>biological process</TD><TD>GO:0015684</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>negative regulation of lipoprotein lipase activity</TD><TD>biological process</TD><TD>GO:0051005</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>regulation of hair follicle maturation</TD><TD>biological process</TD><TD>GO:0048819</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>negative regulation of response to interferon-gamma</TD><TD>biological process</TD><TD>GO:0060331</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>negative regulation of sequestering of triglyceride</TD><TD>biological process</TD><TD>GO:0010891</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>response to aluminum ion</TD><TD>biological process</TD><TD>GO:0010044</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>ribonucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009158</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>negative regulation of interferon-gamma-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0060336</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>purine ribonucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009169</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0032800</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>hypoxanthine biosynthetic process</TD><TD>biological process</TD><TD>GO:0046101</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>regulation of histone deacetylase activity</TD><TD>biological process</TD><TD>GO:1901725</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>Bergmann glial cell differentiation</TD><TD>biological process</TD><TD>GO:0060020</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>localization of cell</TD><TD>biological process</TD><TD>GO:0051674</TD><TD>853</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,ITGB4,CD44,NR2F2,NR2F1</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>cell motility</TD><TD>biological process</TD><TD>GO:0048870</TD><TD>853</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,ITGB4,CD44,NR2F2,NR2F1</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>Hedgehog signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04340</TD><TD>51</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>Hedgehog signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04340</TD><TD>51</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>ZIC2,WNT16</TD></TR>
<TR><TD>1.133e-02</TD><TD>-4.48</TD><TD>TAB2 (TGF-beta activated kinase 1/MAP3K7 binding protein 2)</TD><TD>protein interactions</TD><TD>23118</TD><TD>74</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,TANK</TD></TR>
<TR><TD>1.133e-02</TD><TD>-4.48</TD><TD>SVIL (supervillin)</TD><TD>protein interactions</TD><TD>6840</TD><TD>74</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.137e-02</TD><TD>-4.48</TD><TD>pharynx</TD><TD>COSMIC cancer mutations</TD><TD>pharynx</TD><TD>2803</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>STXBP6,UNC13A,GRHL3,C1orf226,CLSTN2,CSMD3,VIM,CD44,SORCS2,ITGB4,PRPS1,MMP16</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>DUF1041</TD><TD>pfam domains</TD><TD>PF06292</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Sortilin-Vps10</TD><TD>pfam domains</TD><TD>PF15902</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Pribosyltran_N</TD><TD>pfam domains</TD><TD>PF13793</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Laminin_II</TD><TD>pfam domains</TD><TD>PF06009</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Membr_traf_MHD</TD><TD>pfam domains</TD><TD>PF10540</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Sortilin_C</TD><TD>pfam domains</TD><TD>PF15901</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Laminin_I</TD><TD>pfam domains</TD><TD>PF06008</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>Pribosyl_synth</TD><TD>pfam domains</TD><TD>PF14572</TD><TD>5</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>human chr4p16.2</TD><TD>chromosome location</TD><TD>human chr4p16.2</TD><TD>7</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>human chr4q22</TD><TD>chromosome location</TD><TD>human chr4q22</TD><TD>7</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>NEBULIN</TD><TD>prosite domains</TD><TD>PS51216</TD><TD>4</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.142e-02</TD><TD>-4.47</TD><TD>germ_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>germ_cell_tumour</TD><TD>900</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,RNF43,TNIK,CAMK2D,PDE10A</TD></TR>
<TR><TD>1.146e-02</TD><TD>-4.47</TD><TD>V$IK3_01</TD><TD>MSigDB lists</TD><TD>V$IK3_01</TD><TD>214</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,MSX1,VSNL1</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>cell morphogenesis involved in differentiation</TD><TD>biological process</TD><TD>GO:0000904</TD><TD>857</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,CAMK2D,MSX2,FGF9,MSX1,WNT16</TD></TR>
<TR><TD>1.148e-02</TD><TD>-4.47</TD><TD>CTTTGA_V$LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGA_V$LEF1_Q2</TD><TD>1147</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,RNF43,MSX1,NR2F2,PPARG,NR2F1,VSNL1</TD></TR>
<TR><TD>1.156e-02</TD><TD>-4.46</TD><TD>Developmental Biology</TD><TD>REACTOME pathways</TD><TD>R-HSA-1266738</TD><TD>710</TD><TD>6</TD><TD>8202</TD><TD>23</TD>
<TD>EFNB2,FGF9,CAMK2D,NR2F2,PPARG,ANGPTL4</TD></TR>
<TR><TD>1.170e-02</TD><TD>-4.45</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>1482</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,MSX2,CAMK2D,UNC13A,CSMD3,CLSTN2,PDLIM5,NT5E</TD></TR>
<TR><TD>1.175e-02</TD><TD>-4.44</TD><TD>skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048705</TD><TD>211</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,MMP16</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>MODULE_411</TD><TD>MSigDB lists</TD><TD>MODULE_411</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,PDE10A</TD></TR>
<TR><TD>1.190e-02</TD><TD>-4.43</TD><TD>heart morphogenesis</TD><TD>biological process</TD><TD>GO:0003007</TD><TD>212</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>1.191e-02</TD><TD>-4.43</TD><TD>skin-scalp-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma</TD><TD>650</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,NEBL,NR2F2,MMP16,PDE3A</TD></TR>
<TR><TD>1.192e-02</TD><TD>-4.43</TD><TD>GFI1B (growth factor independent 1B transcription repressor)</TD><TD>protein interactions</TD><TD>8328</TD><TD>76</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5,VSNL1</TD></TR>
<TR><TD>1.192e-02</TD><TD>-4.43</TD><TD>PLEC (plectin)</TD><TD>protein interactions</TD><TD>5339</TD><TD>76</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>1.205e-02</TD><TD>-4.42</TD><TD>V$CDPCR3HD_01</TD><TD>MSigDB lists</TD><TD>V$CDPCR3HD_01</TD><TD>218</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,CSMD3,CAMK2D</TD></TR>
<TR><TD>1.205e-02</TD><TD>-4.42</TD><TD>regulation of cellular response to stress</TD><TD>biological process</TD><TD>GO:0080135</TD><TD>620</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,WNT16,MSX1,CD44</TD></TR>
<TR><TD>1.205e-02</TD><TD>-4.42</TD><TD>regulation of neurogenesis</TD><TD>biological process</TD><TD>GO:0050767</TD><TD>620</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,TNIK,PPARG,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.207e-02</TD><TD>-4.42</TD><TD>positive regulation of signal transduction</TD><TD>biological process</TD><TD>GO:0009967</TD><TD>1418</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,MSX1,ZIC2,WNT16,CD44</TD></TR>
<TR><TD>1.208e-02</TD><TD>-4.42</TD><TD>BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP</TD><TD>MSigDB lists</TD><TD>BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP</TD><TD>409</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PPARG,PDLIM5,ANGPTL4</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>MODULE_357</TD><TD>MSigDB lists</TD><TD>MODULE_357</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN</TD><TD>MSigDB lists</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>REACTOME_PLATELET_HOMEOSTASIS</TD><TD>MSigDB lists</TD><TD>REACTOME_PLATELET_HOMEOSTASIS</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>MODULE_297</TD><TD>MSigDB lists</TD><TD>MODULE_297</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,ANGPTL4</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP</TD><TD>MSigDB lists</TD><TD>THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,TANK</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>GGARNTKYCCA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GGARNTKYCCA_UNKNOWN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,MSX1</TD></TR>
<TR><TD>1.210e-02</TD><TD>-4.41</TD><TD>reproductive structure development</TD><TD>biological process</TD><TD>GO:0048608</TD><TD>400</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,CD44,NR2F2,PPARG</TD></TR>
<TR><TD>1.218e-02</TD><TD>-4.41</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>410</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,TNIK,ITGB4,NR2F2</TD></TR>
<TR><TD>1.221e-02</TD><TD>-4.41</TD><TD>NEBU</TD><TD>smart domains</TD><TD>SM00227</TD><TD>4</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.222e-02</TD><TD>-4.40</TD><TD>TRIM24 (tripartite motif containing 24)</TD><TD>protein interactions</TD><TD>8805</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>1.222e-02</TD><TD>-4.40</TD><TD>GTF2F1 (general transcription factor IIF subunit 1)</TD><TD>protein interactions</TD><TD>2962</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,PRPS1</TD></TR>
<TR><TD>1.226e-02</TD><TD>-4.40</TD><TD>chromatin DNA binding</TD><TD>molecular function</TD><TD>GO:0031490</TD><TD>75</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>1.230e-02</TD><TD>-4.40</TD><TD>response to steroid hormone</TD><TD>biological process</TD><TD>GO:0048545</TD><TD>402</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.233e-02</TD><TD>-4.40</TD><TD>regulation of synapse assembly</TD><TD>biological process</TD><TD>GO:0051963</TD><TD>75</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CLSTN2,PDLIM5</TD></TR>
<TR><TD>1.235e-02</TD><TD>-4.39</TD><TD>KONDO_EZH2_TARGETS</TD><TD>MSigDB lists</TD><TD>KONDO_EZH2_TARGETS</TD><TD>220</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,NEBL,NT5E</TD></TR>
<TR><TD>1.240e-02</TD><TD>-4.39</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP</TD><TD>MSigDB lists</TD><TD>LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ANGPTL4</TD></TR>
<TR><TD>1.240e-02</TD><TD>-4.39</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>MSigDB lists</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>1.242e-02</TD><TD>-4.39</TD><TD>regulation of phosphorylation</TD><TD>biological process</TD><TD>GO:0042325</TD><TD>1425</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>reproductive system development</TD><TD>biological process</TD><TD>GO:0061458</TD><TD>404</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,CD44,NR2F2,PPARG</TD></TR>
<TR><TD>1.252e-02</TD><TD>-4.38</TD><TD>Amyotrophic lateral sclerosis(PMID:19734901)</TD><TD>GWAS genes</TD><TD>Amyotrophic lateral sclerosis(PMID:19734901)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.252e-02</TD><TD>-4.38</TD><TD>Brain imaging in schizophrenia (interaction)(PMID:19023125)</TD><TD>GWAS genes</TD><TD>Brain imaging in schizophrenia (interaction)(PMID:19023125)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.252e-02</TD><TD>-4.38</TD><TD>Male infertility(PMID:19478329)</TD><TD>GWAS genes</TD><TD>Male infertility(PMID:19478329)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.256e-02</TD><TD>-4.38</TD><TD>regulation of kinase activity</TD><TD>biological process</TD><TD>GO:0043549</TD><TD>874</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,NR2F2,SLK,PKIB</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>cell morphogenesis</TD><TD>biological process</TD><TD>GO:0000902</TD><TD>1143</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,FGF9,CAMK2D,MSX2,MSX1,WNT16</TD></TR>
<TR><TD>1.267e-02</TD><TD>-4.37</TD><TD>regulation of synapse structure or activity</TD><TD>biological process</TD><TD>GO:0050803</TD><TD>217</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CLSTN2,PDLIM5,UNC13A</TD></TR>
<TR><TD>1.271e-02</TD><TD>-4.37</TD><TD>MODULE_341</TD><TD>MSigDB lists</TD><TD>MODULE_341</TD><TD>78</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,PDE10A</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>CP2</TD><TD>interpro domains</TD><TD>IPR007604</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>DUF4749</TD><TD>interpro domains</TD><TD>IPR031847</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.282e-02</TD><TD>-4.36</TD><TD>skin development</TD><TD>biological process</TD><TD>GO:0043588</TD><TD>218</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16,ITGB4,GRHL3</TD></TR>
<TR><TD>1.296e-02</TD><TD>-4.35</TD><TD>V$NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>V$NFKB_Q6_01</TD><TD>224</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,MSX1,NR2F2</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>interferon-gamma-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0060333</TD><TD>77</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>1.302e-02</TD><TD>-4.34</TD><TD>HARRIS_HYPOXIA</TD><TD>MSigDB lists</TD><TD>HARRIS_HYPOXIA</TD><TD>79</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,PRPS1</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>MAP6 (microtubule associated protein 6)</TD><TD>protein interactions</TD><TD>4135</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>HPS3 (Hermansky-Pudlak syndrome 3)</TD><TD>protein interactions</TD><TD>84343</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>HELZ2 (helicase with zinc finger 2, transcriptional coactivator)</TD><TD>protein interactions</TD><TD>85441</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>BFSP1 (beaded filament structural protein 1, filensin)</TD><TD>protein interactions</TD><TD>631</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>GRHL3 (grainyhead-like transcription factor 3)</TD><TD>protein interactions</TD><TD>57822</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>SLC16A2 (solute carrier family 16, member 2 (thyroid hormone transporter))</TD><TD>protein interactions</TD><TD>6567</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>SLC26A6 (solute carrier family 26 (anion exchanger), member 6)</TD><TD>protein interactions</TD><TD>65010</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>DIP2B (disco-interacting protein 2 homolog B)</TD><TD>protein interactions</TD><TD>57609</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>ROBO4 (roundabout guidance receptor 4)</TD><TD>protein interactions</TD><TD>54538</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>human chr13q32</TD><TD>chromosome location</TD><TD>human chr13q32</TD><TD>8</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.309e-02</TD><TD>-4.34</TD><TD>transcription factor activity, sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0003700</TD><TD>1155</TD><TD>7</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,ZIC2,MSX1,NR2F2,PPARG,NR2F1,GRHL3</TD></TR>
<TR><TD>1.309e-02</TD><TD>-4.34</TD><TD>nucleic acid binding transcription factor activity</TD><TD>molecular function</TD><TD>GO:0001071</TD><TD>1155</TD><TD>7</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,ZIC2,MSX1,NR2F2,PPARG,NR2F1,GRHL3</TD></TR>
<TR><TD>1.309e-02</TD><TD>-4.34</TD><TD>regulation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0006357</TD><TD>1740</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,CAMK2D,FGF9,MSX1,PPARG,GRHL3,NR2F2,NR2F1</TD></TR>
<TR><TD>1.310e-02</TD><TD>-4.34</TD><TD>negative regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0008285</TD><TD>633</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,MSX1,NR2F2,PPARG</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>WALLACE_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>WALLACE_PROSTATE_CANCER_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>WILLIAMS_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>WILLIAMS_ESR1_TARGETS_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>TSAI_DNAJB4_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>TSAI_DNAJB4_TARGETS_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>1.312e-02</TD><TD>-4.33</TD><TD>V$POU1F1_Q6</TD><TD>MSigDB lists</TD><TD>V$POU1F1_Q6</TD><TD>225</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,PDLIM5</TD></TR>
<TR><TD>1.313e-02</TD><TD>-4.33</TD><TD>pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pulmonary_blastoma</TD><TD>666</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,WNT16,ITGB4,NEBL</TD></TR>
<TR><TD>1.313e-02</TD><TD>-4.33</TD><TD>pleura-pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pleura-pulmonary_blastoma</TD><TD>666</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,WNT16,ITGB4,NEBL</TD></TR>
<TR><TD>1.315e-02</TD><TD>-4.33</TD><TD>MARTINEZ_RB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MARTINEZ_RB1_TARGETS_UP</TD><TD>648</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10,PDLIM5,PDE3A,NT5E</TD></TR>
<TR><TD>1.320e-02</TD><TD>-4.33</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,MSX2,TNIK,SLC40A1,NEBL,STXBP6,UNC13A,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,PRPS1,PDE3A</TD></TR>
<TR><TD>1.320e-02</TD><TD>-4.33</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,MSX2,TNIK,SLC40A1,NEBL,STXBP6,UNC13A,CLSTN2,CSMD3,SORCS2,ITGB4,PDLIM5,MMP16,PRPS1,PDE3A</TD></TR>
<TR><TD>1.326e-02</TD><TD>-4.32</TD><TD>regulation of growth</TD><TD>biological process</TD><TD>GO:0040008</TD><TD>635</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,FGF9,MSX1,PPARG,UNC13A</TD></TR>
<TR><TD>1.327e-02</TD><TD>-4.32</TD><TD>MORF_IL13</TD><TD>MSigDB lists</TD><TD>MORF_IL13</TD><TD>226</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,MSX1,NR2F1</TD></TR>
<TR><TD>1.328e-02</TD><TD>-4.32</TD><TD>VIM (vimentin)</TD><TD>protein interactions</TD><TD>7431</TD><TD>228</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,CAMK2D,ITGB4</TD></TR>
<TR><TD>1.329e-02</TD><TD>-4.32</TD><TD>pyrimidine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072527</TD><TD>78</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.333e-02</TD><TD>-4.32</TD><TD>CROMER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>CROMER_METASTASIS_DN</TD><TD>80</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,VSNL1</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>icosanoid binding</TD><TD>molecular function</TD><TD>GO:0050542</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>icosatetraenoic acid binding</TD><TD>molecular function</TD><TD>GO:0050543</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.339e-02</TD><TD>-4.31</TD><TD>fatty acid derivative binding</TD><TD>molecular function</TD><TD>GO:1901567</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>wound healing involved in inflammatory response</TD><TD>biological process</TD><TD>GO:0002246</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>inflammatory response to wounding</TD><TD>biological process</TD><TD>GO:0090594</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>negative regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010871</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>iron ion transmembrane transport</TD><TD>biological process</TD><TD>GO:0034755</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>purine nucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009128</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>negative regulation of CREB transcription factor activity</TD><TD>biological process</TD><TD>GO:0032792</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>negative regulation of cholesterol storage</TD><TD>biological process</TD><TD>GO:0010887</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>lymphatic endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060836</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>hypoxanthine metabolic process</TD><TD>biological process</TD><TD>GO:0046100</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>positive regulation of striated muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010663</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>cGMP catabolic process</TD><TD>biological process</TD><TD>GO:0046069</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>regulation of relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:1901897</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>positive regulation of mesoderm development</TD><TD>biological process</TD><TD>GO:2000382</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>peroxisome proliferator activated receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0035357</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>positive regulation of cardiac muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010666</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.343e-02</TD><TD>-4.31</TD><TD>cellular response to cGMP</TD><TD>biological process</TD><TD>GO:0071321</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.344e-02</TD><TD>-4.31</TD><TD>ABCE1 (ATP binding cassette subfamily E member 1)</TD><TD>protein interactions</TD><TD>6059</TD><TD>229</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,CD44,S100A10</TD></TR>
<TR><TD>1.347e-02</TD><TD>-4.31</TD><TD>signal transduction by protein phosphorylation</TD><TD>biological process</TD><TD>GO:0023014</TD><TD>413</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>1.356e-02</TD><TD>-4.30</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>653</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,TNIK,MSX2,NEBL,NR2F1</TD></TR>
<TR><TD>1.357e-02</TD><TD>-4.30</TD><TD>brainstem</TD><TD>COSMIC cancer mutations</TD><TD>brainstem</TD><TD>3233</TD><TD>13</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,CAMK2D,PPARG,STXBP6,UNC13A,CLSTN2,SLCO5A1,CSMD3,VIM,PDLIM5,MMP16,PDE3A</TD></TR>
<TR><TD>1.359e-02</TD><TD>-4.30</TD><TD>V$ZF5_01</TD><TD>MSigDB lists</TD><TD>V$ZF5_01</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,ZIC2,NR2F2</TD></TR>
<TR><TD>1.359e-02</TD><TD>-4.30</TD><TD>V$NFKAPPAB65_01</TD><TD>MSigDB lists</TD><TD>V$NFKAPPAB65_01</TD><TD>228</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,MSX1,NR2F2</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030509</TD><TD>79</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>DUF4749</TD><TD>pfam domains</TD><TD>PF15936</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>Integrin_B_tail</TD><TD>pfam domains</TD><TD>PF07965</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>CP2</TD><TD>pfam domains</TD><TD>PF04516</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>GRHL3</TD></TR>
<TR><TD>1.365e-02</TD><TD>-4.29</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>81</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,S100A10</TD></TR>
<TR><TD>1.369e-02</TD><TD>-4.29</TD><TD>lipid binding</TD><TD>molecular function</TD><TD>GO:0008289</TD><TD>642</TD><TD>5</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2,S100A10,PPARG,STXBP6,UNC13A</TD></TR>
<TR><TD>1.371e-02</TD><TD>-4.29</TD><TD>negative regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045892</TD><TD>1162</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.375e-02</TD><TD>-4.29</TD><TD>TAGCTTT,MIR-9</TD><TD>MSigDB lists</TD><TD>TAGCTTT,MIR-9</TD><TD>229</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,NR2F2,MMP16</TD></TR>
<TR><TD>1.391e-02</TD><TD>-4.28</TD><TD>STRUCTURAL_MOLECULE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>STRUCTURAL_MOLECULE_ACTIVITY</TD><TD>230</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,VIM,NEBL</TD></TR>
<TR><TD>1.391e-02</TD><TD>-4.28</TD><TD>V$IRF_Q6</TD><TD>MSigDB lists</TD><TD>V$IRF_Q6</TD><TD>230</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,SLC40A1,MSX1</TD></TR>
<TR><TD>1.395e-02</TD><TD>-4.27</TD><TD>regulation of BMP signaling pathway</TD><TD>biological process</TD><TD>GO:0030510</TD><TD>80</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.407e-02</TD><TD>-4.26</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ANGPTL4,NT5E</TD></TR>
<TR><TD>1.407e-02</TD><TD>-4.26</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PKIB,C1orf226</TD></TR>
<TR><TD>1.410e-02</TD><TD>-4.26</TD><TD>PFDN1 (prefoldin subunit 1)</TD><TD>protein interactions</TD><TD>5201</TD><TD>83</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1,NR2F1</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>transmembrane receptor protein serine/threonine kinase signaling pathway</TD><TD>biological process</TD><TD>GO:0007178</TD><TD>226</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,VIM,MSX1</TD></TR>
<TR><TD>1.425e-02</TD><TD>-4.25</TD><TD>MHD2</TD><TD>prosite domains</TD><TD>PS51259</TD><TD>5</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.428e-02</TD><TD>-4.25</TD><TD>midbrain development</TD><TD>biological process</TD><TD>GO:0030901</TD><TD>81</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1</TD></TR>
<TR><TD>1.429e-02</TD><TD>-4.25</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>430</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,CD44,VSNL1,NT5E</TD></TR>
<TR><TD>1.430e-02</TD><TD>-4.25</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>6065</TD><TD>20</TD><TD>17775</TD><TD>38</TD>
<TD>PPARG,GRHL3,CLSTN2,RNF43,VIM,ANGPTL4,NR2F1,PDE3A,CAMK2D,NEBL,PDE10A,UNC13A,CSMD3,SLCO5A1,CD44,NR2F2,SORCS2,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>1.433e-02</TD><TD>-4.25</TD><TD>scalp</TD><TD>COSMIC cancer mutations</TD><TD>scalp</TD><TD>2188</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,FGF9,NEBL,CLSTN2,CSMD3,VIM,NR2F2,MMP16,PDE3A</TD></TR>
<TR><TD>1.456e-02</TD><TD>-4.23</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>234</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLC40A1,MMP16</TD></TR>
<TR><TD>1.456e-02</TD><TD>-4.23</TD><TD>V$HNF1_01</TD><TD>MSigDB lists</TD><TD>V$HNF1_01</TD><TD>234</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ZIC2,NR2F1</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>665</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,PDLIM5,SLK,TANK,NR2F1</TD></TR>
<TR><TD>1.462e-02</TD><TD>-4.23</TD><TD>receptor metabolic process</TD><TD>biological process</TD><TD>GO:0043112</TD><TD>82</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>RNF43,PPARG</TD></TR>
<TR><TD>1.463e-02</TD><TD>-4.22</TD><TD>KIM_GLIS2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KIM_GLIS2_TARGETS_UP</TD><TD>84</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ANGPTL4</TD></TR>
<TR><TD>1.463e-02</TD><TD>-4.22</TD><TD>RUAN_RESPONSE_TO_TNF_DN</TD><TD>MSigDB lists</TD><TD>RUAN_RESPONSE_TO_TNF_DN</TD><TD>84</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PPARG</TD></TR>
<TR><TD>1.473e-02</TD><TD>-4.22</TD><TD>V$ICSBP_Q6</TD><TD>MSigDB lists</TD><TD>V$ICSBP_Q6</TD><TD>235</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX1,ANGPTL4</TD></TR>
<TR><TD>1.473e-02</TD><TD>-4.22</TD><TD>V$GATA4_Q3</TD><TD>MSigDB lists</TD><TD>V$GATA4_Q3</TD><TD>235</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,WNT16,NR2F2</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>SERPINH1 (serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1))</TD><TD>protein interactions</TD><TD>871</TD><TD>85</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PPARG</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Integrin_bsu_tail</TD><TD>interpro domains</TD><TD>IPR012896</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Munc13_1</TD><TD>interpro domains</TD><TD>IPR014770</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Intermed_filament_DNA-bd</TD><TD>interpro domains</TD><TD>IPR006821</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>1.484e-02</TD><TD>-4.21</TD><TD>synapse</TD><TD>cellular component</TD><TD>GO:0045202</TD><TD>679</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>CLSTN2,SLC40A1,PDLIM5,UNC13A,NT5E</TD></TR>
<TR><TD>1.487e-02</TD><TD>-4.21</TD><TD>Krukenberg_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Krukenberg_tumour</TD><TD>7</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>1.489e-02</TD><TD>-4.21</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.10.110.10</TD><TD>72</TD><TD>2</TD><TD>9988</TD><TD>26</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.490e-02</TD><TD>-4.21</TD><TD>V$FOXM1_01</TD><TD>MSigDB lists</TD><TD>V$FOXM1_01</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>STXBP6,NR2F1,VSNL1</TD></TR>
<TR><TD>1.490e-02</TD><TD>-4.21</TD><TD>V$P300_01</TD><TD>MSigDB lists</TD><TD>V$P300_01</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,CAMK2D,NR2F1</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>regulation of striated muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051153</TD><TD>83</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX1</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>MSigDB lists</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>KMCATNNWGGA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>KMCATNNWGGA_UNKNOWN</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>hemidesmosome</TD><TD>cellular component</TD><TD>GO:0030056</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.506e-02</TD><TD>-4.20</TD><TD>RRAGTTGT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RRAGTTGT_UNKNOWN</TD><TD>237</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,MSX2,NR2F1</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>RPS4Y1 (ribosomal protein S4, Y-linked 1)</TD><TD>protein interactions</TD><TD>6192</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>XIRP1 (xin actin binding repeat containing 1)</TD><TD>protein interactions</TD><TD>165904</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>CHRNA4 (cholinergic receptor, nicotinic alpha 4)</TD><TD>protein interactions</TD><TD>1137</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VSNL1</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>MAP7D3 (MAP7 domain containing 3)</TD><TD>protein interactions</TD><TD>79649</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>Rxra (retinoid X receptor alpha)</TD><TD>protein interactions</TD><TD>20181</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>FAM171A2 (family with sequence similarity 171, member A2)</TD><TD>protein interactions</TD><TD>284069</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>Gadd45b (growth arrest and DNA-damage-inducible 45 beta)</TD><TD>protein interactions</TD><TD>17873</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>KISS1 (KiSS-1 metastasis-suppressor)</TD><TD>protein interactions</TD><TD>3814</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MMP16</TD></TR>
<TR><TD>1.523e-02</TD><TD>-4.18</TD><TD>V$ISRE_01</TD><TD>MSigDB lists</TD><TD>V$ISRE_01</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX1,ANGPTL4</TD></TR>
<TR><TD>1.523e-02</TD><TD>-4.18</TD><TD>V$SRY_02</TD><TD>MSigDB lists</TD><TD>V$SRY_02</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,FGF9,ZIC2</TD></TR>
<TR><TD>1.524e-02</TD><TD>-4.18</TD><TD>VPS10</TD><TD>smart domains</TD><TD>SM00602</TD><TD>5</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3</TD><TD>MSigDB lists</TD><TD>BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP</TD><TD>MSigDB lists</TD><TD>MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>LUDWICZEK_TREATING_IRON_OVERLOAD</TD><TD>MSigDB lists</TD><TD>LUDWICZEK_TREATING_IRON_OVERLOAD</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1</TD></TR>
<TR><TD>1.540e-02</TD><TD>-4.17</TD><TD>V$CP2_02</TD><TD>MSigDB lists</TD><TD>V$CP2_02</TD><TD>239</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NR2F1,GRHL3</TD></TR>
<TR><TD>1.542e-02</TD><TD>-4.17</TD><TD>TFAP4 (transcription factor AP-4 (activating enhancer binding protein 4))</TD><TD>protein interactions</TD><TD>7023</TD><TD>87</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>1.543e-02</TD><TD>-4.17</TD><TD>MODULE_18</TD><TD>MSigDB lists</TD><TD>MODULE_18</TD><TD>440</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,MSX1,CD44,VSNL1</TD></TR>
<TR><TD>1.543e-02</TD><TD>-4.17</TD><TD>Homeobox_metazoa</TD><TD>interpro domains</TD><TD>IPR020479</TD><TD>89</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.554e-02</TD><TD>-4.16</TD><TD>response to inorganic substance</TD><TD>biological process</TD><TD>GO:0010035</TD><TD>431</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,CAMK2D,PPARG,NT5E</TD></TR>
<TR><TD>1.560e-02</TD><TD>-4.16</TD><TD>diphosphotransferase activity</TD><TD>molecular function</TD><TD>GO:0016778</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.560e-02</TD><TD>-4.16</TD><TD>iron ion transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0005381</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>regulation of smooth muscle cell proliferation</TD><TD>biological process</TD><TD>GO:0048660</TD><TD>85</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PPARG</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>cerebral cortex regionalization</TD><TD>biological process</TD><TD>GO:0021796</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F1</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>response to cGMP</TD><TD>biological process</TD><TD>GO:0070305</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>negative regulation of collagen biosynthetic process</TD><TD>biological process</TD><TD>GO:0032966</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>AMP biosynthetic process</TD><TD>biological process</TD><TD>GO:0006167</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>endothelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0060839</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.575e-02</TD><TD>-4.15</TD><TD>V$TFIIA_Q6</TD><TD>MSigDB lists</TD><TD>V$TFIIA_Q6</TD><TD>241</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,PRPS1,NR2F1</TD></TR>
<TR><TD>1.584e-02</TD><TD>-4.15</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma</TD><TD>90</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>CAMK2D,PDE3A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>PKD</TD><TD>pfam domains</TD><TD>PF00801</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>GAF</TD><TD>pfam domains</TD><TD>PF01590</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>Filament_head</TD><TD>pfam domains</TD><TD>PF04732</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>VIM</TD></TR>
<TR><TD>1.590e-02</TD><TD>-4.14</TD><TD>positive regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009891</TD><TD>1796</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,ZIC2,NR2F2,NR2F1,PKIB,NT5E</TD></TR>
<TR><TD>1.592e-02</TD><TD>-4.14</TD><TD>V$SF1_Q6</TD><TD>MSigDB lists</TD><TD>V$SF1_Q6</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NEBL,VSNL1</TD></TR>
<TR><TD>1.592e-02</TD><TD>-4.14</TD><TD>V$DR1_Q3</TD><TD>MSigDB lists</TD><TD>V$DR1_Q3</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NR2F2,NR2F1</TD></TR>
<TR><TD>1.592e-02</TD><TD>-4.14</TD><TD>V$NFKAPPAB_01</TD><TD>MSigDB lists</TD><TD>V$NFKAPPAB_01</TD><TD>242</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,ITGB4,NR2F2</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>BENPORATH_NANOG_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_NANOG_TARGETS</TD><TD>942</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,SLC40A1,VIM,ZIC2,NEBL,PKIB</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>LEE_AGING_NEOCORTEX_UP</TD><TD>MSigDB lists</TD><TD>LEE_AGING_NEOCORTEX_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>HUMMERICH_SKIN_CANCER_PROGRESSION_UP</TD><TD>MSigDB lists</TD><TD>HUMMERICH_SKIN_CANCER_PROGRESSION_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>WINTER_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,ANGPTL4</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP</TD><TD>MSigDB lists</TD><TD>NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,FGF9</TD></TR>
<TR><TD>1.602e-02</TD><TD>-4.13</TD><TD>activation of MAPKK activity</TD><TD>biological process</TD><TD>GO:0000186</TD><TD>237</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>molecular transducer activity</TD><TD>molecular function</TD><TD>GO:0060089</TD><TD>1805</TD><TD>9</TD><TD>16491</TD><TD>37</TD>
<TD>EFNB2,TNIK,SLC40A1,PPARG,SORCS2,NR2F2,CD44,ITGB4,NR2F1</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>V$TST1_01</TD><TD>MSigDB lists</TD><TD>V$TST1_01</TD><TD>243</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CSMD3,NR2F2</TD></TR>
<TR><TD>1.611e-02</TD><TD>-4.13</TD><TD>wound healing</TD><TD>biological process</TD><TD>GO:0042060</TD><TD>667</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CD44,PDE10A,PDE3A,GRHL3</TD></TR>
<TR><TD>1.626e-02</TD><TD>-4.12</TD><TD>human chr8q13.3</TD><TD>chromosome location</TD><TD>human chr8q13.3</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>1.626e-02</TD><TD>-4.12</TD><TD>human chr2p24.3</TD><TD>chromosome location</TD><TD>human chr2p24.3</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>VSNL1</TD></TR>
<TR><TD>1.626e-02</TD><TD>-4.12</TD><TD>human chr15q26</TD><TD>chromosome location</TD><TD>human chr15q26</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.627e-02</TD><TD>-4.12</TD><TD>RICKMAN_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>RICKMAN_METASTASIS_DN</TD><TD>244</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,ITGB4,CD44</TD></TR>
<TR><TD>1.627e-02</TD><TD>-4.12</TD><TD>V$MYOD_01</TD><TD>MSigDB lists</TD><TD>V$MYOD_01</TD><TD>244</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,FGF9,SORCS2</TD></TR>
<TR><TD>1.632e-02</TD><TD>-4.12</TD><TD>WNT_SIGNALING</TD><TD>MSigDB lists</TD><TD>WNT_SIGNALING</TD><TD>89</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,WNT16</TD></TR>
<TR><TD>1.632e-02</TD><TD>-4.12</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>89</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SORCS2,PKIB</TD></TR>
<TR><TD>1.635e-02</TD><TD>-4.11</TD><TD>neural tube closure</TD><TD>biological process</TD><TD>GO:0001843</TD><TD>87</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>1.635e-02</TD><TD>-4.11</TD><TD>regulation of DNA binding</TD><TD>biological process</TD><TD>GO:0051101</TD><TD>87</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.638e-02</TD><TD>-4.11</TD><TD>ACTGTGA,MIR-27A,MIR-27B</TD><TD>MSigDB lists</TD><TD>ACTGTGA,MIR-27A,MIR-27B</TD><TD>448</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,PPARG,PDLIM5,PDE3A</TD></TR>
<TR><TD>1.638e-02</TD><TD>-4.11</TD><TD>regulation of cellular response to growth factor stimulus</TD><TD>biological process</TD><TD>GO:0090287</TD><TD>239</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MSX1</TD></TR>
<TR><TD>1.639e-02</TD><TD>-4.11</TD><TD>blood vessel development</TD><TD>biological process</TD><TD>GO:0001568</TD><TD>438</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>1.644e-02</TD><TD>-4.11</TD><TD>EPB41L3 (erythrocyte membrane protein band 4.1-like 3)</TD><TD>protein interactions</TD><TD>23136</TD><TD>90</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CD44,UNC13A</TD></TR>
<TR><TD>1.644e-02</TD><TD>-4.11</TD><TD>NCK1 (NCK adaptor protein 1)</TD><TD>protein interactions</TD><TD>4690</TD><TD>90</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>RHOU,TNIK</TD></TR>
<TR><TD>1.651e-02</TD><TD>-4.10</TD><TD>synovial_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>synovial_sarcoma</TD><TD>92</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>CAMK2D,PDE3A</TD></TR>
<TR><TD>1.652e-02</TD><TD>-4.10</TD><TD>cellular response to chemical stimulus</TD><TD>biological process</TD><TD>GO:0070887</TD><TD>2460</TD><TD>11</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,SLC40A1,CAMK2D,FGF9,MSX1,PPARG,WNT16,CD44,NR2F2,PDE3A,NR2F1</TD></TR>
<TR><TD>1.656e-02</TD><TD>-4.10</TD><TD>negative regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903507</TD><TD>1206</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.663e-02</TD><TD>-4.10</TD><TD>V$OCT_C</TD><TD>MSigDB lists</TD><TD>V$OCT_C</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>STXBP6,GRHL3,VSNL1</TD></TR>
<TR><TD>1.663e-02</TD><TD>-4.10</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,PPARG,NR2F1</TD></TR>
<TR><TD>1.663e-02</TD><TD>-4.10</TD><TD>V$NRF2_Q4</TD><TD>MSigDB lists</TD><TD>V$NRF2_Q4</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,FGF9,CD44</TD></TR>
<TR><TD>1.667e-02</TD><TD>-4.09</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN</TD><TD>90</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16,GRHL3</TD></TR>
<TR><TD>1.667e-02</TD><TD>-4.09</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T4</TD><TD>MSigDB lists</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T4</TD><TD>90</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NT5E</TD></TR>
<TR><TD>1.671e-02</TD><TD>-4.09</TD><TD>tube closure</TD><TD>biological process</TD><TD>GO:0060606</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>1.671e-02</TD><TD>-4.09</TD><TD>purine ribonucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0046129</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.671e-02</TD><TD>-4.09</TD><TD>purine nucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0042451</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>1.671e-02</TD><TD>-4.09</TD><TD>endothelium development</TD><TD>biological process</TD><TD>GO:0003158</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,NR2F2</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>V$NFKB_Q6</TD><TD>MSigDB lists</TD><TD>V$NFKB_Q6</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,NR2F2,TANK</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>V$GATA6_01</TD><TD>MSigDB lists</TD><TD>V$GATA6_01</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,NR2F1,VSNL1</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>GTGCCTT,MIR-506</TD><TD>MSigDB lists</TD><TD>GTGCCTT,MIR-506</TD><TD>690</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,SLCO5A1,VIM,NEBL,PRPS1</TD></TR>
<TR><TD>1.689e-02</TD><TD>-4.08</TD><TD>positive regulation of cell development</TD><TD>biological process</TD><TD>GO:0010720</TD><TD>442</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>S100A10,PPARG,UNC13A,PDE3A</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>Ephrin</TD><TD>interpro domains</TD><TD>IPR031328</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>Ephrin_CS</TD><TD>interpro domains</TD><TD>IPR019765</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>GAF_dom-like</TD><TD>interpro domains</TD><TD>IPR029016</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>GAF</TD><TD>interpro domains</TD><TD>IPR003018</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>Integrin_bsu_N</TD><TD>interpro domains</TD><TD>IPR002369</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>Ephrin_RBD</TD><TD>interpro domains</TD><TD>IPR001799</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.697e-02</TD><TD>-4.08</TD><TD>phosphoric diester hydrolase activity</TD><TD>molecular function</TD><TD>GO:0008081</TD><TD>89</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.699e-02</TD><TD>-4.08</TD><TD>V$PPAR_DR1_Q2</TD><TD>MSigDB lists</TD><TD>V$PPAR_DR1_Q2</TD><TD>248</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NR2F2,NR2F1</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0009117</TD><TD>443</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>response to BMP</TD><TD>biological process</TD><TD>GO:0071772</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>cellular response to BMP stimulus</TD><TD>biological process</TD><TD>GO:0071773</TD><TD>89</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>1.714e-02</TD><TD>-4.07</TD><TD>GGGTGGRR_V$PAX4_03</TD><TD>MSigDB lists</TD><TD>GGGTGGRR_V$PAX4_03</TD><TD>1241</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,MSX2,VIM,ZIC2,S100A10,NR2F1,GRHL3</TD></TR>
<TR><TD>1.717e-02</TD><TD>-4.06</TD><TD>JAEGER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>JAEGER_METASTASIS_DN</TD><TD>249</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NEBL,VSNL1</TD></TR>
<TR><TD>1.717e-02</TD><TD>-4.06</TD><TD>V$OCT1_01</TD><TD>MSigDB lists</TD><TD>V$OCT1_01</TD><TD>249</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,NR2F2,GRHL3</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>MTMR1 (myotubularin related protein 1)</TD><TD>protein interactions</TD><TD>8776</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>KIAA0391 (KIAA0391)</TD><TD>protein interactions</TD><TD>9692</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>METTL6 (methyltransferase like 6)</TD><TD>protein interactions</TD><TD>131965</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>DENND6A (DENN/MADD domain containing 6A)</TD><TD>protein interactions</TD><TD>201627</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>TMEM65 (transmembrane protein 65)</TD><TD>protein interactions</TD><TD>157378</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>SLC47A1 (solute carrier family 47 (multidrug and toxin extrusion), member 1)</TD><TD>protein interactions</TD><TD>55244</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>PLEKHH3 (pleckstrin homology domain containing, family H (with MyTH4 domain) member 3)</TD><TD>protein interactions</TD><TD>79990</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>SLC44A1 (solute carrier family 44 (choline transporter), member 1)</TD><TD>protein interactions</TD><TD>23446</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>PLEKHG4 (pleckstrin homology domain containing, family G (with RhoGef domain) member 4)</TD><TD>protein interactions</TD><TD>25894</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>FNDC3B (fibronectin type III domain containing 3B)</TD><TD>protein interactions</TD><TD>64778</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>ARL8A (ADP-ribosylation factor like GTPase 8A)</TD><TD>protein interactions</TD><TD>127829</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>SH3YL1 (SH3 and SYLF domain containing 1)</TD><TD>protein interactions</TD><TD>26751</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>HSDL1 (hydroxysteroid dehydrogenase like 1)</TD><TD>protein interactions</TD><TD>83693</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.735e-02</TD><TD>-4.05</TD><TD>RACCACAR_V$AML_Q6</TD><TD>MSigDB lists</TD><TD>RACCACAR_V$AML_Q6</TD><TD>250</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,PPARG,GRHL3</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>chr6q26</TD><TD>MSigDB lists</TD><TD>chr6q26</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_DN</TD><TD>MSigDB lists</TD><TD>RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_UP</TD><TD>MSigDB lists</TD><TD>MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_UP</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>MIKKELSEN_PLURIPOTENT_STATE_DN</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_PLURIPOTENT_STATE_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>SCHMIDT_POR_TARGETS_IN_LIMB_BUD_DN</TD><TD>MSigDB lists</TD><TD>SCHMIDT_POR_TARGETS_IN_LIMB_BUD_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.749e-02</TD><TD>-4.05</TD><TD>prostate-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma</TD><TD>9403</TD><TD>27</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,FGF9,SLC40A1,MSX1,PPARG,STXBP6,GRHL3,VSNL1,CLSTN2,RNF43,ANGPTL4,PDE3A,RHOU,MSX2,CAMK2D,NEBL,PDE10A,UNC13A,TANK,SLCO5A1,CSMD3,WNT16,SORCS2,PDLIM5,MMP16,NT5E</TD></TR>
<TR><TD>1.750e-02</TD><TD>-4.05</TD><TD>adenoma</TD><TD>COSMIC cancer mutations</TD><TD>adenoma</TD><TD>2966</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,RHOU,NEBL,UNC13A,CLSTN2,CSMD3,RNF43,ANGPTL4,MMP16,PDE3A,NR2F1,NT5E</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$OCT1_B</TD><TD>MSigDB lists</TD><TD>V$OCT1_B</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,GRHL3,VSNL1</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$STAT4_01</TD><TD>MSigDB lists</TD><TD>V$STAT4_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,GRHL3,VSNL1</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$BACH1_01</TD><TD>MSigDB lists</TD><TD>V$BACH1_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,ITGB4,S100A10</TD></TR>
<TR><TD>1.762e-02</TD><TD>-4.04</TD><TD>negative regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902679</TD><TD>1221</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>1.766e-02</TD><TD>-4.04</TD><TD>receptor activity</TD><TD>molecular function</TD><TD>GO:0004872</TD><TD>1522</TD><TD>8</TD><TD>16491</TD><TD>37</TD>
<TD>EFNB2,SLC40A1,PPARG,SORCS2,NR2F2,CD44,ITGB4,NR2F1</TD></TR>
<TR><TD>1.773e-02</TD><TD>-4.03</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>93</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,STXBP6</TD></TR>
<TR><TD>1.781e-02</TD><TD>-4.03</TD><TD>cAMP-dependent protein kinase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0004862</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>1.781e-02</TD><TD>-4.03</TD><TD>hyalurononglucosaminidase activity</TD><TD>molecular function</TD><TD>GO:0004415</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>1.781e-02</TD><TD>-4.03</TD><TD>MAP kinase kinase kinase kinase activity</TD><TD>molecular function</TD><TD>GO:0008349</TD><TD>8</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>synaptic vesicle docking</TD><TD>biological process</TD><TD>GO:0016081</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>regulation of SNARE complex assembly</TD><TD>biological process</TD><TD>GO:0035542</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>STXBP6</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>nucleoside monophosphate catabolic process</TD><TD>biological process</TD><TD>GO:0009125</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>negative regulation of keratinocyte differentiation</TD><TD>biological process</TD><TD>GO:0045617</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>regulation of nodal signaling pathway</TD><TD>biological process</TD><TD>GO:1900107</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>cellular response to hyperoxia</TD><TD>biological process</TD><TD>GO:0071455</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>cellular response to increased oxygen levels</TD><TD>biological process</TD><TD>GO:0036295</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>stress-induced premature senescence</TD><TD>biological process</TD><TD>GO:0090400</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>adenosine metabolic process</TD><TD>biological process</TD><TD>GO:0046085</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>optic cup morphogenesis involved in camera-type eye development</TD><TD>biological process</TD><TD>GO:0002072</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>negative regulation of cAMP-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:2000480</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>negative regulation of collagen metabolic process</TD><TD>biological process</TD><TD>GO:0010713</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>exocyst localization</TD><TD>biological process</TD><TD>GO:0051601</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>STXBP6</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>activation of JNKK activity</TD><TD>biological process</TD><TD>GO:0007256</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.787e-02</TD><TD>-4.02</TD><TD>bone trabecula formation</TD><TD>biological process</TD><TD>GO:0060346</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>1.788e-02</TD><TD>-4.02</TD><TD>human chr12p12</TD><TD>chromosome location</TD><TD>human chr12p12</TD><TD>11</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PDE3A</TD></TR>
<TR><TD>1.788e-02</TD><TD>-4.02</TD><TD>human chr2q32</TD><TD>chromosome location</TD><TD>human chr2q32</TD><TD>11</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>1.791e-02</TD><TD>-4.02</TD><TD>V$CP2_01</TD><TD>MSigDB lists</TD><TD>V$CP2_01</TD><TD>253</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,ZIC2,GRHL3</TD></TR>
<TR><TD>1.793e-02</TD><TD>-4.02</TD><TD>nucleoside phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0006753</TD><TD>450</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>1.797e-02</TD><TD>-4.02</TD><TD>LIM_DOMAIN_1</TD><TD>prosite domains</TD><TD>PS00478</TD><TD>72</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.797e-02</TD><TD>-4.02</TD><TD>LIM_DOMAIN_2</TD><TD>prosite domains</TD><TD>PS50023</TD><TD>72</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>1.809e-02</TD><TD>-4.01</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.450.40</TD><TD>7</TD><TD>1</TD><TD>9988</TD><TD>26</TD>
<TD>PDE10A</TD></TR>
<TR><TD>1.809e-02</TD><TD>-4.01</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T7</TD><TD>MSigDB lists</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_T7</TD><TD>94</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,PRPS1</TD></TR>
<TR><TD>1.813e-02</TD><TD>-4.01</TD><TD>LEE_BMP2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>LEE_BMP2_TARGETS_UP</TD><TD>703</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,MSX1,ITGB4,SORCS2,STXBP6</TD></TR>
<TR><TD>1.814e-02</TD><TD>-4.01</TD><TD>Ephrin</TD><TD>pfam domains</TD><TD>PF00812</TD><TD>8</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.814e-02</TD><TD>-4.01</TD><TD>Integrin_beta</TD><TD>pfam domains</TD><TD>PF00362</TD><TD>8</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.815e-02</TD><TD>-4.01</TD><TD>primary_central_nervous_system_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>primary_central_nervous_system_lymphoma</TD><TD>723</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,NR2F2,SORCS2,MMP16</TD></TR>
<TR><TD>1.815e-02</TD><TD>-4.01</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma</TD><TD>723</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,NR2F2,SORCS2,MMP16</TD></TR>
<TR><TD>1.817e-02</TD><TD>-4.01</TD><TD>primary neural tube formation</TD><TD>biological process</TD><TD>GO:0014020</TD><TD>92</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>1.820e-02</TD><TD>-4.01</TD><TD>positive regulation of transferase activity</TD><TD>biological process</TD><TD>GO:0051347</TD><TD>688</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,PKIB</TD></TR>
<TR><TD>1.825e-02</TD><TD>-4.00</TD><TD>ATXN1 (ataxin 1)</TD><TD>protein interactions</TD><TD>6310</TD><TD>257</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,ITGB4,VSNL1</TD></TR>
<TR><TD>1.826e-02</TD><TD>-4.00</TD><TD>ossification</TD><TD>biological process</TD><TD>GO:0001503</TD><TD>249</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9,MMP16</TD></TR>
<TR><TD>1.828e-02</TD><TD>-4.00</TD><TD>LU_AGING_BRAIN_UP</TD><TD>MSigDB lists</TD><TD>LU_AGING_BRAIN_UP</TD><TD>255</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,NEBL,PDLIM5</TD></TR>
<TR><TD>1.828e-02</TD><TD>-4.00</TD><TD>V$NFKB_C</TD><TD>MSigDB lists</TD><TD>V$NFKB_C</TD><TD>255</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,ITGB4,S100A10</TD></TR>
<TR><TD>1.833e-02</TD><TD>-4.00</TD><TD>adherens junction</TD><TD>cellular component</TD><TD>GO:0005912</TD><TD>471</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>1.844e-02</TD><TD>-3.99</TD><TD>seminoma</TD><TD>COSMIC cancer mutations</TD><TD>seminoma</TD><TD>726</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,TNIK,CAMK2D,PDE10A</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>CAHOY_NEURONAL</TD><TD>MSigDB lists</TD><TD>CAHOY_NEURONAL</TD><TD>95</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,FGF9</TD></TR>
<TR><TD>1.858e-02</TD><TD>-3.99</TD><TD>cell surface</TD><TD>cellular component</TD><TD>GO:0009986</TD><TD>719</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>CLSTN2,ITGB4,CD44,MMP16,NT5E</TD></TR>
<TR><TD>1.864e-02</TD><TD>-3.98</TD><TD>cell fate commitment</TD><TD>biological process</TD><TD>GO:0045165</TD><TD>251</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16,NR2F2,PPARG</TD></TR>
<TR><TD>1.869e-02</TD><TD>-3.98</TD><TD>G-protein coupled receptor binding</TD><TD>molecular function</TD><TD>GO:0001664</TD><TD>252</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>RNF43,WNT16,ITGB4</TD></TR>
<TR><TD>1.873e-02</TD><TD>-3.98</TD><TD>activation of protein kinase activity</TD><TD>biological process</TD><TD>GO:0032147</TD><TD>456</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.97</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>467</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,CAMK2D,CD44,MMP16</TD></TR>
<TR><TD>1.882e-02</TD><TD>-3.97</TD><TD>CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN</TD><TD>MSigDB lists</TD><TD>CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>1.882e-02</TD><TD>-3.97</TD><TD>NAKAMURA_ADIPOGENESIS_LATE_UP</TD><TD>MSigDB lists</TD><TD>NAKAMURA_ADIPOGENESIS_LATE_UP</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,PDE10A</TD></TR>
<TR><TD>1.885e-02</TD><TD>-3.97</TD><TD>V$IK2_01</TD><TD>MSigDB lists</TD><TD>V$IK2_01</TD><TD>258</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,PDLIM5,VSNL1</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>EEF1D (eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein))</TD><TD>protein interactions</TD><TD>1936</TD><TD>97</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,NR2F1</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>PKD/Chitinase_dom</TD><TD>interpro domains</TD><TD>IPR022409</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SORCS2</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>Integrin_bsu</TD><TD>interpro domains</TD><TD>IPR015812</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>Calx_beta</TD><TD>interpro domains</TD><TD>IPR003644</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.904e-02</TD><TD>-3.96</TD><TD>V$HOXA4_Q2</TD><TD>MSigDB lists</TD><TD>V$HOXA4_Q2</TD><TD>259</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,CAMK2D,NR2F1</TD></TR>
<TR><TD>1.908e-02</TD><TD>-3.96</TD><TD>Sertoli-Leydig_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Sertoli-Leydig_cell_tumour</TD><TD>9</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>1.908e-02</TD><TD>-3.96</TD><TD>ovary-sex_cord-stromal_tumour-Sertoli-Leydig_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-sex_cord-stromal_tumour-Sertoli-Leydig_cell_tumour</TD><TD>9</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>1.915e-02</TD><TD>-3.96</TD><TD>CTGCAGY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTGCAGY_UNKNOWN</TD><TD>713</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,FGF9,CAMK2D,NR2F1,VSNL1</TD></TR>
<TR><TD>1.919e-02</TD><TD>-3.95</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>97</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,VIM</TD></TR>
<TR><TD>1.924e-02</TD><TD>-3.95</TD><TD>ROZANOV_MMP14_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ROZANOV_MMP14_TARGETS_UP</TD><TD>260</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,MSX1,PPARG</TD></TR>
<TR><TD>1.924e-02</TD><TD>-3.95</TD><TD>V$AP1_C</TD><TD>MSigDB lists</TD><TD>V$AP1_C</TD><TD>260</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,CSMD3,FGF9</TD></TR>
<TR><TD>1.927e-02</TD><TD>-3.95</TD><TD>Ser/Thr_dual-sp_kinase</TD><TD>interpro domains</TD><TD>IPR002290</TD><TD>268</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>1.930e-02</TD><TD>-3.95</TD><TD>CD4 (CD4 molecule)</TD><TD>protein interactions</TD><TD>920</TD><TD>98</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,CD44</TD></TR>
<TR><TD>1.932e-02</TD><TD>-3.95</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>MSigDB lists</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>471</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,CD44,STXBP6,ANGPTL4</TD></TR>
<TR><TD>1.943e-02</TD><TD>-3.94</TD><TD>HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS</TD><TD>MSigDB lists</TD><TD>HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS</TD><TD>261</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>1.945e-02</TD><TD>-3.94</TD><TD>SWEET_LUNG_CANCER_KRAS_UP</TD><TD>MSigDB lists</TD><TD>SWEET_LUNG_CANCER_KRAS_UP</TD><TD>472</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PPARG,TANK,NR2F1</TD></TR>
<TR><TD>1.947e-02</TD><TD>-3.94</TD><TD>FGFR3b ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190371</TD><TD>7</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>SLC7A2 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 2)</TD><TD>protein interactions</TD><TD>6542</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>FLVCR1 (feline leukemia virus subgroup C cellular receptor 1)</TD><TD>protein interactions</TD><TD>28982</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>OSBP2 (oxysterol binding protein 2)</TD><TD>protein interactions</TD><TD>23762</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>DIS3L2 (DIS3 like 3'-5' exoribonuclease 2)</TD><TD>protein interactions</TD><TD>129563</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>KCNK3 (potassium channel, two pore domain subfamily K, member 3)</TD><TD>protein interactions</TD><TD>3777</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>ALOX12 (arachidonate 12-lipoxygenase)</TD><TD>protein interactions</TD><TD>239</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>EPHA5 (EPH receptor A5)</TD><TD>protein interactions</TD><TD>2044</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>LOR (loricrin)</TD><TD>protein interactions</TD><TD>4014</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>PPM1E (protein phosphatase, Mg2+/Mn2+ dependent, 1E)</TD><TD>protein interactions</TD><TD>22843</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>PDZRN3 (PDZ domain containing ring finger 3)</TD><TD>protein interactions</TD><TD>23024</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>DNAL4 (dynein, axonemal, light chain 4)</TD><TD>protein interactions</TD><TD>10126</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>TNP1 (transition protein 1 (during histone to protamine replacement))</TD><TD>protein interactions</TD><TD>7141</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>IFNGR2 (interferon gamma receptor 2 (interferon gamma transducer 1))</TD><TD>protein interactions</TD><TD>3460</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>1.948e-02</TD><TD>-3.94</TD><TD>EPHB4 (EPH receptor B4)</TD><TD>protein interactions</TD><TD>2050</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.949e-02</TD><TD>-3.94</TD><TD>human chr15q26.2</TD><TD>chromosome location</TD><TD>human chr15q26.2</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>NR2F2-AS1</TD></TR>
<TR><TD>1.949e-02</TD><TD>-3.94</TD><TD>human chr3q26.31</TD><TD>chromosome location</TD><TD>human chr3q26.31</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>TNIK</TD></TR>
<TR><TD>1.949e-02</TD><TD>-3.94</TD><TD>human chr10q24.33</TD><TD>chromosome location</TD><TD>human chr10q24.33</TD><TD>12</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>SLK</TD></TR>
<TR><TD>1.955e-02</TD><TD>-3.93</TD><TD>vasculature development</TD><TD>biological process</TD><TD>GO:0001944</TD><TD>462</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,NR2F2,ANGPTL4</TD></TR>
<TR><TD>1.956e-02</TD><TD>-3.93</TD><TD>MCCLUNG_CREB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MCCLUNG_CREB1_TARGETS_UP</TD><TD>98</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16,NR2F1</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>THILLAINADESAN_ZNF217_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>THILLAINADESAN_ZNF217_TARGETS_DN</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>XU_HGF_TARGETS_REPRESSED_BY_AKT1_UP</TD><TD>MSigDB lists</TD><TD>XU_HGF_TARGETS_REPRESSED_BY_AKT1_UP</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>chr2p</TD><TD>MSigDB lists</TD><TD>chr2p</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VSNL1</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>OHASHI_AURKB_TARGETS</TD><TD>MSigDB lists</TD><TD>OHASHI_AURKB_TARGETS</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>1.982e-02</TD><TD>-3.92</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>488</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,SORCS2,PDLIM5,PDE3A</TD></TR>
<TR><TD>1.982e-02</TD><TD>-3.92</TD><TD>carbohydrate derivative binding</TD><TD>molecular function</TD><TD>GO:0097367</TD><TD>2195</TD><TD>10</TD><TD>16491</TD><TD>37</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,SLK,PDE10A,VIM,CD44,PRPS1,PDE3A</TD></TR>
<TR><TD>1.984e-02</TD><TD>-3.92</TD><TD>muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0042692</TD><TD>257</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,NEBL,PDLIM5</TD></TR>
<TR><TD>1.985e-02</TD><TD>-3.92</TD><TD>Platelet homeostasis</TD><TD>REACTOME pathways</TD><TD>R-HSA-418346</TD><TD>78</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>1.989e-02</TD><TD>-3.92</TD><TD>MHD1</TD><TD>prosite domains</TD><TD>PS51258</TD><TD>7</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>UNC13A</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.92</TD><TD>GTGTTGA,MIR-505</TD><TD>MSigDB lists</TD><TD>GTGTTGA,MIR-505</TD><TD>99</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,ZIC2</TD></TR>
<TR><TD>1.997e-02</TD><TD>-3.91</TD><TD>PPAR signaling pathway</TD><TD>KEGG pathways</TD><TD>ko03320</TD><TD>69</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.997e-02</TD><TD>-3.91</TD><TD>PPAR signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa03320</TD><TD>69</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>1.999e-02</TD><TD>-3.91</TD><TD>protein homodimerization activity</TD><TD>molecular function</TD><TD>GO:0042803</TD><TD>707</TD><TD>5</TD><TD>16491</TD><TD>37</TD>
<TD>CAMK2D,NR2F2,S100A10,PRPS1,SLK</TD></TR>
<TR><TD>2.002e-02</TD><TD>-3.91</TD><TD>filamin binding</TD><TD>molecular function</TD><TD>GO:0031005</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.002e-02</TD><TD>-3.91</TD><TD>prostaglandin receptor activity</TD><TD>molecular function</TD><TD>GO:0004955</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.004e-02</TD><TD>-3.91</TD><TD>muscle system process</TD><TD>biological process</TD><TD>GO:0003012</TD><TD>258</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,CAMK2D,PDLIM5</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>cGMP-mediated signaling</TD><TD>biological process</TD><TD>GO:0019934</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>multicellular organismal iron ion homeostasis</TD><TD>biological process</TD><TD>GO:0060586</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>diet induced thermogenesis</TD><TD>biological process</TD><TD>GO:0002024</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>regulation of oocyte development</TD><TD>biological process</TD><TD>GO:0060281</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>negative regulation of multicellular organismal metabolic process</TD><TD>biological process</TD><TD>GO:0044252</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>regulation of cell communication by electrical coupling involved in cardiac conduction</TD><TD>biological process</TD><TD>GO:1901844</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>adaptive thermogenesis</TD><TD>biological process</TD><TD>GO:1990845</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>regulation of relaxation of muscle</TD><TD>biological process</TD><TD>GO:1901077</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.008e-02</TD><TD>-3.91</TD><TD>enamel mineralization</TD><TD>biological process</TD><TD>GO:0070166</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>positive regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001934</TD><TD>970</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>2.021e-02</TD><TD>-3.90</TD><TD>response to stress</TD><TD>biological process</TD><TD>GO:0006950</TD><TD>3601</TD><TD>14</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,TNIK,CAMK2D,FGF9,PPARG,SLK,PDE10A,TANK,GRHL3,WNT16,ITGB4,CD44,ANGPTL4,PDE3A</TD></TR>
<TR><TD>2.031e-02</TD><TD>-3.90</TD><TD>LIM</TD><TD>smart domains</TD><TD>SM00132</TD><TD>72</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.032e-02</TD><TD>-3.90</TD><TD>ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN</TD><TD>MSigDB lists</TD><TD>ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN</TD><TD>100</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,NR2F2</TD></TR>
<TR><TD>2.032e-02</TD><TD>-3.90</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>100</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,VSNL1</TD></TR>
<TR><TD>2.037e-02</TD><TD>-3.89</TD><TD>positive regulation of intracellular signal transduction</TD><TD>biological process</TD><TD>GO:1902533</TD><TD>973</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,MSX1,CD44</TD></TR>
<TR><TD>2.038e-02</TD><TD>-3.89</TD><TD>Calx-beta</TD><TD>pfam domains</TD><TD>PF03160</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.038e-02</TD><TD>-3.89</TD><TD>Synaptobrevin</TD><TD>pfam domains</TD><TD>PF00957</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>1322</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,CSMD3,LAMA4,MSX2,TNIK,NEBL,SORCS2</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>plasma_cell_myeloma</TD><TD>1322</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,CSMD3,LAMA4,MSX2,TNIK,NEBL,SORCS2</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>large_intestine-rectum-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-rectum-adenoma</TD><TD>103</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,ANGPTL4</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>TUBB2A (tubulin, beta 2A class IIa)</TD><TD>protein interactions</TD><TD>7280</TD><TD>101</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4,TNIK</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>KRAS.600.LUNG.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.600.LUNG.BREAST_UP.V1_UP</TD><TD>266</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>2.046e-02</TD><TD>-3.89</TD><TD>inner ear morphogenesis</TD><TD>biological process</TD><TD>GO:0042472</TD><TD>98</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,GRHL3</TD></TR>
<TR><TD>2.054e-02</TD><TD>-3.89</TD><TD>oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>oligoastrocytoma_Grade_III</TD><TD>274</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,PDE10A,GRHL3</TD></TR>
<TR><TD>2.069e-02</TD><TD>-3.88</TD><TD>negative regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051253</TD><TD>1261</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.070e-02</TD><TD>-3.88</TD><TD>KEGG_MELANOGENESIS</TD><TD>MSigDB lists</TD><TD>KEGG_MELANOGENESIS</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,WNT16</TD></TR>
<TR><TD>2.070e-02</TD><TD>-3.88</TD><TD>ACTGCAG,MIR-17-3P</TD><TD>MSigDB lists</TD><TD>ACTGCAG,MIR-17-3P</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,SORCS2</TD></TR>
<TR><TD>2.079e-02</TD><TD>-3.87</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>104</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,RNF43</TD></TR>
<TR><TD>2.085e-02</TD><TD>-3.87</TD><TD>regulation of striated muscle tissue development</TD><TD>biological process</TD><TD>GO:0016202</TD><TD>99</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.086e-02</TD><TD>-3.87</TD><TD>regulation of binding</TD><TD>biological process</TD><TD>GO:0051098</TD><TD>262</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,S100A10</TD></TR>
<TR><TD>2.100e-02</TD><TD>-3.86</TD><TD>regulation of intracellular signal transduction</TD><TD>biological process</TD><TD>GO:1902531</TD><TD>1566</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,MSX1,PDE10A,WNT16,CD44</TD></TR>
<TR><TD>2.100e-02</TD><TD>-3.86</TD><TD>anchoring junction</TD><TD>cellular component</TD><TD>GO:0070161</TD><TD>491</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>EFNB2,RHOU,VIM,CD44</TD></TR>
<TR><TD>2.103e-02</TD><TD>-3.86</TD><TD>STK33_NOMO_UP</TD><TD>MSigDB lists</TD><TD>STK33_NOMO_UP</TD><TD>269</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CAMK2D,ZIC2</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>human chr6q26</TD><TD>chromosome location</TD><TD>human chr6q26</TD><TD>13</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.112e-02</TD><TD>-3.86</TD><TD>protein N-terminus binding</TD><TD>molecular function</TD><TD>GO:0047485</TD><TD>100</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PDLIM5,UNC13A</TD></TR>
<TR><TD>2.118e-02</TD><TD>-3.85</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>10</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.123e-02</TD><TD>-3.85</TD><TD>V$GATA1_05</TD><TD>MSigDB lists</TD><TD>V$GATA1_05</TD><TD>270</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NR2F2,VSNL1</TD></TR>
<TR><TD>2.123e-02</TD><TD>-3.85</TD><TD>IVANOVA_HEMATOPOIESIS_MATURE_CELL</TD><TD>MSigDB lists</TD><TD>IVANOVA_HEMATOPOIESIS_MATURE_CELL</TD><TD>270</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,SLC40A1,SLK</TD></TR>
<TR><TD>2.124e-02</TD><TD>-3.85</TD><TD>negative regulation of inflammatory response</TD><TD>biological process</TD><TD>GO:0050728</TD><TD>100</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>2.124e-02</TD><TD>-3.85</TD><TD>positive regulation of synaptic transmission</TD><TD>biological process</TD><TD>GO:0050806</TD><TD>100</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CLSTN2,UNC13A</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>MORF_NOS2A</TD><TD>MSigDB lists</TD><TD>MORF_NOS2A</TD><TD>271</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,MSX1,NR2F1</TD></TR>
<TR><TD>2.147e-02</TD><TD>-3.84</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>MSigDB lists</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,GRHL3</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>PDYN (prodynorphin)</TD><TD>protein interactions</TD><TD>5173</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>GLI2 (GLI family zinc finger 2)</TD><TD>protein interactions</TD><TD>2736</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ZIC2</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>TIAM2 (T-cell lymphoma invasion and metastasis 2)</TD><TD>protein interactions</TD><TD>26230</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>VANGL2 (VANGL planar cell polarity protein 2)</TD><TD>protein interactions</TD><TD>57216</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>ZBTB5 (zinc finger and BTB domain containing 5)</TD><TD>protein interactions</TD><TD>9925</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>NFE2L3 (nuclear factor, erythroid 2-like 3)</TD><TD>protein interactions</TD><TD>9603</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>AGTPBP1 (ATP/GTP binding protein 1)</TD><TD>protein interactions</TD><TD>23287</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>TIGD5 (tigger transposable element derived 5)</TD><TD>protein interactions</TD><TD>84948</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>DAD1 (defender against cell death 1)</TD><TD>protein interactions</TD><TD>1603</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>WASF3 (WAS protein family, member 3)</TD><TD>protein interactions</TD><TD>10810</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>APBA3 (amyloid beta (A4) precursor protein-binding, family A, member 3)</TD><TD>protein interactions</TD><TD>9546</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>UPP1 (uridine phosphorylase 1)</TD><TD>protein interactions</TD><TD>7378</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.162e-02</TD><TD>-3.83</TD><TD>ZNF384 (zinc finger protein 384)</TD><TD>protein interactions</TD><TD>171017</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.164e-02</TD><TD>-3.83</TD><TD>regulation of muscle tissue development</TD><TD>biological process</TD><TD>GO:1901861</TD><TD>101</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.164e-02</TD><TD>-3.83</TD><TD>regulation of muscle organ development</TD><TD>biological process</TD><TD>GO:0048634</TD><TD>101</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>2.165e-02</TD><TD>-3.83</TD><TD>CAGGTA_V$AREB6_01</TD><TD>MSigDB lists</TD><TD>CAGGTA_V$AREB6_01</TD><TD>736</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,RNF43,FGF9,MSX1,VSNL1</TD></TR>
<TR><TD>2.169e-02</TD><TD>-3.83</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>488</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,NR2F2,PKIB,C1orf226</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>LOPEZ_MESOTHELIOMA_SURVIVAL_DN</TD><TD>MSigDB lists</TD><TD>LOPEZ_MESOTHELIOMA_SURVIVAL_DN</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>CAFFAREL_RESPONSE_TO_THC_8HR_3_DN</TD><TD>MSigDB lists</TD><TD>CAFFAREL_RESPONSE_TO_THC_8HR_3_DN</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>POSITIVE_REGULATION_OF_ANGIOGENESIS</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_ANGIOGENESIS</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>REACTOME_HYALURONAN_UPTAKE_AND_DEGRADATION</TD><TD>MSigDB lists</TD><TD>REACTOME_HYALURONAN_UPTAKE_AND_DEGRADATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>REACTOME_PURINE_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_PURINE_CATABOLISM</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.178e-02</TD><TD>-3.83</TD><TD>NABA_MATRISOME</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME</TD><TD>1010</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,FGF9,WNT16,S100A10,MMP16,ANGPTL4</TD></TR>
<TR><TD>2.196e-02</TD><TD>-3.82</TD><TD>RAD23B (RAD23 homolog B, nucleotide excision repair protein)</TD><TD>protein interactions</TD><TD>5887</TD><TD>105</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PDLIM5</TD></TR>
<TR><TD>2.199e-02</TD><TD>-3.82</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME_ASSOCIATED</TD><TD>739</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,WNT16,S100A10,MMP16,ANGPTL4</TD></TR>
<TR><TD>2.204e-02</TD><TD>-3.81</TD><TD>ribonucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0042455</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>2.204e-02</TD><TD>-3.81</TD><TD>regulation of fat cell differentiation</TD><TD>biological process</TD><TD>GO:0045598</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,PPARG</TD></TR>
<TR><TD>2.204e-02</TD><TD>-3.81</TD><TD>multicellular organismal metabolic process</TD><TD>biological process</TD><TD>GO:0044236</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,MMP16</TD></TR>
<TR><TD>2.213e-02</TD><TD>-3.81</TD><TD>BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING</TD><TD>MSigDB lists</TD><TD>BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING</TD><TD>491</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NR2F2,NR2F1,NT5E</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>prostanoid receptor activity</TD><TD>molecular function</TD><TD>GO:0004954</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>3',5'-cyclic-AMP phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004115</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>3',5'-cyclic-GMP phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0047555</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>RNF mutants show enhanced WNT signaling and proliferation</TD><TD>REACTOME pathways</TD><TD>R-HSA-5340588</TD><TD>8</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.226e-02</TD><TD>-3.80</TD><TD>COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP</TD><TD>MSigDB lists</TD><TD>COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,VIM</TD></TR>
<TR><TD>2.226e-02</TD><TD>-3.80</TD><TD>REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>2.226e-02</TD><TD>-3.80</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN</TD><TD>MSigDB lists</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,CAMK2D</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>cranial suture morphogenesis</TD><TD>biological process</TD><TD>GO:0060363</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>positive regulation of cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000727</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>cellular response to iron ion</TD><TD>biological process</TD><TD>GO:0071281</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>membrane raft assembly</TD><TD>biological process</TD><TD>GO:0001765</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>S100A10</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>negative regulation of vascular permeability</TD><TD>biological process</TD><TD>GO:0043116</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>positive regulation of phagocytosis, engulfment</TD><TD>biological process</TD><TD>GO:0060100</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>synaptic vesicle maturation</TD><TD>biological process</TD><TD>GO:0016188</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>positive regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051798</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>chondrocyte proliferation</TD><TD>biological process</TD><TD>GO:0035988</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MMP16</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>negative regulation of sodium ion transmembrane transporter activity</TD><TD>biological process</TD><TD>GO:2000650</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.228e-02</TD><TD>-3.80</TD><TD>positive regulation of heterotypic cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0034116</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>2.235e-02</TD><TD>-3.80</TD><TD>TLE1 (transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila))</TD><TD>protein interactions</TD><TD>7088</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>2.235e-02</TD><TD>-3.80</TD><TD>NCOA1 (nuclear receptor coactivator 1)</TD><TD>protein interactions</TD><TD>8648</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>2.248e-02</TD><TD>-3.79</TD><TD>TATTATA,MIR-374</TD><TD>MSigDB lists</TD><TD>TATTATA,MIR-374</TD><TD>276</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,WNT16,NR2F2</TD></TR>
<TR><TD>2.266e-02</TD><TD>-3.79</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>106</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,C1orf226</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>human chr3p25</TD><TD>chromosome location</TD><TD>human chr3p25</TD><TD>14</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>human chr12q14.3</TD><TD>chromosome location</TD><TD>human chr12q14.3</TD><TD>14</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>LOC100507065</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>EPHRIN_RBD_1</TD><TD>prosite domains</TD><TD>PS01299</TD><TD>8</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>EPHRIN_RBD_2</TD><TD>prosite domains</TD><TD>PS51551</TD><TD>8</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.276e-02</TD><TD>-3.78</TD><TD>fibrous_tissue_and_uncertain_origin</TD><TD>COSMIC cancer mutations</TD><TD>fibrous_tissue_and_uncertain_origin</TD><TD>285</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CAMK2D,CD44,PDE3A</TD></TR>
<TR><TD>2.278e-02</TD><TD>-3.78</TD><TD>renal system development</TD><TD>biological process</TD><TD>GO:0072001</TD><TD>271</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,ITGB4,CD44</TD></TR>
<TR><TD>2.279e-02</TD><TD>-3.78</TD><TD>Z disc</TD><TD>cellular component</TD><TD>GO:0030018</TD><TD>108</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.286e-02</TD><TD>-3.78</TD><TD>regulation of synapse organization</TD><TD>biological process</TD><TD>GO:0050807</TD><TD>104</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CLSTN2,PDLIM5</TD></TR>
<TR><TD>2.286e-02</TD><TD>-3.78</TD><TD>neural tube formation</TD><TD>biological process</TD><TD>GO:0001841</TD><TD>104</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>2.292e-02</TD><TD>-3.78</TD><TD>regulation of biological quality</TD><TD>biological process</TD><TD>GO:0065008</TD><TD>3288</TD><TD>13</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,SLC40A1,CAMK2D,MSX1,PPARG,PDE10A,UNC13A,GRHL3,CLSTN2,CD44,PDLIM5,ANGPTL4,PDE3A</TD></TR>
<TR><TD>2.306e-02</TD><TD>-3.77</TD><TD>WANG_HCP_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>WANG_HCP_PROSTATE_CANCER</TD><TD>107</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.306e-02</TD><TD>-3.77</TD><TD>HOOI_ST7_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HOOI_ST7_TARGETS_DN</TD><TD>107</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ANGPTL4</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043565</TD><TD>1004</TD><TD>6</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,MSX1,NR2F2,PPARG,NR2F1,GRHL3</TD></TR>
<TR><TD>2.312e-02</TD><TD>-3.77</TD><TD>GATAAGR_V$GATA_C</TD><TD>MSigDB lists</TD><TD>GATAAGR_V$GATA_C</TD><TD>279</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,NEBL,NR2F1</TD></TR>
<TR><TD>2.314e-02</TD><TD>-3.77</TD><TD>ion channel binding</TD><TD>molecular function</TD><TD>GO:0044325</TD><TD>105</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>CAMK2D,S100A10</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>PKD_dom</TD><TD>interpro domains</TD><TD>IPR000601</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>single-organism process</TD><TD>biological process</TD><TD>GO:0044699</TD><TD>12803</TD><TD>34</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,TNIK,STXBP6,SLK,RNF43,ZIC2,PDE3A,NEBL,S100A10,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,FGF9,SLC40A1,MSX1,PPARG,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,CAMK2D,MSX2,SLCO5A1,ITGB4,SORCS2,NR2F2,PDLIM5,MMP16</TD></TR>
<TR><TD>2.327e-02</TD><TD>-3.76</TD><TD>regulation of dendrite development</TD><TD>biological process</TD><TD>GO:0050773</TD><TD>105</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,PDLIM5</TD></TR>
<TR><TD>2.328e-02</TD><TD>-3.76</TD><TD>response to hormone</TD><TD>biological process</TD><TD>GO:0009725</TD><TD>1003</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>CCANNAGRKGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CCANNAGRKGGC_UNKNOWN</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,SORCS2</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>ATGCTGG,MIR-338</TD><TD>MSigDB lists</TD><TD>ATGCTGG,MIR-338</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,SLK</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,SORCS2</TD></TR>
<TR><TD>2.354e-02</TD><TD>-3.75</TD><TD>SIRT6 (sirtuin 6)</TD><TD>protein interactions</TD><TD>51548</TD><TD>109</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PDLIM5</TD></TR>
<TR><TD>2.356e-02</TD><TD>-3.75</TD><TD>MODULE_205</TD><TD>MSigDB lists</TD><TD>MODULE_205</TD><TD>281</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NEBL,STXBP6</TD></TR>
<TR><TD>2.359e-02</TD><TD>-3.75</TD><TD>positive regulation of phosphorylation</TD><TD>biological process</TD><TD>GO:0042327</TD><TD>1006</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>SYT11 (synaptotagmin XI)</TD><TD>protein interactions</TD><TD>23208</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>ADIPOR1 (adiponectin receptor 1)</TD><TD>protein interactions</TD><TD>51094</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>NCOA4 (nuclear receptor coactivator 4)</TD><TD>protein interactions</TD><TD>8031</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>KDM4C (lysine (K)-specific demethylase 4C)</TD><TD>protein interactions</TD><TD>23081</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>PI4K2B (phosphatidylinositol 4-kinase type 2 beta)</TD><TD>protein interactions</TD><TD>55300</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>EML4 (echinoderm microtubule associated protein like 4)</TD><TD>protein interactions</TD><TD>27436</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>TRIOBP (TRIO and F-actin binding protein)</TD><TD>protein interactions</TD><TD>11078</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>ARL2BP (ADP-ribosylation factor like GTPase 2 binding protein)</TD><TD>protein interactions</TD><TD>23568</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>MYPN (myopalladin)</TD><TD>protein interactions</TD><TD>84665</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>FAM131C (family with sequence similarity 131, member C)</TD><TD>protein interactions</TD><TD>348487</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VSNL1</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>PAX9 (paired box 9)</TD><TD>protein interactions</TD><TD>5083</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>AAAS (achalasia, adrenocortical insufficiency, alacrimia)</TD><TD>protein interactions</TD><TD>8086</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>BRD1 (bromodomain containing 1)</TD><TD>protein interactions</TD><TD>23774</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>EPHB3 (EPH receptor B3)</TD><TD>protein interactions</TD><TD>2049</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.387e-02</TD><TD>-3.74</TD><TD>MODULE_321</TD><TD>MSigDB lists</TD><TD>MODULE_321</TD><TD>109</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10</TD></TR>
<TR><TD>2.387e-02</TD><TD>-3.74</TD><TD>MODULE_180</TD><TD>MSigDB lists</TD><TD>MODULE_180</TD><TD>109</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,NEBL</TD></TR>
<TR><TD>2.387e-02</TD><TD>-3.74</TD><TD>bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>112</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>NEBL,UNC13A</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>WHITESIDE_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>WHITESIDE_CISPLATIN_RESISTANCE_UP</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>REACTOME_SIGNALING_BY_ACTIVATED_POINT_MUTANTS_OF_FGFR1</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_ACTIVATED_POINT_MUTANTS_OF_FGFR1</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>PID_INTEGRIN4_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_INTEGRIN4_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>REACTOME_SIGNALING_BY_FGFR3_MUTANTS</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_FGFR3_MUTANTS</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>REACTOME_PYRIMIDINE_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_PYRIMIDINE_CATABOLISM</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>IIZUKA_LIVER_CANCER_EARLY_RECURRENCE</TD><TD>MSigDB lists</TD><TD>IIZUKA_LIVER_CANCER_EARLY_RECURRENCE</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>BIOCARTA_MONOCYTE_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_MONOCYTE_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP</TD><TD>MSigDB lists</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>2.394e-02</TD><TD>-3.73</TD><TD>JUP (junction plakoglobin)</TD><TD>protein interactions</TD><TD>3728</TD><TD>110</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4,PDE3A</TD></TR>
<TR><TD>2.396e-02</TD><TD>-3.73</TD><TD>drug binding</TD><TD>molecular function</TD><TD>GO:0008144</TD><TD>107</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG,PDE10A</TD></TR>
<TR><TD>2.411e-02</TD><TD>-3.73</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.120.200</TD><TD>93</TD><TD>2</TD><TD>9988</TD><TD>26</TD>
<TD>CLSTN2,LAMA4</TD></TR>
<TR><TD>2.428e-02</TD><TD>-3.72</TD><TD>Calx_beta</TD><TD>smart domains</TD><TD>SM00237</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.428e-02</TD><TD>-3.72</TD><TD>GAF</TD><TD>smart domains</TD><TD>SM00065</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>PDE10A</TD></TR>
<TR><TD>2.428e-02</TD><TD>-3.72</TD><TD>INB</TD><TD>smart domains</TD><TD>SM00187</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.431e-02</TD><TD>-3.72</TD><TD>enzyme linked receptor protein signaling pathway</TD><TD>biological process</TD><TD>GO:0007167</TD><TD>1013</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,VIM,CAMK2D,FGF9,MSX1</TD></TR>
<TR><TD>2.434e-02</TD><TD>-3.72</TD><TD>regulation of epithelial cell proliferation</TD><TD>biological process</TD><TD>GO:0050678</TD><TD>278</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,NR2F2</TD></TR>
<TR><TD>2.441e-02</TD><TD>-3.71</TD><TD>diacylglycerol binding</TD><TD>molecular function</TD><TD>GO:0019992</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.441e-02</TD><TD>-3.71</TD><TD>AMP binding</TD><TD>molecular function</TD><TD>GO:0016208</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.443e-02</TD><TD>-3.71</TD><TD>MORF_ARL3</TD><TD>MSigDB lists</TD><TD>MORF_ARL3</TD><TD>285</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,PDE10A,NR2F1</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>positive regulation of vascular permeability</TD><TD>biological process</TD><TD>GO:0043117</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>lipoprotein transport</TD><TD>biological process</TD><TD>GO:0042953</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>bone trabecula morphogenesis</TD><TD>biological process</TD><TD>GO:0061430</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>negative regulation of acute inflammatory response</TD><TD>biological process</TD><TD>GO:0002674</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>positive regulation of neurotransmitter secretion</TD><TD>biological process</TD><TD>GO:0001956</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>negative regulation of sodium ion transmembrane transport</TD><TD>biological process</TD><TD>GO:1902306</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>lung-associated mesenchyme development</TD><TD>biological process</TD><TD>GO:0060484</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>positive regulation of hair cycle</TD><TD>biological process</TD><TD>GO:0042635</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>lipoprotein localization</TD><TD>biological process</TD><TD>GO:0044872</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>replicative senescence</TD><TD>biological process</TD><TD>GO:0090399</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.452e-02</TD><TD>-3.71</TD><TD>gland morphogenesis</TD><TD>biological process</TD><TD>GO:0022612</TD><TD>108</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CD44</TD></TR>
<TR><TD>2.469e-02</TD><TD>-3.70</TD><TD>KEGG_OOCYTE_MEIOSIS</TD><TD>MSigDB lists</TD><TD>KEGG_OOCYTE_MEIOSIS</TD><TD>111</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,SLK</TD></TR>
<TR><TD>2.479e-02</TD><TD>-3.70</TD><TD>breast-carcinoma-lobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-lobular_carcinoma</TD><TD>784</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>TNIK,CAMK2D,VIM,SORCS2,UNC13A</TD></TR>
<TR><TD>2.479e-02</TD><TD>-3.70</TD><TD>lobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lobular_carcinoma</TD><TD>784</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>TNIK,CAMK2D,VIM,SORCS2,UNC13A</TD></TR>
<TR><TD>2.490e-02</TD><TD>-3.69</TD><TD>Insulin-like growth factors(PMID:21216879)</TD><TD>GWAS genes</TD><TD>Insulin-like growth factors(PMID:21216879)</TD><TD>4</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.494e-02</TD><TD>-3.69</TD><TD>negative regulation of cellular macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:2000113</TD><TD>1310</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>2.497e-02</TD><TD>-3.69</TD><TD>Type I hemidesmosome assembly</TD><TD>REACTOME pathways</TD><TD>R-HSA-446107</TD><TD>9</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>112</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NT5E</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>TGANNYRGCA_V$TCF11MAFG_01</TD><TD>MSigDB lists</TD><TD>TGANNYRGCA_V$TCF11MAFG_01</TD><TD>288</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,PPARG,ANGPTL4</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>288</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,S100A10,SORCS2</TD></TR>
<TR><TD>2.517e-02</TD><TD>-3.68</TD><TD>TGCTGAY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGCTGAY_UNKNOWN</TD><TD>511</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,RNF43,FGF9,GRHL3</TD></TR>
<TR><TD>2.529e-02</TD><TD>-3.68</TD><TD>OA_transporter</TD><TD>interpro domains</TD><TD>IPR004156</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>2.529e-02</TD><TD>-3.68</TD><TD>PRTase-like</TD><TD>interpro domains</TD><TD>IPR029057</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.529e-02</TD><TD>-3.68</TD><TD>Synaptobrevin</TD><TD>interpro domains</TD><TD>IPR001388</TD><TD>12</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>STXBP6</TD></TR>
<TR><TD>2.541e-02</TD><TD>-3.67</TD><TD>Degradation of the extracellular matrix</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474228</TD><TD>89</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>CD44,MMP16</TD></TR>
<TR><TD>2.541e-02</TD><TD>-3.67</TD><TD>anion binding</TD><TD>molecular function</TD><TD>GO:0043168</TD><TD>2626</TD><TD>11</TD><TD>16491</TD><TD>37</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,PPARG,STXBP6,SLK,PDE10A,NR2F2,PRPS1,PDE3A</TD></TR>
<TR><TD>2.550e-02</TD><TD>-3.67</TD><TD>INTEGRIN_BETA</TD><TD>prosite domains</TD><TD>PS00243</TD><TD>9</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.551e-02</TD><TD>-3.67</TD><TD>Proteoglycans in cancer</TD><TD>KEGG pathways</TD><TD>ko05205</TD><TD>203</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,WNT16,CD44</TD></TR>
<TR><TD>2.551e-02</TD><TD>-3.67</TD><TD>Proteoglycans in cancer</TD><TD>KEGG pathways</TD><TD>hsa05205</TD><TD>203</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,WNT16,CD44</TD></TR>
<TR><TD>2.552e-02</TD><TD>-3.67</TD><TD>HOSHIDA_LIVER_CANCER_SUBCLASS_S2</TD><TD>MSigDB lists</TD><TD>HOSHIDA_LIVER_CANCER_SUBCLASS_S2</TD><TD>113</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>2.580e-02</TD><TD>-3.66</TD><TD>nucleoside biosynthetic process</TD><TD>biological process</TD><TD>GO:0009163</TD><TD>111</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>RSPO1 (R-spondin 1)</TD><TD>protein interactions</TD><TD>284654</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>SCRN2 (secernin 2)</TD><TD>protein interactions</TD><TD>90507</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>ZNF703 (zinc finger protein 703)</TD><TD>protein interactions</TD><TD>80139</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>MCAM (melanoma cell adhesion molecule)</TD><TD>protein interactions</TD><TD>4162</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>PKN3 (protein kinase N3)</TD><TD>protein interactions</TD><TD>29941</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>SRGN (serglycin)</TD><TD>protein interactions</TD><TD>5552</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>SLC27A6 (solute carrier family 27 (fatty acid transporter), member 6)</TD><TD>protein interactions</TD><TD>28965</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>ITGB1BP1 (integrin beta 1 binding protein 1)</TD><TD>protein interactions</TD><TD>9270</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>ELF2 (E74-like factor 2 (ets domain transcription factor))</TD><TD>protein interactions</TD><TD>1998</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.589e-02</TD><TD>-3.65</TD><TD>KIF15 (kinesin family member 15)</TD><TD>protein interactions</TD><TD>56992</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.593e-02</TD><TD>-3.65</TD><TD>nucleobase-containing small molecule metabolic process</TD><TD>biological process</TD><TD>GO:0055086</TD><TD>504</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PRPS1,PDE3A,NT5E</TD></TR>
<TR><TD>2.597e-02</TD><TD>-3.65</TD><TD>MODULE_11</TD><TD>MSigDB lists</TD><TD>MODULE_11</TD><TD>516</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS</TD><TD>MSigDB lists</TD><TD>REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>REGULATION_OF_ACTIN_FILAMENT_LENGTH</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_ACTIN_FILAMENT_LENGTH</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>XU_RESPONSE_TO_TRETINOIN_DN</TD><TD>MSigDB lists</TD><TD>XU_RESPONSE_TO_TRETINOIN_DN</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>chr13q11</TD><TD>MSigDB lists</TD><TD>chr13q11</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>TRANSITION_METAL_ION_TRANSPORT</TD><TD>MSigDB lists</TD><TD>TRANSITION_METAL_ION_TRANSPORT</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>SUZUKI_CTCFL_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SUZUKI_CTCFL_TARGETS_UP</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>MODULE_56</TD><TD>MSigDB lists</TD><TD>MODULE_56</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.614e-02</TD><TD>-3.64</TD><TD>COPS6 (COP9 signalosome subunit 6)</TD><TD>protein interactions</TD><TD>10980</TD><TD>295</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4,VIM,S100A10</TD></TR>
<TR><TD>2.619e-02</TD><TD>-3.64</TD><TD>liver-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-carcinoma</TD><TD>16152</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.623e-02</TD><TD>-3.64</TD><TD>neuron migration</TD><TD>biological process</TD><TD>GO:0001764</TD><TD>112</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,NR2F1</TD></TR>
<TR><TD>2.623e-02</TD><TD>-3.64</TD><TD>regulation of embryonic development</TD><TD>biological process</TD><TD>GO:0045995</TD><TD>112</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>LAMA4,GRHL3</TD></TR>
<TR><TD>2.630e-02</TD><TD>-3.64</TD><TD>TGCGCANK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGCGCANK_UNKNOWN</TD><TD>518</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NR2F2,PKIB,VSNL1</TD></TR>
<TR><TD>2.638e-02</TD><TD>-3.64</TD><TD>pancreas-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-adenocarcinoma</TD><TD>533</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,NEBL,PDE10A,GRHL3</TD></TR>
<TR><TD>2.641e-02</TD><TD>-3.63</TD><TD>positive regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010557</TD><TD>1634</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,MSX1,PPARG,GRHL3,ZIC2,NR2F2,NR2F1,PKIB</TD></TR>
<TR><TD>2.642e-02</TD><TD>-3.63</TD><TD>camera-type eye development</TD><TD>biological process</TD><TD>GO:0043010</TD><TD>287</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,WNT16,GRHL3</TD></TR>
<TR><TD>2.643e-02</TD><TD>-3.63</TD><TD>regulation of neuron differentiation</TD><TD>biological process</TD><TD>GO:0045664</TD><TD>507</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>2.643e-02</TD><TD>-3.63</TD><TD>NCOA3 (nuclear receptor coactivator 3)</TD><TD>protein interactions</TD><TD>8202</TD><TD>116</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>2.647e-02</TD><TD>-3.63</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>MSigDB lists</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>294</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,S100A10,NT5E</TD></TR>
<TR><TD>2.652e-02</TD><TD>-3.63</TD><TD>structure-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043566</TD><TD>113</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>2.660e-02</TD><TD>-3.63</TD><TD>EPHRIN</TD><TD>prints domains</TD><TD>PR01347</TD><TD>8</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.660e-02</TD><TD>-3.63</TD><TD>INTEGRINB</TD><TD>prints domains</TD><TD>PR01186</TD><TD>8</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.660e-02</TD><TD>-3.63</TD><TD>5'-nucleotidase activity</TD><TD>molecular function</TD><TD>GO:0008253</TD><TD>12</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>negative regulation of epithelial cell proliferation</TD><TD>biological process</TD><TD>GO:0050680</TD><TD>113</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,NR2F2</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>glycosyl compound biosynthetic process</TD><TD>biological process</TD><TD>GO:1901659</TD><TD>113</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>EphrinB-EPHB pathway</TD><TD>Pathway Interaction DB</TD><TD>ephrinb_ephbpathway</TD><TD>6</TD><TD>1</TD><TD>2227</TD><TD>10</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>hemidesmosome assembly</TD><TD>biological process</TD><TD>GO:0031581</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>tooth mineralization</TD><TD>biological process</TD><TD>GO:0034505</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>eyelid development in camera-type eye</TD><TD>biological process</TD><TD>GO:0061029</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>regulation of cardiac muscle cell action potential involved in regulation of contraction</TD><TD>biological process</TD><TD>GO:0098909</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>negative regulation of epidermal cell differentiation</TD><TD>biological process</TD><TD>GO:0045605</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>embryonic camera-type eye formation</TD><TD>biological process</TD><TD>GO:0060900</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>regulation of phagocytosis, engulfment</TD><TD>biological process</TD><TD>GO:0060099</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>regulation of sequestering of triglyceride</TD><TD>biological process</TD><TD>GO:0010889</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>cartilage morphogenesis</TD><TD>biological process</TD><TD>GO:0060536</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>wound healing, spreading of epidermal cells</TD><TD>biological process</TD><TD>GO:0035313</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>keratinocyte proliferation</TD><TD>biological process</TD><TD>GO:0043616</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>WNT16</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>positive regulation of receptor biosynthetic process</TD><TD>biological process</TD><TD>GO:0010870</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F1</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>cellular potassium ion homeostasis</TD><TD>biological process</TD><TD>GO:0030007</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:0055119</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>purine nucleobase biosynthetic process</TD><TD>biological process</TD><TD>GO:0009113</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>negative regulation of sodium ion transport</TD><TD>biological process</TD><TD>GO:0010766</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>regulation of timing of cell differentiation</TD><TD>biological process</TD><TD>GO:0048505</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>planar cell polarity pathway involved in neural tube closure</TD><TD>biological process</TD><TD>GO:0090179</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>regulation of Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0035020</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.668e-02</TD><TD>-3.62</TD><TD>nephric duct morphogenesis</TD><TD>biological process</TD><TD>GO:0072178</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.675e-02</TD><TD>-3.62</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>16161</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.675e-02</TD><TD>-3.62</TD><TD>BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP</TD><TD>MSigDB lists</TD><TD>BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP</TD><TD>778</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,PPARG,PDE10A,SLK,TANK</TD></TR>
<TR><TD>2.676e-02</TD><TD>-3.62</TD><TD>regulation of cell projection organization</TD><TD>biological process</TD><TD>GO:0031344</TD><TD>509</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,TNIK,PDLIM5,UNC13A</TD></TR>
<TR><TD>2.679e-02</TD><TD>-3.62</TD><TD>chr4p16</TD><TD>MSigDB lists</TD><TD>chr4p16</TD><TD>116</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,SORCS2</TD></TR>
<TR><TD>2.680e-02</TD><TD>-3.62</TD><TD>cell adhesion</TD><TD>biological process</TD><TD>GO:0007155</TD><TD>1036</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,CLSTN2,LAMA4,ITGB4,CD44,NT5E</TD></TR>
<TR><TD>2.700e-02</TD><TD>-3.61</TD><TD>head_neck</TD><TD>COSMIC cancer mutations</TD><TD>head_neck</TD><TD>16165</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>2.702e-02</TD><TD>-3.61</TD><TD>Interferon gamma signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-877300</TD><TD>92</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>2.709e-02</TD><TD>-3.61</TD><TD>OATP</TD><TD>pfam domains</TD><TD>PF03137</TD><TD>12</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>2.710e-02</TD><TD>-3.61</TD><TD>epithelial cell differentiation</TD><TD>biological process</TD><TD>GO:0030855</TD><TD>511</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>VIM,WNT16,NR2F2,PPARG</TD></TR>
<TR><TD>2.711e-02</TD><TD>-3.61</TD><TD>positive regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046330</TD><TD>114</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>2.712e-02</TD><TD>-3.61</TD><TD>MODULE_100</TD><TD>MSigDB lists</TD><TD>MODULE_100</TD><TD>523</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>2.721e-02</TD><TD>-3.60</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP</TD><TD>MSigDB lists</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP</TD><TD>117</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,EFNB2</TD></TR>
<TR><TD>2.721e-02</TD><TD>-3.60</TD><TD>BURTON_ADIPOGENESIS_5</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_5</TD><TD>117</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,PRPS1</TD></TR>
<TR><TD>2.725e-02</TD><TD>-3.60</TD><TD>biological adhesion</TD><TD>biological process</TD><TD>GO:0022610</TD><TD>1040</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,CLSTN2,LAMA4,ITGB4,CD44,NT5E</TD></TR>
<TR><TD>2.727e-02</TD><TD>-3.60</TD><TD>PKD</TD><TD>smart domains</TD><TD>SM00089</TD><TD>9</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.734e-02</TD><TD>-3.60</TD><TD>tat (p14)</TD><TD>protein interactions</TD><TD>155871</TD><TD>1701</TD><TD>8</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4,FGF9,PPARG,PDE10A,CD44,ITGB4,NR2F1,PDE3A</TD></TR>
<TR><TD>2.738e-02</TD><TD>-3.60</TD><TD>response to oxygen levels</TD><TD>biological process</TD><TD>GO:0070482</TD><TD>291</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PPARG,ANGPTL4</TD></TR>
<TR><TD>2.745e-02</TD><TD>-3.60</TD><TD>ovary-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-transitional_cell_carcinoma</TD><TD>13</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.762e-02</TD><TD>-3.59</TD><TD>MODULE_137</TD><TD>MSigDB lists</TD><TD>MODULE_137</TD><TD>526</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>2.771e-02</TD><TD>-3.59</TD><TD>Purine catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-74259</TD><TD>10</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.775e-02</TD><TD>-3.58</TD><TD>transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0006366</TD><TD>768</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1,PPARG,NR2F1,GRHL3</TD></TR>
<TR><TD>2.788e-02</TD><TD>-3.58</TD><TD>Ser/Thr_kinase_AS</TD><TD>interpro domains</TD><TD>IPR008271</TD><TD>309</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>2.788e-02</TD><TD>-3.58</TD><TD>JIANG_HYPOXIA_NORMAL</TD><TD>MSigDB lists</TD><TD>JIANG_HYPOXIA_NORMAL</TD><TD>300</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,ANGPTL4,NT5E</TD></TR>
<TR><TD>2.799e-02</TD><TD>-3.58</TD><TD>positive regulation of lipid metabolic process</TD><TD>biological process</TD><TD>GO:0045834</TD><TD>116</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>STEAP3 (STEAP family member 3, metalloreductase)</TD><TD>protein interactions</TD><TD>55240</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>JMJD1C (jumonji domain containing 1C)</TD><TD>protein interactions</TD><TD>221037</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>PCDH7 (protocadherin 7)</TD><TD>protein interactions</TD><TD>5099</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>PITHD1 (PITH (C-terminal proteasome-interacting domain of thioredoxin-like) domain containing 1)</TD><TD>protein interactions</TD><TD>57095</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>SLK</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>FABP4 (fatty acid binding protein 4, adipocyte)</TD><TD>protein interactions</TD><TD>2167</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>RETSAT (retinol saturase (all-trans-retinol 13,14-reductase))</TD><TD>protein interactions</TD><TD>54884</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>LMBR1 (limb development membrane protein 1)</TD><TD>protein interactions</TD><TD>64327</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>HOXC8 (homeobox C8)</TD><TD>protein interactions</TD><TD>3224</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>HBEGF (heparin-binding EGF-like growth factor)</TD><TD>protein interactions</TD><TD>1839</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>2.802e-02</TD><TD>-3.58</TD><TD>COL17A1 (collagen, type XVII, alpha 1)</TD><TD>protein interactions</TD><TD>1308</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>2.808e-02</TD><TD>-3.57</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL,PDE10A</TD></TR>
<TR><TD>2.808e-02</TD><TD>-3.57</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>2.808e-02</TD><TD>-3.57</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_DN</TD><TD>MSigDB lists</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_DN</TD><TD>119</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4,NR2F2</TD></TR>
<TR><TD>2.814e-02</TD><TD>-3.57</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>1412</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>SLCO5A1,CSMD3,VIM,PDE10A,STXBP6,UNC13A,GRHL3</TD></TR>
<TR><TD>2.816e-02</TD><TD>-3.57</TD><TD>cell migration</TD><TD>biological process</TD><TD>GO:0016477</TD><TD>771</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,CD44,NR2F2,NR2F1</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>BIOCARTA_CACAM_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_CACAM_PATHWAY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_SIZE</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_CELLULAR_COMPONENT_SIZE</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NEBL</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>GERHOLD_RESPONSE_TO_TZD_DN</TD><TD>MSigDB lists</TD><TD>GERHOLD_RESPONSE_TO_TZD_DN</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>IVANOV_MUTATED_IN_COLON_CANCER</TD><TD>MSigDB lists</TD><TD>IVANOV_MUTATED_IN_COLON_CANCER</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>INAMURA_LUNG_CANCER_SCC_DN</TD><TD>MSigDB lists</TD><TD>INAMURA_LUNG_CANCER_SCC_DN</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F1</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.40.670</TD><TD>11</TD><TD>1</TD><TD>9988</TD><TD>26</TD>
<TD>SORCS2</TD></TR>
<TR><TD>2.835e-02</TD><TD>-3.56</TD><TD>angiogenesis</TD><TD>biological process</TD><TD>GO:0001525</TD><TD>295</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,FGF9,ANGPTL4</TD></TR>
<TR><TD>2.844e-02</TD><TD>-3.56</TD><TD>response to estradiol</TD><TD>biological process</TD><TD>GO:0032355</TD><TD>117</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2</TD></TR>
<TR><TD>2.847e-02</TD><TD>-3.56</TD><TD>MODULE_66</TD><TD>MSigDB lists</TD><TD>MODULE_66</TD><TD>531</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,NEBL,VSNL1</TD></TR>
<TR><TD>2.847e-02</TD><TD>-3.56</TD><TD>YCATTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YCATTAA_UNKNOWN</TD><TD>531</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,NEBL,NR2F2,NR2F1</TD></TR>
<TR><TD>2.847e-02</TD><TD>-3.56</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>MSigDB lists</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>791</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44,S100A10,NT5E,GRHL3</TD></TR>
<TR><TD>2.852e-02</TD><TD>-3.56</TD><TD>REACTOME_G_ALPHA_S_SIGNALLING_EVENTS</TD><TD>MSigDB lists</TD><TD>REACTOME_G_ALPHA_S_SIGNALLING_EVENTS</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>2.852e-02</TD><TD>-3.56</TD><TD>ARGGGTTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ARGGGTTAA_UNKNOWN</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,FGF9</TD></TR>
<TR><TD>2.857e-02</TD><TD>-3.56</TD><TD>RXRA (retinoid X receptor alpha)</TD><TD>protein interactions</TD><TD>6256</TD><TD>121</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>2.879e-02</TD><TD>-3.55</TD><TD>long-chain fatty acid binding</TD><TD>molecular function</TD><TD>GO:0036041</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.879e-02</TD><TD>-3.55</TD><TD>intermediate filament binding</TD><TD>molecular function</TD><TD>GO:0019215</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>trophoblast giant cell differentiation</TD><TD>biological process</TD><TD>GO:0060707</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>telencephalon regionalization</TD><TD>biological process</TD><TD>GO:0021978</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>white fat cell differentiation</TD><TD>biological process</TD><TD>GO:0050872</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>regulation of development, heterochronic</TD><TD>biological process</TD><TD>GO:0040034</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>regulation of cholesterol storage</TD><TD>biological process</TD><TD>GO:0010885</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>male sex determination</TD><TD>biological process</TD><TD>GO:0030238</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902166</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>positive regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043517</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>branching involved in prostate gland morphogenesis</TD><TD>biological process</TD><TD>GO:0060442</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>negative regulation of macrophage derived foam cell differentiation</TD><TD>biological process</TD><TD>GO:0010745</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>negative regulation of keratinocyte proliferation</TD><TD>biological process</TD><TD>GO:0010839</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>regulation of cAMP-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:2000479</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>mesenchymal cell proliferation</TD><TD>biological process</TD><TD>GO:0010463</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>urate metabolic process</TD><TD>biological process</TD><TD>GO:0046415</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>positive regulation of muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010661</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>outflow tract septum morphogenesis</TD><TD>biological process</TD><TD>GO:0003148</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>negative regulation of DNA damage response, signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:0043518</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>regulation of cell communication by electrical coupling</TD><TD>biological process</TD><TD>GO:0010649</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>response to low-density lipoprotein particle</TD><TD>biological process</TD><TD>GO:0055098</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>regulation of establishment of planar polarity involved in neural tube closure</TD><TD>biological process</TD><TD>GO:0090178</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.54</TD><TD>negative regulation of telomerase activity</TD><TD>biological process</TD><TD>GO:0051974</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>2.889e-02</TD><TD>-3.54</TD><TD>lipid homeostasis</TD><TD>biological process</TD><TD>GO:0055088</TD><TD>118</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>2.889e-02</TD><TD>-3.54</TD><TD>BRUINS_UVC_RESPONSE_LATE</TD><TD>MSigDB lists</TD><TD>BRUINS_UVC_RESPONSE_LATE</TD><TD>1078</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,ITGB4,SORCS2,SLK,ANGPTL4,TANK</TD></TR>
<TR><TD>2.900e-02</TD><TD>-3.54</TD><TD>I band</TD><TD>cellular component</TD><TD>GO:0031674</TD><TD>123</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>2.909e-02</TD><TD>-3.54</TD><TD>human chr6q22.31</TD><TD>chromosome location</TD><TD>human chr6q22.31</TD><TD>18</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PKIB</TD></TR>
<TR><TD>2.913e-02</TD><TD>-3.54</TD><TD>regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043408</TD><TD>778</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44</TD></TR>
<TR><TD>2.933e-02</TD><TD>-3.53</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>536</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ZIC2,S100A10,NR2F2</TD></TR>
<TR><TD>2.933e-02</TD><TD>-3.53</TD><TD>MODULE_19</TD><TD>MSigDB lists</TD><TD>MODULE_19</TD><TD>306</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,NR2F1,VSNL1</TD></TR>
<TR><TD>2.934e-02</TD><TD>-3.53</TD><TD>negative regulation of protein serine/threonine kinase activity</TD><TD>biological process</TD><TD>GO:0071901</TD><TD>119</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>2.938e-02</TD><TD>-3.53</TD><TD>cellular component organization</TD><TD>biological process</TD><TD>GO:0016043</TD><TD>5336</TD><TD>18</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,VIM,ZIC2,ANGPTL4,RHOU,MSX2,CAMK2D,S100A10,NEBL,UNC13A,WNT16,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>2.940e-02</TD><TD>-3.53</TD><TD>V$GRE_C</TD><TD>MSigDB lists</TD><TD>V$GRE_C</TD><TD>122</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TANK,NR2F1</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>Link_dom</TD><TD>interpro domains</TD><TD>IPR000538</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>2.950e-02</TD><TD>-3.52</TD><TD>middle_lobe</TD><TD>COSMIC cancer mutations</TD><TD>middle_lobe</TD><TD>1426</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>SLCO5A1,CSMD3,VIM,STXBP6,PDE10A,UNC13A,GRHL3</TD></TR>
<TR><TD>2.955e-02</TD><TD>-3.52</TD><TD>regulation of phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0019220</TD><TD>1669</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>2.968e-02</TD><TD>-3.52</TD><TD>FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP</TD><TD>MSigDB lists</TD><TD>FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP</TD><TD>538</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,CD44,PDLIM5,TANK</TD></TR>
<TR><TD>2.984e-02</TD><TD>-3.51</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3</TD><TD>123</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CD44</TD></TR>
<TR><TD>3.007e-02</TD><TD>-3.50</TD><TD>YGCGYRCGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YGCGYRCGC_UNKNOWN</TD><TD>309</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,NR2F2,MMP16</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>ASB11 (ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>140456</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>CACNA1B (calcium channel, voltage-dependent, N type, alpha 1B subunit)</TD><TD>protein interactions</TD><TD>774</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>SELE (selectin E)</TD><TD>protein interactions</TD><TD>6401</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>RGS7 (regulator of G-protein signaling 7)</TD><TD>protein interactions</TD><TD>6000</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>SPATA24 (spermatogenesis associated 24)</TD><TD>protein interactions</TD><TD>202051</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>ELMSAN1 (ELM2 and Myb/SANT-like domain containing 1)</TD><TD>protein interactions</TD><TD>91748</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>POU1F1 (POU class 1 homeobox 1)</TD><TD>protein interactions</TD><TD>5449</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>TRIM16 (tripartite motif containing 16)</TD><TD>protein interactions</TD><TD>10626</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>HECW1 (HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1)</TD><TD>protein interactions</TD><TD>23072</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>KIF14 (kinesin family member 14)</TD><TD>protein interactions</TD><TD>9928</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>SAR1B (secretion associated, Ras related GTPase 1B)</TD><TD>protein interactions</TD><TD>51128</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>DLC1 (DLC1 Rho GTPase activating protein)</TD><TD>protein interactions</TD><TD>10395</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.025e-02</TD><TD>-3.50</TD><TD>extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0022617</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CD44,MMP16</TD></TR>
<TR><TD>3.025e-02</TD><TD>-3.50</TD><TD>negative regulation of binding</TD><TD>biological process</TD><TD>GO:0051100</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.026e-02</TD><TD>-3.50</TD><TD>CNH</TD><TD>smart domains</TD><TD>SM00036</TD><TD>10</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.029e-02</TD><TD>-3.50</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>124</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,MMP16</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>MATZUK_OVULATION</TD><TD>MSigDB lists</TD><TD>MATZUK_OVULATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE3A</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>chr13q33</TD><TD>MSigDB lists</TD><TD>chr13q33</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C3</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C3</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>HUMMEL_BURKITTS_LYMPHOMA_DN</TD><TD>MSigDB lists</TD><TD>HUMMEL_BURKITTS_LYMPHOMA_DN</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN</TD><TD>MSigDB lists</TD><TD>WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TANK</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>SA_MMP_CYTOKINE_CONNECTION</TD><TD>MSigDB lists</TD><TD>SA_MMP_CYTOKINE_CONNECTION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>REACTOME_HYALURONAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_HYALURONAN_METABOLISM</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>BIOCARTA_NUCLEARRS_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_NUCLEARRS_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.033e-02</TD><TD>-3.50</TD><TD>ANXA7 (annexin A7)</TD><TD>protein interactions</TD><TD>310</TD><TD>125</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>3.044e-02</TD><TD>-3.49</TD><TD>Signaling by activated point mutants of FGFR1</TD><TD>REACTOME pathways</TD><TD>R-HSA-1839122</TD><TD>11</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.063e-02</TD><TD>-3.49</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>2109</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,NEBL,PPARG,CSMD3,RNF43,PDLIM5,ANGPTL4,PDE3A,NT5E</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>TRAF2 (TNF receptor-associated factor 2)</TD><TD>protein interactions</TD><TD>7186</TD><TD>314</TD><TD>3</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK,NEBL,TANK</TD></TR>
<TR><TD>3.068e-02</TD><TD>-3.48</TD><TD>human chr7q31</TD><TD>chromosome location</TD><TD>human chr7q31</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.068e-02</TD><TD>-3.48</TD><TD>human chr8q21.3</TD><TD>chromosome location</TD><TD>human chr8q21.3</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.068e-02</TD><TD>-3.48</TD><TD>human chr2q24.2</TD><TD>chromosome location</TD><TD>human chr2q24.2</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>TANK</TD></TR>
<TR><TD>3.072e-02</TD><TD>-3.48</TD><TD>regulation of cyclin-dependent protein kinase activity</TD><TD>biological process</TD><TD>GO:1904029</TD><TD>122</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PKIB</TD></TR>
<TR><TD>3.072e-02</TD><TD>-3.48</TD><TD>cell-matrix adhesion</TD><TD>biological process</TD><TD>GO:0007160</TD><TD>122</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ITGB4,CD44</TD></TR>
<TR><TD>3.074e-02</TD><TD>-3.48</TD><TD>ZHU_CMV_ALL_DN</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_ALL_DN</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,NR2F2</TD></TR>
<TR><TD>3.074e-02</TD><TD>-3.48</TD><TD>GERY_CEBP_TARGETS</TD><TD>MSigDB lists</TD><TD>GERY_CEBP_TARGETS</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>3.078e-02</TD><TD>-3.48</TD><TD>NCK2 (NCK adaptor protein 2)</TD><TD>protein interactions</TD><TD>8440</TD><TD>126</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2,TNIK</TD></TR>
<TR><TD>3.078e-02</TD><TD>-3.48</TD><TD>regulation of phosphorus metabolic process</TD><TD>biological process</TD><TD>GO:0051174</TD><TD>1682</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.50.2020</TD><TD>12</TD><TD>1</TD><TD>9988</TD><TD>26</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.082e-02</TD><TD>-3.48</TD><TD>TTGCCAA,MIR-182</TD><TD>MSigDB lists</TD><TD>TTGCCAA,MIR-182</TD><TD>312</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,FGF9,MMP16</TD></TR>
<TR><TD>3.083e-02</TD><TD>-3.48</TD><TD>NUYTTEN_NIPP1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>NUYTTEN_NIPP1_TARGETS_DN</TD><TD>808</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,NEBL,S100A10,NR2F2,PRPS1</TD></TR>
<TR><TD>3.087e-02</TD><TD>-3.48</TD><TD>urogenital system development</TD><TD>biological process</TD><TD>GO:0001655</TD><TD>305</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,ITGB4,CD44</TD></TR>
<TR><TD>3.088e-02</TD><TD>-3.48</TD><TD>chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastoma</TD><TD>560</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,LAMA4,RNF43</TD></TR>
<TR><TD>3.097e-02</TD><TD>-3.47</TD><TD>nucleotidase activity</TD><TD>molecular function</TD><TD>GO:0008252</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.097e-02</TD><TD>-3.47</TD><TD>titin binding</TD><TD>molecular function</TD><TD>GO:0031432</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.097e-02</TD><TD>-3.47</TD><TD>tropomyosin binding</TD><TD>molecular function</TD><TD>GO:0005523</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NEBL</TD></TR>
<TR><TD>3.103e-02</TD><TD>-3.47</TD><TD>Prostate cancer(PMID:19767753)</TD><TD>GWAS genes</TD><TD>Prostate cancer(PMID:19767753)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>lens fiber cell development</TD><TD>biological process</TD><TD>GO:0070307</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>purine ribonucleoside catabolic process</TD><TD>biological process</TD><TD>GO:0046130</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902165</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>positive regulation of fatty acid oxidation</TD><TD>biological process</TD><TD>GO:0046321</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>purine nucleoside catabolic process</TD><TD>biological process</TD><TD>GO:0006152</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>beta-amyloid metabolic process</TD><TD>biological process</TD><TD>GO:0050435</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>positive regulation of oligodendrocyte differentiation</TD><TD>biological process</TD><TD>GO:0048714</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.108e-02</TD><TD>-3.47</TD><TD>PKD</TD><TD>prosite domains</TD><TD>PS50093</TD><TD>11</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>SORCS2</TD></TR>
<TR><TD>3.118e-02</TD><TD>-3.47</TD><TD>osteoblast differentiation</TD><TD>biological process</TD><TD>GO:0001649</TD><TD>123</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,FGF9</TD></TR>
<TR><TD>3.143e-02</TD><TD>-3.46</TD><TD>transcription cofactor activity</TD><TD>molecular function</TD><TD>GO:0003712</TD><TD>537</TD><TD>4</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.152e-02</TD><TD>-3.46</TD><TD>CNH_dom</TD><TD>interpro domains</TD><TD>IPR001180</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.152e-02</TD><TD>-3.46</TD><TD>Pept_M10A_Zn_BS</TD><TD>interpro domains</TD><TD>IPR021158</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>EF-hand_1</TD><TD>pfam domains</TD><TD>PF00036</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>VSNL1</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>Xlink</TD><TD>pfam domains</TD><TD>PF00193</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>CD44</TD></TR>
<TR><TD>3.160e-02</TD><TD>-3.45</TD><TD>dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.160e-02</TD><TD>-3.45</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.160e-02</TD><TD>-3.45</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>15</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.165e-02</TD><TD>-3.45</TD><TD>mammary gland development</TD><TD>biological process</TD><TD>GO:0030879</TD><TD>124</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.165e-02</TD><TD>-3.45</TD><TD>embryonic epithelial tube formation</TD><TD>biological process</TD><TD>GO:0001838</TD><TD>124</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>3.165e-02</TD><TD>-3.45</TD><TD>blood circulation</TD><TD>biological process</TD><TD>GO:0008015</TD><TD>308</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PPARG,PDE3A</TD></TR>
<TR><TD>3.190e-02</TD><TD>-3.44</TD><TD>cellular response to organic substance</TD><TD>biological process</TD><TD>GO:0071310</TD><TD>2021</TD><TD>9</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,FGF9,MSX1,PPARG,NR2F2,CD44,PDE3A,NR2F1</TD></TR>
<TR><TD>3.203e-02</TD><TD>-3.44</TD><TD>response to organic cyclic compound</TD><TD>biological process</TD><TD>GO:0014070</TD><TD>798</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1,PDE3A</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>KRAS.BREAST_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.BREAST_UP.V1_UP</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2,WNT16</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,NR2F1</TD></TR>
<TR><TD>3.212e-02</TD><TD>-3.44</TD><TD>epithelial tube formation</TD><TD>biological process</TD><TD>GO:0072175</TD><TD>125</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>3.219e-02</TD><TD>-3.44</TD><TD>GGATTA_V$PITX2_Q2</TD><TD>MSigDB lists</TD><TD>GGATTA_V$PITX2_Q2</TD><TD>552</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,RNF43,MSX1,NEBL</TD></TR>
<TR><TD>3.223e-02</TD><TD>-3.43</TD><TD>cervix-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-squamous_cell_carcinoma</TD><TD>12377</TD><TD>32</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,NR2F1,RHOU,CAMK2D,CSMD3,SLCO5A1,ITGB4,NR2F2,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>GRM1 (glutamate receptor, metabotropic 1)</TD><TD>protein interactions</TD><TD>2911</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>ZC3H12A (zinc finger CCCH-type containing 12A)</TD><TD>protein interactions</TD><TD>80149</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>MAN2A2 (mannosidase, alpha, class 2A, member 2)</TD><TD>protein interactions</TD><TD>4122</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>GADD45B (growth arrest and DNA-damage-inducible, beta)</TD><TD>protein interactions</TD><TD>4616</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>PRPH (peripherin)</TD><TD>protein interactions</TD><TD>5630</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>GOLGA4 (golgin A4)</TD><TD>protein interactions</TD><TD>2803</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>COL14A1 (collagen, type XIV, alpha 1)</TD><TD>protein interactions</TD><TD>7373</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>HSP90AB4P (heat shock protein 90kDa alpha (cytosolic), class B member 4, pseudogene)</TD><TD>protein interactions</TD><TD>664618</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.226e-02</TD><TD>-3.43</TD><TD>PILRA (paired immunoglobin-like type 2 receptor alpha)</TD><TD>protein interactions</TD><TD>29992</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>LAMA4</TD></TR>
<TR><TD>3.227e-02</TD><TD>-3.43</TD><TD>human chr17q24.3</TD><TD>chromosome location</TD><TD>human chr17q24.3</TD><TD>20</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>LINC00511</TD></TR>
<TR><TD>3.229e-02</TD><TD>-3.43</TD><TD>humerus</TD><TD>COSMIC cancer mutations</TD><TD>humerus</TD><TD>568</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,LAMA4,NEBL,UNC13A</TD></TR>
<TR><TD>3.230e-02</TD><TD>-3.43</TD><TD>regulation of cell cycle process</TD><TD>biological process</TD><TD>GO:0010564</TD><TD>540</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,PDE3A</TD></TR>
<TR><TD>3.244e-02</TD><TD>-3.43</TD><TD>cervix</TD><TD>COSMIC cancer mutations</TD><TD>cervix</TD><TD>12381</TD><TD>32</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,GRHL3,VIM,NR2F1,RHOU,CAMK2D,CSMD3,SLCO5A1,ITGB4,NR2F2,SORCS2,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.244e-02</TD><TD>-3.43</TD><TD>circulatory system process</TD><TD>biological process</TD><TD>GO:0003013</TD><TD>311</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PPARG,PDE3A</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>OZANNE_AP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OZANNE_AP1_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII</TD><TD>MSigDB lists</TD><TD>REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>FINETTI_BREAST_CANCERS_KINOME_GRAY</TD><TD>MSigDB lists</TD><TD>FINETTI_BREAST_CANCERS_KINOME_GRAY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLK</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>CARBOHYDRATE_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>CARBOHYDRATE_KINASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP</TD><TD>MSigDB lists</TD><TD>RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>3.257e-02</TD><TD>-3.42</TD><TD>GGGNNTTTCC_V$NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>GGGNNTTTCC_V$NFKB_Q6_01</TD><TD>129</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,NR2F2</TD></TR>
<TR><TD>3.257e-02</TD><TD>-3.42</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP</TD><TD>129</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TANK,PDE3A</TD></TR>
<TR><TD>3.259e-02</TD><TD>-3.42</TD><TD>purine nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0006164</TD><TD>126</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.260e-02</TD><TD>-3.42</TD><TD>ACTN1 (actinin, alpha 1)</TD><TD>protein interactions</TD><TD>87</TD><TD>130</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL,PDLIM5</TD></TR>
<TR><TD>3.265e-02</TD><TD>-3.42</TD><TD>regulation of protein modification process</TD><TD>biological process</TD><TD>GO:0031399</TD><TD>1701</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK,WNT16,NR2F2,CD44,PKIB</TD></TR>
<TR><TD>3.286e-02</TD><TD>-3.42</TD><TD>LIPID_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>LIPID_METABOLIC_PROCESS</TD><TD>320</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PPARG,PDE3A</TD></TR>
<TR><TD>3.303e-02</TD><TD>-3.41</TD><TD>V$TAXCREB_01</TD><TD>MSigDB lists</TD><TD>V$TAXCREB_01</TD><TD>130</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,NR2F1</TD></TR>
<TR><TD>3.304e-02</TD><TD>-3.41</TD><TD>negative regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045934</TD><TD>1389</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.306e-02</TD><TD>-3.41</TD><TD>cellular response to interferon-gamma</TD><TD>biological process</TD><TD>GO:0071346</TD><TD>127</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>3.315e-02</TD><TD>-3.41</TD><TD>hexosaminidase activity</TD><TD>molecular function</TD><TD>GO:0015929</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>3.315e-02</TD><TD>-3.41</TD><TD>icosanoid receptor activity</TD><TD>molecular function</TD><TD>GO:0004953</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>FGFR3 mutant receptor activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-2033514</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>FGFR3 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190239</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>FGFR3c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190372</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Pyrimidine catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-73621</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Hyaluronan uptake and degradation</TD><TD>REACTOME pathways</TD><TD>R-HSA-2160916</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>CD44</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Signaling by activated point mutants of FGFR3</TD><TD>REACTOME pathways</TD><TD>R-HSA-1839130</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Caspase-mediated cleavage of cytoskeletal proteins</TD><TD>REACTOME pathways</TD><TD>R-HSA-264870</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>VIM</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>FGFR1c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190373</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>transition metal ion binding</TD><TD>molecular function</TD><TD>GO:0046914</TD><TD>1395</TD><TD>7</TD><TD>16491</TD><TD>37</TD>
<TD>RNF43,NR2F2,PPARG,PDLIM5,MMP16,NR2F1,NT5E</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>positive regulation of neurotransmitter transport</TD><TD>biological process</TD><TD>GO:0051590</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>establishment of tissue polarity</TD><TD>biological process</TD><TD>GO:0007164</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>negative regulation of lipase activity</TD><TD>biological process</TD><TD>GO:0060192</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>positive regulation of telomere capping</TD><TD>biological process</TD><TD>GO:1904355</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>cell migration involved in sprouting angiogenesis</TD><TD>biological process</TD><TD>GO:0002042</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051797</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>establishment of planar polarity</TD><TD>biological process</TD><TD>GO:0001736</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>hyaluronan catabolic process</TD><TD>biological process</TD><TD>GO:0030214</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>response to vitamin E</TD><TD>biological process</TD><TD>GO:0033197</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>nephric duct development</TD><TD>biological process</TD><TD>GO:0072176</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>regulation of lipoprotein lipase activity</TD><TD>biological process</TD><TD>GO:0051004</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>negative regulation of epidermis development</TD><TD>biological process</TD><TD>GO:0045683</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.330e-02</TD><TD>-3.40</TD><TD>MARTINEZ_RB1_AND_TP53_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MARTINEZ_RB1_AND_TP53_TARGETS_DN</TD><TD>558</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,MSX2,PDE3A,NR2F1</TD></TR>
<TR><TD>3.334e-02</TD><TD>-3.40</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.40.420</TD><TD>13</TD><TD>1</TD><TD>9988</TD><TD>26</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.342e-02</TD><TD>-3.40</TD><TD>Morphine addiction</TD><TD>KEGG pathways</TD><TD>hsa05032</TD><TD>91</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.342e-02</TD><TD>-3.40</TD><TD>Morphine addiction</TD><TD>KEGG pathways</TD><TD>ko05032</TD><TD>91</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>3.351e-02</TD><TD>-3.40</TD><TD>cellular response to fibroblast growth factor stimulus</TD><TD>biological process</TD><TD>GO:0044344</TD><TD>315</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,FGF9,CD44</TD></TR>
<TR><TD>3.353e-02</TD><TD>-3.40</TD><TD>MFS_dom</TD><TD>interpro domains</TD><TD>IPR020846</TD><TD>135</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>SLCO5A1,SLC40A1</TD></TR>
<TR><TD>3.354e-02</TD><TD>-3.39</TD><TD>embryonic skeletal system development</TD><TD>biological process</TD><TD>GO:0048706</TD><TD>128</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MMP16</TD></TR>
<TR><TD>3.354e-02</TD><TD>-3.39</TD><TD>cell growth</TD><TD>biological process</TD><TD>GO:0016049</TD><TD>128</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDLIM5</TD></TR>
<TR><TD>3.358e-02</TD><TD>-3.39</TD><TD>EGF_extracell</TD><TD>interpro domains</TD><TD>IPR013111</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.368e-02</TD><TD>-3.39</TD><TD>ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>ORGAN_DEVELOPMENT</TD><TD>560</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ZIC2,MSX1,ANGPTL4</TD></TR>
<TR><TD>3.375e-02</TD><TD>-3.39</TD><TD>CNH</TD><TD>pfam domains</TD><TD>PF00780</TD><TD>15</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.379e-02</TD><TD>-3.39</TD><TD>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</TD><TD>molecular function</TD><TD>GO:0001228</TD><TD>317</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>MSX1,PPARG,GRHL3</TD></TR>
<TR><TD>3.386e-02</TD><TD>-3.39</TD><TD>V_SNARE</TD><TD>prosite domains</TD><TD>PS50892</TD><TD>12</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>STXBP6</TD></TR>
<TR><TD>3.386e-02</TD><TD>-3.39</TD><TD>LINK_1</TD><TD>prosite domains</TD><TD>PS01241</TD><TD>12</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>CD44</TD></TR>
<TR><TD>3.397e-02</TD><TD>-3.38</TD><TD>KRAS.LUNG_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.LUNG_UP.V1_UP</TD><TD>132</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,ANGPTL4</TD></TR>
<TR><TD>3.402e-02</TD><TD>-3.38</TD><TD>kidney epithelium development</TD><TD>biological process</TD><TD>GO:0072073</TD><TD>129</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,CD44</TD></TR>
<TR><TD>3.405e-02</TD><TD>-3.38</TD><TD>regulation of actin filament-based process</TD><TD>biological process</TD><TD>GO:0032970</TD><TD>317</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,S100A10,GRHL3</TD></TR>
<TR><TD>3.406e-02</TD><TD>-3.38</TD><TD>negative regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010558</TD><TD>1398</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>NR0B1 (nuclear receptor subfamily 0, group B, member 1)</TD><TD>protein interactions</TD><TD>190</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>ARL2 (ADP-ribosylation factor like GTPase 2)</TD><TD>protein interactions</TD><TD>402</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>PDIA2 (protein disulfide isomerase family A, member 2)</TD><TD>protein interactions</TD><TD>64714</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>GDNF (glial cell derived neurotrophic factor)</TD><TD>protein interactions</TD><TD>2668</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>BBOX1 (butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1)</TD><TD>protein interactions</TD><TD>8424</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>CNKSR2 (connector enhancer of kinase suppressor of Ras 2)</TD><TD>protein interactions</TD><TD>22866</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>GHITM (growth hormone inducible transmembrane protein)</TD><TD>protein interactions</TD><TD>27069</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>RAB9A (RAB9A, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>9367</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>HGH1 (HGH1 homolog)</TD><TD>protein interactions</TD><TD>51236</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>SLK</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>IQCF1 (IQ motif containing F1)</TD><TD>protein interactions</TD><TD>132141</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>ERC2 (ELKS/RAB6-interacting/CAST family member 2)</TD><TD>protein interactions</TD><TD>26059</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>RNF43 (ring finger protein 43)</TD><TD>protein interactions</TD><TD>54894</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.437e-02</TD><TD>-3.37</TD><TD>TM2D3 (TM2 domain containing 3)</TD><TD>protein interactions</TD><TD>80213</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.443e-02</TD><TD>-3.37</TD><TD>meninges-meningioma</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma</TD><TD>335</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CSMD3,CAMK2D,ITGB4</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>SERVITJA_LIVER_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_LIVER_HNF1A_TARGETS_UP</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,PPARG</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CD44</TD></TR>
<TR><TD>3.446e-02</TD><TD>-3.37</TD><TD>SETDB1 (SET domain, bifurcated 1)</TD><TD>protein interactions</TD><TD>9869</TD><TD>134</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,S100A10</TD></TR>
<TR><TD>3.449e-02</TD><TD>-3.37</TD><TD>Pathways in cancer</TD><TD>KEGG pathways</TD><TD>hsa05200</TD><TD>397</TD><TD>4</TD><TD>6908</TD><TD>22</TD>
<TD>LAMA4,FGF9,WNT16,PPARG</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>MSigDB lists</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>chr4q26</TD><TD>MSigDB lists</TD><TD>chr4q26</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>KANG_FLUOROURACIL_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>KANG_FLUOROURACIL_RESISTANCE_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2</TD><TD>MSigDB lists</TD><TD>REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>NGO_MALIGNANT_GLIOMA_1P_LOH</TD><TD>MSigDB lists</TD><TD>NGO_MALIGNANT_GLIOMA_1P_LOH</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>FARMER_BREAST_CANCER_CLUSTER_6</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_6</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>V$PAX5_02</TD><TD>MSigDB lists</TD><TD>V$PAX5_02</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.463e-02</TD><TD>-3.36</TD><TD>negative regulation of catalytic activity</TD><TD>biological process</TD><TD>GO:0043086</TD><TD>815</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>CD44,NR2F2,PPARG,ANGPTL4,PKIB</TD></TR>
<TR><TD>3.465e-02</TD><TD>-3.36</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>1157</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,SORCS2,UNC13A,GRHL3,C1orf226</TD></TR>
<TR><TD>3.487e-02</TD><TD>-3.36</TD><TD>response to fibroblast growth factor</TD><TD>biological process</TD><TD>GO:0071774</TD><TD>320</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,FGF9,CD44</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,STXBP6</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>ALK_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>ALK_DN.V1_UP</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ANGPTL4,UNC13A</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>RUIZ_TNC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RUIZ_TNC_TARGETS_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PRPS1</TD></TR>
<TR><TD>3.493e-02</TD><TD>-3.35</TD><TD>LCK (LCK proto-oncogene, Src family tyrosine kinase)</TD><TD>protein interactions</TD><TD>3932</TD><TD>135</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CD44,NR2F2</TD></TR>
<TR><TD>3.499e-02</TD><TD>-3.35</TD><TD>positive regulation of stress-activated MAPK cascade</TD><TD>biological process</TD><TD>GO:0032874</TD><TD>131</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>3.501e-02</TD><TD>-3.35</TD><TD>HOMEOBOX</TD><TD>prints domains</TD><TD>PR00024</TD><TD>89</TD><TD>2</TD><TD>4759</TD><TD>16</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>3.518e-02</TD><TD>-3.35</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma</TD><TD>1480</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CD44,ITGB4,MMP16,STXBP6,PRPS1,UNC13A,GRHL3</TD></TR>
<TR><TD>3.518e-02</TD><TD>-3.35</TD><TD>nasopharyngeal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>nasopharyngeal_carcinoma</TD><TD>1480</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CD44,ITGB4,MMP16,STXBP6,PRPS1,UNC13A,GRHL3</TD></TR>
<TR><TD>3.532e-02</TD><TD>-3.34</TD><TD>retinoid X receptor binding</TD><TD>molecular function</TD><TD>GO:0046965</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.532e-02</TD><TD>-3.34</TD><TD>cGMP binding</TD><TD>molecular function</TD><TD>GO:0030553</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.532e-02</TD><TD>-3.34</TD><TD>GTP-Rho binding</TD><TD>molecular function</TD><TD>GO:0017049</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>STXBP6</TD></TR>
<TR><TD>3.539e-02</TD><TD>-3.34</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK</TD><TD>MSigDB lists</TD><TD>WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK</TD><TD>135</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG,TANK</TD></TR>
<TR><TD>3.540e-02</TD><TD>-3.34</TD><TD>IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta)</TD><TD>protein interactions</TD><TD>3551</TD><TD>136</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG,TANK</TD></TR>
<TR><TD>3.540e-02</TD><TD>-3.34</TD><TD>PPARG (peroxisome proliferator-activated receptor gamma)</TD><TD>protein interactions</TD><TD>5468</TD><TD>136</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2,PPARG</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>regulation of cell morphogenesis involved in differentiation</TD><TD>biological process</TD><TD>GO:0010769</TD><TD>322</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,S100A10,PDLIM5</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>regulation of short-term neuronal synaptic plasticity</TD><TD>biological process</TD><TD>GO:0048172</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>monocyte differentiation</TD><TD>biological process</TD><TD>GO:0030224</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>cardiac myofibril assembly</TD><TD>biological process</TD><TD>GO:0055003</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NEBL</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>negative regulation of lipid storage</TD><TD>biological process</TD><TD>GO:0010888</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>cellular response to prostaglandin E stimulus</TD><TD>biological process</TD><TD>GO:0071380</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>regulation of mesoderm development</TD><TD>biological process</TD><TD>GO:2000380</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>astrocyte development</TD><TD>biological process</TD><TD>GO:0014002</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>regulation of telomere capping</TD><TD>biological process</TD><TD>GO:1904353</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>response to caffeine</TD><TD>biological process</TD><TD>GO:0031000</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.542e-02</TD><TD>-3.34</TD><TD>positive regulation of vascular endothelial growth factor receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0030949</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.548e-02</TD><TD>-3.34</TD><TD>positive regulation of stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0070304</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>3.548e-02</TD><TD>-3.34</TD><TD>cell maturation</TD><TD>biological process</TD><TD>GO:0048469</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PDE3A</TD></TR>
<TR><TD>3.565e-02</TD><TD>-3.33</TD><TD>Hemopexin_CS</TD><TD>interpro domains</TD><TD>IPR018486</TD><TD>17</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.574e-02</TD><TD>-3.33</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>17</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.587e-02</TD><TD>-3.33</TD><TD>V$MEIS1BHOXA9_01</TD><TD>MSigDB lists</TD><TD>V$MEIS1BHOXA9_01</TD><TD>136</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,NR2F2</TD></TR>
<TR><TD>3.587e-02</TD><TD>-3.33</TD><TD>Dissolution of Fibrin Clot</TD><TD>REACTOME pathways</TD><TD>R-HSA-75205</TD><TD>13</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.587e-02</TD><TD>-3.33</TD><TD>FGFR2c ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190375</TD><TD>13</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.588e-02</TD><TD>-3.33</TD><TD>DYNLL1 (dynein, light chain, LC8-type 1)</TD><TD>protein interactions</TD><TD>8655</TD><TD>137</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>VIM,PKIB</TD></TR>
<TR><TD>3.592e-02</TD><TD>-3.33</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>842</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,ZIC2,MSX1,PRPS1,ANGPTL4</TD></TR>
<TR><TD>3.596e-02</TD><TD>-3.33</TD><TD>EGF_2</TD><TD>pfam domains</TD><TD>PF07974</TD><TD>16</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.635e-02</TD><TD>-3.31</TD><TD>BMI1_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>BMI1_DN.V1_DN</TD><TD>137</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,WNT16</TD></TR>
<TR><TD>3.635e-02</TD><TD>-3.31</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>137</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,NEBL</TD></TR>
<TR><TD>3.640e-02</TD><TD>-3.31</TD><TD>LINKMODULE</TD><TD>prints domains</TD><TD>PR01265</TD><TD>11</TD><TD>1</TD><TD>4759</TD><TD>16</TD>
<TD>CD44</TD></TR>
<TR><TD>3.641e-02</TD><TD>-3.31</TD><TD>positive regulation of apoptotic process</TD><TD>biological process</TD><TD>GO:0043065</TD><TD>561</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>NR2E3 (nuclear receptor subfamily 2, group E, member 3)</TD><TD>protein interactions</TD><TD>10002</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>POU2AF1 (POU class 2 associating factor 1)</TD><TD>protein interactions</TD><TD>5450</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>NR2F6 (nuclear receptor subfamily 2, group F, member 6)</TD><TD>protein interactions</TD><TD>2063</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>RABL2A (RAB, member of RAS oncogene family-like 2A)</TD><TD>protein interactions</TD><TD>11159</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>SLK</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>DNTTIP2 (deoxynucleotidyltransferase, terminal, interacting protein 2)</TD><TD>protein interactions</TD><TD>30836</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>ZNHIT3 (zinc finger, HIT-type containing 3)</TD><TD>protein interactions</TD><TD>9326</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>PRPS2 (phosphoribosyl pyrophosphate synthetase 2)</TD><TD>protein interactions</TD><TD>5634</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>MIF4GD (MIF4G domain containing)</TD><TD>protein interactions</TD><TD>57409</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>RAD54L2 (RAD54-like 2 (S. cerevisiae))</TD><TD>protein interactions</TD><TD>23132</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>PITX2 (paired-like homeodomain 2)</TD><TD>protein interactions</TD><TD>5308</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>SLC30A5 (solute carrier family 30 (zinc transporter), member 5)</TD><TD>protein interactions</TD><TD>64924</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>CEP350 (centrosomal protein 350kDa)</TD><TD>protein interactions</TD><TD>9857</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>TRPV6 (transient receptor potential cation channel, subfamily V, member 6)</TD><TD>protein interactions</TD><TD>55503</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>FAM46A (family with sequence similarity 46, member A)</TD><TD>protein interactions</TD><TD>55603</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>UROD (uroporphyrinogen decarboxylase)</TD><TD>protein interactions</TD><TD>7389</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>SBF1 (SET binding factor 1)</TD><TD>protein interactions</TD><TD>6305</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.648e-02</TD><TD>-3.31</TD><TD>MAP4K5 (mitogen-activated protein kinase kinase kinase kinase 5)</TD><TD>protein interactions</TD><TD>11183</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>3.667e-02</TD><TD>-3.31</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>10869</TD><TD>29</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,SLC40A1,PPARG,GRHL3,VSNL1,C1orf226,CLSTN2,RNF43,VIM,NR2F1,PDE3A,CAMK2D,NEBL,PDE10A,UNC13A,TANK,SLCO5A1,CSMD3,WNT16,CD44,SORCS2,ITGB4,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>3.667e-02</TD><TD>-3.31</TD><TD>right_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>right_upper_lobe</TD><TD>10869</TD><TD>29</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,SLC40A1,PPARG,GRHL3,VSNL1,C1orf226,CLSTN2,RNF43,VIM,NR2F1,PDE3A,CAMK2D,NEBL,PDE10A,UNC13A,TANK,SLCO5A1,CSMD3,WNT16,CD44,SORCS2,ITGB4,PDLIM5,MMP16,PRPS1,NT5E</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>FARMER_BREAST_CANCER_CLUSTER_7</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_7</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>ZEMBUTSU_SENSITIVITY_TO_FLUOROURACIL</TD><TD>MSigDB lists</TD><TD>ZEMBUTSU_SENSITIVITY_TO_FLUOROURACIL</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>KOBAYASHI_RESPONSE_TO_ROMIDEPSIN</TD><TD>MSigDB lists</TD><TD>KOBAYASHI_RESPONSE_TO_ROMIDEPSIN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>RESPONSE_TO_NUTRIENT</TD><TD>MSigDB lists</TD><TD>RESPONSE_TO_NUTRIENT</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>LI_ADIPOGENESIS_BY_ACTIVATED_PPARG</TD><TD>MSigDB lists</TD><TD>LI_ADIPOGENESIS_BY_ACTIVATED_PPARG</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_UP</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR</TD><TD>MSigDB lists</TD><TD>REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>HDAC4 (histone deacetylase 4)</TD><TD>protein interactions</TD><TD>9759</TD><TD>139</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D,PPARG</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP</TD><TD>MSigDB lists</TD><TD>GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,ANGPTL4</TD></TR>
<TR><TD>3.700e-02</TD><TD>-3.30</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>1781</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,SLK,GRHL3,VSNL1,ZIC2,VIM,RNF43,PDLIM5</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>developmental growth</TD><TD>biological process</TD><TD>GO:0048589</TD><TD>328</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,PDLIM5</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>negative regulation of transferase activity</TD><TD>biological process</TD><TD>GO:0051348</TD><TD>328</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG,PKIB</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>Alzheimer&#39;s disease(PMID:22005930)</TD><TD>GWAS genes</TD><TD>Alzheimer&#39;s disease(PMID:22005930)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>VSNL1</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>Response to fenofibrate(PMID:22890011)</TD><TD>GWAS genes</TD><TD>Response to fenofibrate(PMID:22890011)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>Pancreatic cancer(PMID:20686608)</TD><TD>GWAS genes</TD><TD>Pancreatic cancer(PMID:20686608)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>Type 2 diabetes(PMID:17463246)</TD><TD>GWAS genes</TD><TD>Type 2 diabetes(PMID:17463246)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>GWAS genes</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.722e-02</TD><TD>-3.29</TD><TD>receptor binding</TD><TD>molecular function</TD><TD>GO:0005102</TD><TD>1429</TD><TD>7</TD><TD>16491</TD><TD>37</TD>
<TD>EFNB2,LAMA4,RNF43,FGF9,WNT16,ITGB4,PPARG</TD></TR>
<TR><TD>3.732e-02</TD><TD>-3.29</TD><TD>BMI1_DN_MEL18_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>BMI1_DN_MEL18_DN.V1_DN</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5,PDE3A</TD></TR>
<TR><TD>3.732e-02</TD><TD>-3.29</TD><TD>V$STAT3_02</TD><TD>MSigDB lists</TD><TD>V$STAT3_02</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLCO5A1,VSNL1</TD></TR>
<TR><TD>3.737e-02</TD><TD>-3.29</TD><TD>cellular component organization or biogenesis</TD><TD>biological process</TD><TD>GO:0071840</TD><TD>5468</TD><TD>18</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,LAMA4,TNIK,FGF9,MSX1,VIM,ZIC2,ANGPTL4,RHOU,MSX2,CAMK2D,S100A10,NEBL,UNC13A,WNT16,ITGB4,CD44,MMP16</TD></TR>
<TR><TD>3.738e-02</TD><TD>-3.29</TD><TD>MARTINEZ_RB1_AND_TP53_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MARTINEZ_RB1_AND_TP53_TARGETS_UP</TD><TD>579</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,S100A10,PDLIM5,NT5E</TD></TR>
<TR><TD>3.743e-02</TD><TD>-3.29</TD><TD>positive regulation of programmed cell death</TD><TD>biological process</TD><TD>GO:0043068</TD><TD>566</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,PPARG</TD></TR>
<TR><TD>3.748e-02</TD><TD>-3.28</TD><TD>syntaxin-1 binding</TD><TD>molecular function</TD><TD>GO:0017075</TD><TD>17</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.748e-02</TD><TD>-3.28</TD><TD>nitric-oxide synthase binding</TD><TD>molecular function</TD><TD>GO:0050998</TD><TD>17</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.754e-02</TD><TD>-3.28</TD><TD>Alpha6-Beta4 Integrin Signaling Pathway</TD><TD>WikiPathways</TD><TD>WP244</TD><TD>69</TD><TD>2</TD><TD>4455</TD><TD>20</TD>
<TD>VIM,ITGB4</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>membrane raft organization</TD><TD>biological process</TD><TD>GO:0031579</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>receptor catabolic process</TD><TD>biological process</TD><TD>GO:0032801</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>RNF43</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>regulation of cardiac muscle cell action potential</TD><TD>biological process</TD><TD>GO:0098901</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>positive regulation of telomere maintenance via telomerase</TD><TD>biological process</TD><TD>GO:0032212</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>oocyte maturation</TD><TD>biological process</TD><TD>GO:0001556</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE3A</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>establishment of skin barrier</TD><TD>biological process</TD><TD>GO:0061436</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>3.759e-02</TD><TD>-3.28</TD><TD>negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator</TD><TD>biological process</TD><TD>GO:1902254</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>3.770e-02</TD><TD>-3.28</TD><TD>Pept_M10A_stromelysin-type</TD><TD>interpro domains</TD><TD>IPR016293</TD><TD>18</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Mitochondrial DNA depletion syndrome</TD><TD>SMPDB pathways</TD><TD>SMP00536</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Myoadenylate deaminase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00537</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenosine Deaminase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00144</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthine Dehydrogenase Deficiency (Xanthinuria)</TD><TD>SMPDB pathways</TD><TD>SMP00220</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Lesch-Nyhan Syndrome (LNS)</TD><TD>SMPDB pathways</TD><TD>SMP00364</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenine phosphoribosyltransferase deficiency (APRT)</TD><TD>SMPDB pathways</TD><TD>SMP00535</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthinuria type II</TD><TD>SMPDB pathways</TD><TD>SMP00513</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Purine Nucleoside Phosphorylase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00210</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Purine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00050</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Molybdenum Cofactor Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00203</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>AICA-Ribosiduria</TD><TD>SMPDB pathways</TD><TD>SMP00168</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Gout or Kelley-Seegmiller Syndrome</TD><TD>SMPDB pathways</TD><TD>SMP00365</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Xanthinuria type I</TD><TD>SMPDB pathways</TD><TD>SMP00512</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.783e-02</TD><TD>-3.27</TD><TD>Adenylosuccinate Lyase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00167</TD><TD>37</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.788e-02</TD><TD>-3.27</TD><TD>positive regulation of cellular protein metabolic process</TD><TD>biological process</TD><TD>GO:0032270</TD><TD>1430</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,PPARG,SLK</TD></TR>
<TR><TD>3.821e-02</TD><TD>-3.26</TD><TD>presynapse</TD><TD>cellular component</TD><TD>GO:0098793</TD><TD>143</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>SLC40A1,UNC13A</TD></TR>
<TR><TD>3.824e-02</TD><TD>-3.26</TD><TD>exocyst</TD><TD>cellular component</TD><TD>GO:0000145</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>STXBP6</TD></TR>
<TR><TD>3.831e-02</TD><TD>-3.26</TD><TD>PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN</TD><TD>MSigDB lists</TD><TD>PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN</TD><TD>141</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,CD44</TD></TR>
<TR><TD>3.847e-02</TD><TD>-3.26</TD><TD>digestive tract development</TD><TD>biological process</TD><TD>GO:0048565</TD><TD>138</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,ITGB4</TD></TR>
<TR><TD>3.847e-02</TD><TD>-3.26</TD><TD>regulation of DNA replication</TD><TD>biological process</TD><TD>GO:0006275</TD><TD>138</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PKIB</TD></TR>
<TR><TD>3.858e-02</TD><TD>-3.25</TD><TD>FGFR4 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190322</TD><TD>14</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>NEFM (neurofilament, medium polypeptide)</TD><TD>protein interactions</TD><TD>4741</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>FCGR3B (Fc fragment of IgG, low affinity IIIb, receptor (CD16b))</TD><TD>protein interactions</TD><TD>2215</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>NR4A2 (nuclear receptor subfamily 4, group A, member 2)</TD><TD>protein interactions</TD><TD>4929</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>DPP8 (dipeptidyl-peptidase 8)</TD><TD>protein interactions</TD><TD>54878</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>GRM5 (glutamate receptor, metabotropic 5)</TD><TD>protein interactions</TD><TD>2915</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>SRGAP3 (SLIT-ROBO Rho GTPase activating protein 3)</TD><TD>protein interactions</TD><TD>9901</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>RDH13 (retinol dehydrogenase 13 (all-trans/9-cis))</TD><TD>protein interactions</TD><TD>112724</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>MMP1 (matrix metallopeptidase 1)</TD><TD>protein interactions</TD><TD>4312</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>ALS2CR11 (amyotrophic lateral sclerosis 2 chromosome region candidate 11)</TD><TD>protein interactions</TD><TD>151254</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>EPHB6 (EPH receptor B6)</TD><TD>protein interactions</TD><TD>2051</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>NMNAT1 (nicotinamide nucleotide adenylyltransferase 1)</TD><TD>protein interactions</TD><TD>64802</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>PRPSAP2 (phosphoribosyl pyrophosphate synthetase-associated protein 2)</TD><TD>protein interactions</TD><TD>5636</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.860e-02</TD><TD>-3.25</TD><TD>human chr4q26</TD><TD>chromosome location</TD><TD>human chr4q26</TD><TD>24</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.878e-02</TD><TD>-3.25</TD><TD>NONO (non-POU domain containing, octamer-binding)</TD><TD>protein interactions</TD><TD>4841</TD><TD>143</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>RNF43,SLK</TD></TR>
<TR><TD>3.880e-02</TD><TD>-3.25</TD><TD>PPARA activates gene expression</TD><TD>REACTOME pathways</TD><TD>R-HSA-1989781</TD><TD>112</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>3.880e-02</TD><TD>-3.25</TD><TD>ORGAN_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>ORGAN_MORPHOGENESIS</TD><TD>142</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,ANGPTL4</TD></TR>
<TR><TD>3.880e-02</TD><TD>-3.25</TD><TD>PODAR_RESPONSE_TO_ADAPHOSTIN_UP</TD><TD>MSigDB lists</TD><TD>PODAR_RESPONSE_TO_ADAPHOSTIN_UP</TD><TD>142</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_SYNOVIAL_SARCOMA_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP</TD><TD>MSigDB lists</TD><TD>MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>MODULE_102</TD><TD>MSigDB lists</TD><TD>MODULE_102</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>YIH_RESPONSE_TO_ARSENITE_C2</TD><TD>MSigDB lists</TD><TD>YIH_RESPONSE_TO_ARSENITE_C2</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TANK</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>NELSON_RESPONSE_TO_ANDROGEN_DN</TD><TD>MSigDB lists</TD><TD>NELSON_RESPONSE_TO_ANDROGEN_DN</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>VERNOCHET_ADIPOGENESIS</TD><TD>MSigDB lists</TD><TD>VERNOCHET_ADIPOGENESIS</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>MSigDB lists</TD><TD>HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>BIOCARTA_TNFR2_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_TNFR2_PATHWAY</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TANK</TD></TR>
<TR><TD>3.898e-02</TD><TD>-3.24</TD><TD>purine-containing compound biosynthetic process</TD><TD>biological process</TD><TD>GO:0072522</TD><TD>139</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1,NT5E</TD></TR>
<TR><TD>3.910e-02</TD><TD>-3.24</TD><TD>biliary_tract-gallbladder-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>biliary_tract-gallbladder-carcinoma-adenocarcinoma</TD><TD>2936</TD><TD>11</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,PPARG,PDE10A,UNC13A,CSMD3,RNF43,VIM,CD44,PDLIM5,PDE3A</TD></TR>
<TR><TD>3.910e-02</TD><TD>-3.24</TD><TD>gallbladder</TD><TD>COSMIC cancer mutations</TD><TD>gallbladder</TD><TD>2936</TD><TD>11</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,PPARG,PDE10A,UNC13A,CSMD3,RNF43,VIM,CD44,PDLIM5,PDE3A</TD></TR>
<TR><TD>3.931e-02</TD><TD>-3.24</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>MSigDB lists</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>863</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,ITGB4,NEBL,NR2F2,GRHL3</TD></TR>
<TR><TD>3.940e-02</TD><TD>-3.23</TD><TD>LINK_2</TD><TD>prosite domains</TD><TD>PS50963</TD><TD>14</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>CD44</TD></TR>
<TR><TD>3.949e-02</TD><TD>-3.23</TD><TD>tube formation</TD><TD>biological process</TD><TD>GO:0035148</TD><TD>140</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>3.949e-02</TD><TD>-3.23</TD><TD>negative regulation of defense response</TD><TD>biological process</TD><TD>GO:0031348</TD><TD>140</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>3.966e-02</TD><TD>-3.23</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic</TD><TD>15548</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.966e-02</TD><TD>-3.23</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic</TD><TD>15548</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.966e-02</TD><TD>-3.23</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>15548</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.966e-02</TD><TD>-3.23</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>15548</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.971e-02</TD><TD>-3.23</TD><TD>Melanogenesis</TD><TD>KEGG pathways</TD><TD>ko04916</TD><TD>100</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,WNT16</TD></TR>
<TR><TD>3.971e-02</TD><TD>-3.23</TD><TD>Melanogenesis</TD><TD>KEGG pathways</TD><TD>hsa04916</TD><TD>100</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,WNT16</TD></TR>
<TR><TD>3.974e-02</TD><TD>-3.23</TD><TD>classic</TD><TD>COSMIC cancer mutations</TD><TD>classic</TD><TD>15549</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Fibrinogen_CS</TD><TD>interpro domains</TD><TD>IPR020837</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Cupredoxin</TD><TD>interpro domains</TD><TD>IPR008972</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Wnt</TD><TD>interpro domains</TD><TD>IPR005817</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>PDEase</TD><TD>interpro domains</TD><TD>IPR023088</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Wnt_CS</TD><TD>interpro domains</TD><TD>IPR018161</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>WNT16</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>filopodium assembly</TD><TD>biological process</TD><TD>GO:0046847</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>ITGB4</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of cardiac muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010665</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of dendrite extension</TD><TD>biological process</TD><TD>GO:1903861</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of protein kinase A signaling</TD><TD>biological process</TD><TD>GO:0010738</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of cardiac conduction</TD><TD>biological process</TD><TD>GO:1903779</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of cardiac muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000725</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>epithelial cell fate commitment</TD><TD>biological process</TD><TD>GO:0072148</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of telomere maintenance via telomere lengthening</TD><TD>biological process</TD><TD>GO:1904358</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of signal transduction by p53 class mediator</TD><TD>biological process</TD><TD>GO:1901798</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>cellular response to vitamin</TD><TD>biological process</TD><TD>GO:0071295</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>endochondral bone developmental growth</TD><TD>biological process</TD><TD>GO:0003416</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>bone growth</TD><TD>biological process</TD><TD>GO:0098868</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0014742</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>microvillus assembly</TD><TD>biological process</TD><TD>GO:0030033</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>nucleobase biosynthetic process</TD><TD>biological process</TD><TD>GO:0046112</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PRPS1</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of cardiac muscle hypertrophy</TD><TD>biological process</TD><TD>GO:0010613</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>cellular response to lithium ion</TD><TD>biological process</TD><TD>GO:0071285</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of dendrite extension</TD><TD>biological process</TD><TD>GO:1903859</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>UNC13A</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>regulation of heterotypic cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0034114</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>positive regulation of cardiac muscle cell proliferation</TD><TD>biological process</TD><TD>GO:0060045</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>3.990e-02</TD><TD>-3.22</TD><TD>positive regulation of phosphorus metabolic process</TD><TD>biological process</TD><TD>GO:0010562</TD><TD>1138</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>3.990e-02</TD><TD>-3.22</TD><TD>positive regulation of phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0045937</TD><TD>1138</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>4.000e-02</TD><TD>-3.22</TD><TD>regulation of response to DNA damage stimulus</TD><TD>biological process</TD><TD>GO:2001020</TD><TD>141</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>4.006e-02</TD><TD>-3.22</TD><TD>medulla</TD><TD>COSMIC cancer mutations</TD><TD>medulla</TD><TD>15553</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.006e-02</TD><TD>-3.22</TD><TD>face</TD><TD>COSMIC cancer mutations</TD><TD>face</TD><TD>2212</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,NEBL,PPARG,CSMD3,RNF43,PDLIM5,ANGPTL4,PDE3A,NT5E</TD></TR>
<TR><TD>4.014e-02</TD><TD>-3.22</TD><TD>desmoplastic</TD><TD>COSMIC cancer mutations</TD><TD>desmoplastic</TD><TD>15554</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.021e-02</TD><TD>-3.21</TD><TD>transcription factor activity, transcription factor binding</TD><TD>molecular function</TD><TD>GO:0000989</TD><TD>581</TD><TD>4</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.030e-02</TD><TD>-3.21</TD><TD>YTAAYNGCT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YTAAYNGCT_UNKNOWN</TD><TD>145</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,WNT16</TD></TR>
<TR><TD>4.035e-02</TD><TD>-3.21</TD><TD>CHEN_METABOLIC_SYNDROM_NETWORK</TD><TD>MSigDB lists</TD><TD>CHEN_METABOLIC_SYNDROM_NETWORK</TD><TD>1167</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2,VIM,CD44,PPARG,SLK,PKIB</TD></TR>
<TR><TD>4.051e-02</TD><TD>-3.21</TD><TD>placenta development</TD><TD>biological process</TD><TD>GO:0001890</TD><TD>142</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>NR2F2,PPARG</TD></TR>
<TR><TD>4.057e-02</TD><TD>-3.20</TD><TD>YANG_BCL3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>YANG_BCL3_TARGETS_UP</TD><TD>348</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,FGF9,ANGPTL4</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>SDC4 (syndecan 4)</TD><TD>protein interactions</TD><TD>6385</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TANK</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>SDCCAG3 (serologically defined colon cancer antigen 3)</TD><TD>protein interactions</TD><TD>10807</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>FSHR (follicle stimulating hormone receptor)</TD><TD>protein interactions</TD><TD>2492</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>MICAL1 (microtubule associated monooxygenase, calponin and LIM domain containing 1)</TD><TD>protein interactions</TD><TD>64780</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>ASB15 (ankyrin repeat and SOCS box containing 15)</TD><TD>protein interactions</TD><TD>142685</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>TLE4 (transducin-like enhancer of split 4)</TD><TD>protein interactions</TD><TD>7091</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>FGFR4 (fibroblast growth factor receptor 4)</TD><TD>protein interactions</TD><TD>2264</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>HMMR (hyaluronan-mediated motility receptor (RHAMM))</TD><TD>protein interactions</TD><TD>3161</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>MAGEB4 (MAGE family member B4)</TD><TD>protein interactions</TD><TD>4115</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.069e-02</TD><TD>-3.20</TD><TD>EPHB1 (EPH receptor B1)</TD><TD>protein interactions</TD><TD>2047</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.071e-02</TD><TD>-3.20</TD><TD>Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)</TD><TD>REACTOME pathways</TD><TD>R-HSA-400206</TD><TD>115</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PPARG,ANGPTL4</TD></TR>
<TR><TD>4.087e-02</TD><TD>-3.20</TD><TD>breast-carcinoma-ductal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-ductal_carcinoma</TD><TD>15563</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>MSigDB lists</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>ALONSO_METASTASIS_NEURAL_UP</TD><TD>MSigDB lists</TD><TD>ALONSO_METASTASIS_NEURAL_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>RUAN_RESPONSE_TO_TROGLITAZONE_DN</TD><TD>MSigDB lists</TD><TD>RUAN_RESPONSE_TO_TROGLITAZONE_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>BIOCARTA_STATHMIN_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_STATHMIN_PATHWAY</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>INTEGRIN_COMPLEX</TD><TD>MSigDB lists</TD><TD>INTEGRIN_COMPLEX</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.103e-02</TD><TD>-3.19</TD><TD>regeneration</TD><TD>biological process</TD><TD>GO:0031099</TD><TD>143</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PRPS1</TD></TR>
<TR><TD>4.103e-02</TD><TD>-3.19</TD><TD>branching morphogenesis of an epithelial tube</TD><TD>biological process</TD><TD>GO:0048754</TD><TD>143</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CD44</TD></TR>
<TR><TD>4.107e-02</TD><TD>-3.19</TD><TD>transcription factor activity, protein binding</TD><TD>molecular function</TD><TD>GO:0000988</TD><TD>585</TD><TD>4</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.130e-02</TD><TD>-3.19</TD><TD>zinc ion binding</TD><TD>molecular function</TD><TD>GO:0008270</TD><TD>1151</TD><TD>6</TD><TD>16491</TD><TD>37</TD>
<TD>RNF43,NR2F2,PPARG,PDLIM5,MMP16,NR2F1</TD></TR>
<TR><TD>4.131e-02</TD><TD>-3.19</TD><TD>MODULE_92</TD><TD>MSigDB lists</TD><TD>MODULE_92</TD><TD>147</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>4.160e-02</TD><TD>-3.18</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>MSigDB lists</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>2165</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,MSX1,PPARG,STXBP6,ZIC2,VIM,NR2F2,CD44,NR2F1</TD></TR>
<TR><TD>4.171e-02</TD><TD>-3.18</TD><TD>negative regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031327</TD><TD>1460</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.174e-02</TD><TD>-3.18</TD><TD>YOSHIMURA_MAPK8_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>YOSHIMURA_MAPK8_TARGETS_DN</TD><TD>352</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10,NR2F2,SLK</TD></TR>
<TR><TD>4.174e-02</TD><TD>-3.18</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>352</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,ZIC2,CD44</TD></TR>
<TR><TD>4.175e-02</TD><TD>-3.18</TD><TD>human chrXq22.3</TD><TD>chromosome location</TD><TD>human chrXq22.3</TD><TD>26</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.177e-02</TD><TD>-3.18</TD><TD>myelodysplastic_syndrome</TD><TD>COSMIC cancer mutations</TD><TD>myelodysplastic_syndrome</TD><TD>1210</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,TNIK,CAMK2D,SORCS2,PDE3A</TD></TR>
<TR><TD>4.177e-02</TD><TD>-3.18</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome</TD><TD>1210</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,TNIK,CAMK2D,SORCS2,PDE3A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>functioning</TD><TD>COSMIC cancer mutations</TD><TD>functioning</TD><TD>1876</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>TANK,SLCO5A1,CLSTN2,VIM,RNF43,ITGB4,ANGPTL4,PDE3A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning</TD><TD>1876</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>TANK,SLCO5A1,CLSTN2,VIM,RNF43,ITGB4,ANGPTL4,PDE3A</TD></TR>
<TR><TD>4.181e-02</TD><TD>-3.17</TD><TD>Peptidoglycan-bd-like</TD><TD>interpro domains</TD><TD>IPR002477</TD><TD>20</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.182e-02</TD><TD>-3.17</TD><TD>RTTTNNNYTGGM_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RTTTNNNYTGGM_UNKNOWN</TD><TD>148</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,TANK</TD></TR>
<TR><TD>4.190e-02</TD><TD>-3.17</TD><TD>neuron part</TD><TD>cellular component</TD><TD>GO:0097458</TD><TD>1197</TD><TD>6</TD><TD>17570</TD><TD>38</TD>
<TD>CLSTN2,VIM,SLC40A1,PDLIM5,PDE10A,UNC13A</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>regulation of water loss via skin</TD><TD>biological process</TD><TD>GO:0033561</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>osteoblast development</TD><TD>biological process</TD><TD>GO:0002076</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion</TD><TD>biological process</TD><TD>GO:0010881</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>response to lipoprotein particle</TD><TD>biological process</TD><TD>GO:0055094</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>Rac protein signal transduction</TD><TD>biological process</TD><TD>GO:0016601</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>response to vitamin A</TD><TD>biological process</TD><TD>GO:0033189</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.193e-02</TD><TD>-3.17</TD><TD>intermediate filament organization</TD><TD>biological process</TD><TD>GO:0045109</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>4.204e-02</TD><TD>-3.17</TD><TD>WANG_SMARCE1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>WANG_SMARCE1_TARGETS_DN</TD><TD>353</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,PDLIM5,NT5E</TD></TR>
<TR><TD>4.211e-02</TD><TD>-3.17</TD><TD>LINK</TD><TD>smart domains</TD><TD>SM00445</TD><TD>14</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>CD44</TD></TR>
<TR><TD>4.215e-02</TD><TD>-3.17</TD><TD>CNH</TD><TD>prosite domains</TD><TD>PS50219</TD><TD>15</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.215e-02</TD><TD>-3.17</TD><TD>CYSTEINE_SWITCH</TD><TD>prosite domains</TD><TD>PS00546</TD><TD>15</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.233e-02</TD><TD>-3.16</TD><TD>V$OCT1_07</TD><TD>MSigDB lists</TD><TD>V$OCT1_07</TD><TD>149</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F1,GRHL3</TD></TR>
<TR><TD>4.233e-02</TD><TD>-3.16</TD><TD>KEGG_WNT_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_WNT_SIGNALING_PATHWAY</TD><TD>149</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,WNT16</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>wnt</TD><TD>pfam domains</TD><TD>PF00110</TD><TD>19</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>WNT16</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>negative regulation of cell differentiation</TD><TD>biological process</TD><TD>GO:0045596</TD><TD>590</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,VIM,MSX1,PPARG</TD></TR>
<TR><TD>4.260e-02</TD><TD>-3.16</TD><TD>response to purine-containing compound</TD><TD>biological process</TD><TD>GO:0014074</TD><TD>146</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,PDE3A</TD></TR>
<TR><TD>4.263e-02</TD><TD>-3.16</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN</TD><TD>MSigDB lists</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN</TD><TD>355</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,GRHL3,NT5E</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>RFX5 (regulatory factor X, 5 (influences HLA class II expression))</TD><TD>protein interactions</TD><TD>5993</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>SLC9A1 (solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1)</TD><TD>protein interactions</TD><TD>6548</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>CRCT1 (cysteine rich C-terminal 1)</TD><TD>protein interactions</TD><TD>54544</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>CD74 (CD74 molecule, major histocompatibility complex, class II invariant chain)</TD><TD>protein interactions</TD><TD>972</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>THOC3 (THO complex 3)</TD><TD>protein interactions</TD><TD>84321</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>ME1 (malic enzyme 1, NADP(+)-dependent, cytosolic)</TD><TD>protein interactions</TD><TD>4199</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>NMT2 (N-myristoyltransferase 2)</TD><TD>protein interactions</TD><TD>9397</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>MOAP1 (modulator of apoptosis 1)</TD><TD>protein interactions</TD><TD>64112</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>ASB16 (ankyrin repeat and SOCS box containing 16)</TD><TD>protein interactions</TD><TD>92591</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.278e-02</TD><TD>-3.15</TD><TD>VPS33A (vacuolar protein sorting 33 homolog A (S. cerevisiae))</TD><TD>protein interactions</TD><TD>65082</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>VIM</TD></TR>
<TR><TD>4.284e-02</TD><TD>-3.15</TD><TD>GSE6269_FLU_VS_E_COLI_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_FLU_VS_E_COLI_INF_PBMC_DN</TD><TD>150</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,CD44</TD></TR>
<TR><TD>4.293e-02</TD><TD>-3.15</TD><TD>YATTNATC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YATTNATC_UNKNOWN</TD><TD>356</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,CAMK2D,ZIC2</TD></TR>
<TR><TD>4.302e-02</TD><TD>-3.15</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4562</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,SLC40A1,PDE10A,UNC13A,CLSTN2,CSMD3,RNF43,VIM,SORCS2,PDLIM5,MMP16,PRPS1,PDE3A,NR2F1</TD></TR>
<TR><TD>4.302e-02</TD><TD>-3.15</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4562</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,LAMA4,SLC40A1,PDE10A,UNC13A,CLSTN2,CSMD3,RNF43,VIM,SORCS2,PDLIM5,MMP16,PRPS1,PDE3A,NR2F1</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN</TD><TD>MSigDB lists</TD><TD>PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>HEDENFALK_BREAST_CANCER_BRACX_UP</TD><TD>MSigDB lists</TD><TD>HEDENFALK_BREAST_CANCER_BRACX_UP</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TANK</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>ZHU_SKIL_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ZHU_SKIL_TARGETS_UP</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>ST_WNT_CA2_CYCLIC_GMP_PATHWAY</TD><TD>MSigDB lists</TD><TD>ST_WNT_CA2_CYCLIC_GMP_PATHWAY</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN</TD><TD>MSigDB lists</TD><TD>WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VSNL1</TD></TR>
<TR><TD>4.313e-02</TD><TD>-3.14</TD><TD>response to interferon-gamma</TD><TD>biological process</TD><TD>GO:0034341</TD><TD>147</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>4.319e-02</TD><TD>-3.14</TD><TD>Type 2 diabetes(PMID:17463248)</TD><TD>GWAS genes</TD><TD>Type 2 diabetes(PMID:17463248)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.319e-02</TD><TD>-3.14</TD><TD>QT interval(PMID:20031603)</TD><TD>GWAS genes</TD><TD>QT interval(PMID:20031603)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PDE3A</TD></TR>
<TR><TD>4.332e-02</TD><TD>-3.14</TD><TD>nucleobase-containing compound catabolic process</TD><TD>biological process</TD><TD>GO:0034655</TD><TD>349</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>4.336e-02</TD><TD>-3.14</TD><TD>GROSS_HYPOXIA_VIA_ELK3_DN</TD><TD>MSigDB lists</TD><TD>GROSS_HYPOXIA_VIA_ELK3_DN</TD><TD>151</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PDLIM5</TD></TR>
<TR><TD>4.366e-02</TD><TD>-3.13</TD><TD>regulation of intrinsic apoptotic signaling pathway</TD><TD>biological process</TD><TD>GO:2001242</TD><TD>148</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,CD44</TD></TR>
<TR><TD>4.383e-02</TD><TD>-3.13</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>359</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,NEBL,NT5E</TD></TR>
<TR><TD>4.388e-02</TD><TD>-3.13</TD><TD>ATGTTTC,MIR-494</TD><TD>MSigDB lists</TD><TD>ATGTTTC,MIR-494</TD><TD>152</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,ZIC2</TD></TR>
<TR><TD>4.391e-02</TD><TD>-3.13</TD><TD>positive regulation of cell death</TD><TD>biological process</TD><TD>GO:0010942</TD><TD>596</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,CAMK2D,MSX1,PPARG</TD></TR>
<TR><TD>4.391e-02</TD><TD>-3.13</TD><TD>positive regulation of protein kinase activity</TD><TD>biological process</TD><TD>GO:0045860</TD><TD>596</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>4.392e-02</TD><TD>-3.13</TD><TD>stomach</TD><TD>COSMIC cancer mutations</TD><TD>stomach</TD><TD>16373</TD><TD>38</TD><TD>17775</TD><TD>38</TD>
<TD>EFNB2,TNIK,STXBP6,C1orf226,CLSTN2,RNF43,ZIC2,PDE3A,S100A10,NEBL,PDE10A,UNC13A,TANK,WNT16,CD44,PRPS1,NT5E,LAMA4,SLC40A1,FGF9,MSX1,PPARG,VSNL1,GRHL3,VIM,ANGPTL4,NR2F1,RHOU,MSX2,CAMK2D,CSMD3,SLCO5A1,NR2F2,SORCS2,ITGB4,PDLIM5,MMP16,PKIB</TD></TR>
<TR><TD>4.395e-02</TD><TD>-3.12</TD><TD>structural constituent of eye lens</TD><TD>molecular function</TD><TD>GO:0005212</TD><TD>20</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>VIM</TD></TR>
<TR><TD>4.398e-02</TD><TD>-3.12</TD><TD>FGFR1 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190242</TD><TD>16</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>Wnt signaling pathway, planar cell polarity pathway</TD><TD>biological process</TD><TD>GO:0060071</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>microvillus organization</TD><TD>biological process</TD><TD>GO:0032528</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>wound healing, spreading of cells</TD><TD>biological process</TD><TD>GO:0044319</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>response to immobilization stress</TD><TD>biological process</TD><TD>GO:0035902</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>positive regulation of focal adhesion assembly</TD><TD>biological process</TD><TD>GO:0051894</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>endoplasmic reticulum calcium ion homeostasis</TD><TD>biological process</TD><TD>GO:0032469</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>positive regulation of cardiac muscle tissue growth</TD><TD>biological process</TD><TD>GO:0055023</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>regulation of vesicle fusion</TD><TD>biological process</TD><TD>GO:0031338</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.408e-02</TD><TD>-3.12</TD><TD>epiboly involved in wound healing</TD><TD>biological process</TD><TD>GO:0090505</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.419e-02</TD><TD>-3.12</TD><TD>protein localization to plasma membrane</TD><TD>biological process</TD><TD>GO:0072659</TD><TD>149</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,S100A10</TD></TR>
<TR><TD>4.426e-02</TD><TD>-3.12</TD><TD>regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0042127</TD><TD>1479</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX2,CAMK2D,FGF9,MSX1,NR2F2,PPARG</TD></TR>
<TR><TD>4.440e-02</TD><TD>-3.11</TD><TD>REACTOME_INTERFERON_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_INTERFERON_SIGNALING</TD><TD>153</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,CD44</TD></TR>
<TR><TD>4.444e-02</TD><TD>-3.11</TD><TD>pleura-mesothelioma-epithelial</TD><TD>COSMIC cancer mutations</TD><TD>pleura-mesothelioma-epithelial</TD><TD>371</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>ITGB4,MMP16,PDE10A</TD></TR>
<TR><TD>4.447e-02</TD><TD>-3.11</TD><TD>podosome</TD><TD>cellular component</TD><TD>GO:0002102</TD><TD>21</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>RHOU</TD></TR>
<TR><TD>4.454e-02</TD><TD>-3.11</TD><TD>negative regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009890</TD><TD>1481</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.472e-02</TD><TD>-3.11</TD><TD>regulation of muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051147</TD><TD>150</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>EFNB2,MSX1</TD></TR>
<TR><TD>4.474e-02</TD><TD>-3.11</TD><TD>positive regulation of protein modification process</TD><TD>biological process</TD><TD>GO:0031401</TD><TD>1170</TD><TD>6</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,WNT16,CD44,SLK</TD></TR>
<TR><TD>4.474e-02</TD><TD>-3.11</TD><TD>BENPORATH_ES_1</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_1</TD><TD>362</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZIC2,PRPS1,VSNL1</TD></TR>
<TR><TD>4.475e-02</TD><TD>-3.11</TD><TD>PG_binding_1</TD><TD>pfam domains</TD><TD>PF01471</TD><TD>20</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.486e-02</TD><TD>-3.10</TD><TD>CAV1 (caveolin 1)</TD><TD>protein interactions</TD><TD>857</TD><TD>155</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>CD44,PPARG</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ACTN3 (actinin, alpha 3 (gene/pseudogene))</TD><TD>protein interactions</TD><TD>89</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ANK1 (ankyrin 1, erythrocytic)</TD><TD>protein interactions</TD><TD>286</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>DPH1 (diphthamide biosynthesis 1)</TD><TD>protein interactions</TD><TD>1801</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>DEGS1 (delta(4)-desaturase, sphingolipid 1)</TD><TD>protein interactions</TD><TD>8560</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>TRPV5 (transient receptor potential cation channel, subfamily V, member 5)</TD><TD>protein interactions</TD><TD>56302</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ITGA3 (integrin alpha 3)</TD><TD>protein interactions</TD><TD>3675</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>CAND2 (cullin-associated and neddylation-dissociated 2 (putative))</TD><TD>protein interactions</TD><TD>23066</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ANK2 (ankyrin 2, neuronal)</TD><TD>protein interactions</TD><TD>287</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ARHGEF12 (Rho guanine nucleotide exchange factor (GEF) 12)</TD><TD>protein interactions</TD><TD>23365</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CD44</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>SNF5_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>SNF5_DN.V1_DN</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM5,ANGPTL4</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_1H_DN</TD><TD>MSigDB lists</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_1H_DN</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>4.503e-02</TD><TD>-3.10</TD><TD>epithelial</TD><TD>COSMIC cancer mutations</TD><TD>epithelial</TD><TD>373</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>ITGB4,MMP16,PDE10A</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>WILLERT_WNT_SIGNALING</TD><TD>MSigDB lists</TD><TD>WILLERT_WNT_SIGNALING</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>WANG_NEOPLASTIC_TRANSFORMATION_BY_CCND1_MYC</TD><TD>MSigDB lists</TD><TD>WANG_NEOPLASTIC_TRANSFORMATION_BY_CCND1_MYC</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>chr3q23</TD><TD>MSigDB lists</TD><TD>chr3q23</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CLSTN2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>MSigDB lists</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>MSigDB lists</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>ROY_WOUND_BLOOD_VESSEL_DN</TD><TD>MSigDB lists</TD><TD>ROY_WOUND_BLOOD_VESSEL_DN</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>STEGER_ADIPOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>STEGER_ADIPOGENESIS_UP</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>BASAL_LAMINA</TD><TD>MSigDB lists</TD><TD>BASAL_LAMINA</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4</TD></TR>
<TR><TD>4.526e-02</TD><TD>-3.10</TD><TD>positive regulation of developmental growth</TD><TD>biological process</TD><TD>GO:0048639</TD><TD>151</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,UNC13A</TD></TR>
<TR><TD>4.526e-02</TD><TD>-3.10</TD><TD>digestive system development</TD><TD>biological process</TD><TD>GO:0055123</TD><TD>151</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,ITGB4</TD></TR>
<TR><TD>4.526e-02</TD><TD>-3.10</TD><TD>protein localization to cell periphery</TD><TD>biological process</TD><TD>GO:1990778</TD><TD>151</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,S100A10</TD></TR>
<TR><TD>4.535e-02</TD><TD>-3.09</TD><TD>MORF_RAD51L3</TD><TD>MSigDB lists</TD><TD>MORF_RAD51L3</TD><TD>364</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TNIK,PDE10A,NR2F1</TD></TR>
<TR><TD>4.537e-02</TD><TD>-3.09</TD><TD>negative regulation of nitrogen compound metabolic process</TD><TD>biological process</TD><TD>GO:0051172</TD><TD>1487</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.545e-02</TD><TD>-3.09</TD><TD>GSE15659_TREG_VS_TCONV_DN</TD><TD>MSigDB lists</TD><TD>GSE15659_TREG_VS_TCONV_DN</TD><TD>155</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,MMP16</TD></TR>
<TR><TD>4.545e-02</TD><TD>-3.09</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_UP</TD><TD>155</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1,PPARG</TD></TR>
<TR><TD>4.547e-02</TD><TD>-3.09</TD><TD>phosphoric ester hydrolase activity</TD><TD>molecular function</TD><TD>GO:0042578</TD><TD>357</TD><TD>3</TD><TD>16491</TD><TD>37</TD>
<TD>PDE10A,PDE3A,NT5E</TD></TR>
<TR><TD>4.550e-02</TD><TD>-3.09</TD><TD>forebrain development</TD><TD>biological process</TD><TD>GO:0030900</TD><TD>356</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,NR2F2,NR2F1</TD></TR>
<TR><TD>4.586e-02</TD><TD>-3.08</TD><TD>kidney-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma</TD><TD>3789</TD><TD>13</TD><TD>17775</TD><TD>38</TD>
<TD>RHOU,TNIK,CAMK2D,PPARG,TANK,CSMD3,VIM,CD44,NR2F2,ITGB4,MMP16,PRPS1,NR2F1</TD></TR>
<TR><TD>4.589e-02</TD><TD>-3.08</TD><TD>Fibroblast_GF_fam</TD><TD>interpro domains</TD><TD>IPR002209</TD><TD>22</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.591e-02</TD><TD>-3.08</TD><TD>identical protein binding</TD><TD>molecular function</TD><TD>GO:0042802</TD><TD>1181</TD><TD>6</TD><TD>16491</TD><TD>37</TD>
<TD>VIM,CAMK2D,NR2F2,S100A10,PRPS1,SLK</TD></TR>
<TR><TD>4.597e-02</TD><TD>-3.08</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>156</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,CD44</TD></TR>
<TR><TD>4.597e-02</TD><TD>-3.08</TD><TD>SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM</TD><TD>MSigDB lists</TD><TD>SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM</TD><TD>156</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2,PRPS1</TD></TR>
<TR><TD>4.600e-02</TD><TD>-3.08</TD><TD>Pkinase</TD><TD>pfam domains</TD><TD>PF00069</TD><TD>352</TD><TD>3</TD><TD>16629</TD><TD>38</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>4.610e-02</TD><TD>-3.08</TD><TD>sodium-independent organic anion transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0015347</TD><TD>21</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>SLCO5A1</TD></TR>
<TR><TD>4.610e-02</TD><TD>-3.08</TD><TD>alpha-actinin binding</TD><TD>molecular function</TD><TD>GO:0051393</TD><TD>21</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.613e-02</TD><TD>-3.08</TD><TD>cellular response to insulin stimulus</TD><TD>biological process</TD><TD>GO:0032869</TD><TD>358</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,FGF9,PPARG</TD></TR>
<TR><TD>4.618e-02</TD><TD>-3.08</TD><TD>chemical homeostasis</TD><TD>biological process</TD><TD>GO:0048878</TD><TD>882</TD><TD>5</TD><TD>16441</TD><TD>37</TD>
<TD>SLC40A1,CAMK2D,PPARG,ANGPTL4,GRHL3</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>regulation of striated muscle cell apoptotic process</TD><TD>biological process</TD><TD>GO:0010662</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>cellular response to prostaglandin stimulus</TD><TD>biological process</TD><TD>GO:0071379</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>epiboly</TD><TD>biological process</TD><TD>GO:0090504</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>regulation of establishment of planar polarity</TD><TD>biological process</TD><TD>GO:0090175</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>positive regulation of adherens junction organization</TD><TD>biological process</TD><TD>GO:1903393</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>ectoderm development</TD><TD>biological process</TD><TD>GO:0007398</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>chondrocyte development</TD><TD>biological process</TD><TD>GO:0002063</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>cochlea morphogenesis</TD><TD>biological process</TD><TD>GO:0090103</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>GRHL3</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>relaxation of muscle</TD><TD>biological process</TD><TD>GO:0090075</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.624e-02</TD><TD>-3.07</TD><TD>middle ear morphogenesis</TD><TD>biological process</TD><TD>GO:0042474</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.627e-02</TD><TD>-3.07</TD><TD>Protein_kinase_ATP_BS</TD><TD>interpro domains</TD><TD>IPR017441</TD><TD>378</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>4.634e-02</TD><TD>-3.07</TD><TD>negative regulation of response to wounding</TD><TD>biological process</TD><TD>GO:1903035</TD><TD>153</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG,NT5E</TD></TR>
<TR><TD>4.643e-02</TD><TD>-3.07</TD><TD>SFPQ (splicing factor proline/glutamine-rich)</TD><TD>protein interactions</TD><TD>6421</TD><TD>158</TD><TD>2</TD><TD>16036</TD><TD>35</TD>
<TD>RNF43,PPARG</TD></TR>
<TR><TD>4.650e-02</TD><TD>-3.07</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>MSigDB lists</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,FGF9</TD></TR>
<TR><TD>4.650e-02</TD><TD>-3.07</TD><TD>GSE29614_CTRL_VS_TIV_FLU_VACCINE_PBMC_2007_DN</TD><TD>MSigDB lists</TD><TD>GSE29614_CTRL_VS_TIV_FLU_VACCINE_PBMC_2007_DN</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1,GRHL3</TD></TR>
<TR><TD>4.650e-02</TD><TD>-3.07</TD><TD>AMIT_EGF_RESPONSE_480_HELA</TD><TD>MSigDB lists</TD><TD>AMIT_EGF_RESPONSE_480_HELA</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,PDLIM5</TD></TR>
<TR><TD>4.650e-02</TD><TD>-3.07</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_1H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_1H_ACT_CD4_TCELL_UP</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SORCS2,UNC13A</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>Activated point mutants of FGFR2</TD><TD>REACTOME pathways</TD><TD>R-HSA-2033519</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>Unblocking of NMDA receptor, glutamate binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-438066</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>Hyaluronan metabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-2142845</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>CD44</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>FGFR2 mutant receptor activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-1839126</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>CREB phosphorylation through the activation of CaMKII</TD><TD>REACTOME pathways</TD><TD>R-HSA-442729</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.689e-02</TD><TD>-3.06</TD><TD>protein localization to nucleus</TD><TD>biological process</TD><TD>GO:0034504</TD><TD>154</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>FGF9,MSX1</TD></TR>
<TR><TD>4.695e-02</TD><TD>-3.06</TD><TD>HTLV-I infection</TD><TD>KEGG pathways</TD><TD>hsa05166</TD><TD>258</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>4.695e-02</TD><TD>-3.06</TD><TD>HTLV-I infection</TD><TD>KEGG pathways</TD><TD>ko05166</TD><TD>258</TD><TD>3</TD><TD>6908</TD><TD>22</TD>
<TD>MSX2,MSX1,WNT16</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>LAMA1 (laminin, alpha 1)</TD><TD>protein interactions</TD><TD>284217</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>METTL13 (methyltransferase like 13)</TD><TD>protein interactions</TD><TD>51603</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>GLI1 (GLI family zinc finger 1)</TD><TD>protein interactions</TD><TD>2735</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>CD5 (CD5 molecule)</TD><TD>protein interactions</TD><TD>921</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>KLF4 (Kruppel-like factor 4 (gut))</TD><TD>protein interactions</TD><TD>9314</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>HBS1L (HBS1-like translational GTPase)</TD><TD>protein interactions</TD><TD>10767</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>RHOG (ras homolog family member G)</TD><TD>protein interactions</TD><TD>391</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>TTC5 (tetratricopeptide repeat domain 5)</TD><TD>protein interactions</TD><TD>91875</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>CLSTN1 (calsyntenin 1)</TD><TD>protein interactions</TD><TD>22883</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>SLK</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>GLI3 (GLI family zinc finger 3)</TD><TD>protein interactions</TD><TD>2737</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ZIC2</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>DNAJC8 (DnaJ (Hsp40) homolog, subfamily C, member 8)</TD><TD>protein interactions</TD><TD>22826</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>4.696e-02</TD><TD>-3.06</TD><TD>ARRDC3 (arrestin domain containing 3)</TD><TD>protein interactions</TD><TD>57561</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>ITGB4</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>BIOCARTA_PGC1A_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_PGC1A_PATHWAY</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>REACTOME_METAL_ION_SLC_TRANSPORTERS</TD><TD>MSigDB lists</TD><TD>REACTOME_METAL_ION_SLC_TRANSPORTERS</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>PARK_TRETINOIN_RESPONSE_AND_RARA_PLZF_FUSION</TD><TD>MSigDB lists</TD><TD>PARK_TRETINOIN_RESPONSE_AND_RARA_PLZF_FUSION</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>chr8q23</TD><TD>MSigDB lists</TD><TD>chr8q23</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>DI___TRI_VALENT_INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>DI___TRI_VALENT_INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>FINAK_BREAST_CANCER_SDPP_SIGNATURE</TD><TD>MSigDB lists</TD><TD>FINAK_BREAST_CANCER_SDPP_SIGNATURE</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC40A1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP</TD><TD>MSigDB lists</TD><TD>HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>DALESSIO_TSA_RESPONSE</TD><TD>MSigDB lists</TD><TD>DALESSIO_TSA_RESPONSE</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>KANG_FLUOROURACIL_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>KANG_FLUOROURACIL_RESISTANCE_UP</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.743e-02</TD><TD>-3.05</TD><TD>neural tube development</TD><TD>biological process</TD><TD>GO:0021915</TD><TD>155</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>ZIC2,GRHL3</TD></TR>
<TR><TD>4.743e-02</TD><TD>-3.05</TD><TD>second-messenger-mediated signaling</TD><TD>biological process</TD><TD>GO:0019932</TD><TD>155</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,PDE3A</TD></TR>
<TR><TD>4.753e-02</TD><TD>-3.05</TD><TD>extracellular region part</TD><TD>cellular component</TD><TD>GO:0044421</TD><TD>3764</TD><TD>13</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4,TNIK,FGF9,NEBL,S100A10,SLK,VIM,WNT16,ITGB4,CD44,ANGPTL4,MMP16,NT5E</TD></TR>
<TR><TD>4.757e-02</TD><TD>-3.05</TD><TD>GSE15659_TREG_VS_TCONV_UP</TD><TD>MSigDB lists</TD><TD>GSE15659_TREG_VS_TCONV_UP</TD><TD>159</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,NEBL</TD></TR>
<TR><TD>4.761e-02</TD><TD>-3.04</TD><TD>cellular response to organonitrogen compound</TD><TD>biological process</TD><TD>GO:0071417</TD><TD>612</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D,FGF9,PPARG,PDE3A</TD></TR>
<TR><TD>4.764e-02</TD><TD>-3.04</TD><TD>HEMOPEXIN</TD><TD>prosite domains</TD><TD>PS00024</TD><TD>17</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.772e-02</TD><TD>-3.04</TD><TD>S_TKc</TD><TD>smart domains</TD><TD>SM00220</TD><TD>268</TD><TD>3</TD><TD>9131</TD><TD>28</TD>
<TD>TNIK,CAMK2D,SLK</TD></TR>
<TR><TD>4.772e-02</TD><TD>-3.04</TD><TD>transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding</TD><TD>molecular function</TD><TD>GO:0001227</TD><TD>156</TD><TD>2</TD><TD>16491</TD><TD>37</TD>
<TD>MSX2,MSX1</TD></TR>
<TR><TD>4.773e-02</TD><TD>-3.04</TD><TD>regulation of sequence-specific DNA binding transcription factor activity</TD><TD>biological process</TD><TD>GO:0051090</TD><TD>363</TD><TD>3</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,PPARG</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>IL-1_fam/FGF_fam</TD><TD>interpro domains</TD><TD>IPR028142</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>Hemopexin-like_dom</TD><TD>interpro domains</TD><TD>IPR000585</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>Pept_M10_metallopeptidase</TD><TD>interpro domains</TD><TD>IPR001818</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>Hemopexin-like_repeat</TD><TD>interpro domains</TD><TD>IPR018487</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>Pept_M10A</TD><TD>interpro domains</TD><TD>IPR021190</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.795e-02</TD><TD>-3.04</TD><TD>pleura</TD><TD>COSMIC cancer mutations</TD><TD>pleura</TD><TD>5040</TD><TD>16</TD><TD>17775</TD><TD>38</TD>
<TD>LAMA4,TNIK,VIM,NR2F1,RHOU,CAMK2D,NEBL,PDE10A,TANK,CSMD3,WNT16,ITGB4,NR2F2,CD44,PRPS1,MMP16</TD></TR>
<TR><TD>4.798e-02</TD><TD>-3.04</TD><TD>stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0031098</TD><TD>156</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,SLK</TD></TR>
<TR><TD>4.798e-02</TD><TD>-3.04</TD><TD>regulation of organ morphogenesis</TD><TD>biological process</TD><TD>GO:2000027</TD><TD>156</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>MSX1,GRHL3</TD></TR>
<TR><TD>4.802e-02</TD><TD>-3.04</TD><TD>human chr5q35.2</TD><TD>chromosome location</TD><TD>human chr5q35.2</TD><TD>30</TD><TD>1</TD><TD>26250</TD><TD>43</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Azathioprine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00427</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Mercaptopurine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00428</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>Thioguanine Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00430</TD><TD>47</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>ovary-carcinoma-mixed_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-mixed_carcinoma</TD><TD>23</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>ovary-germ_cell_tumour-teratoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-teratoma</TD><TD>23</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>RNF43</TD></TR>
<TR><TD>4.809e-02</TD><TD>-3.03</TD><TD>intracellular signal transduction</TD><TD>biological process</TD><TD>GO:0035556</TD><TD>1835</TD><TD>8</TD><TD>16441</TD><TD>37</TD>
<TD>RHOU,TNIK,CAMK2D,FGF9,SLK,TANK,UNC13A,PDE3A</TD></TR>
<TR><TD>4.811e-02</TD><TD>-3.03</TD><TD>V$NCX_01</TD><TD>MSigDB lists</TD><TD>V$NCX_01</TD><TD>160</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,NR2F1</TD></TR>
<TR><TD>4.811e-02</TD><TD>-3.03</TD><TD>CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP</TD><TD>MSigDB lists</TD><TD>CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP</TD><TD>160</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,TANK</TD></TR>
<TR><TD>4.824e-02</TD><TD>-3.03</TD><TD>hyaluronic acid binding</TD><TD>molecular function</TD><TD>GO:0005540</TD><TD>22</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>CD44</TD></TR>
<TR><TD>4.824e-02</TD><TD>-3.03</TD><TD>retinoic acid binding</TD><TD>molecular function</TD><TD>GO:0001972</TD><TD>22</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NR2F2</TD></TR>
<TR><TD>4.824e-02</TD><TD>-3.03</TD><TD>ferrous iron binding</TD><TD>molecular function</TD><TD>GO:0008198</TD><TD>22</TD><TD>1</TD><TD>16491</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.836e-02</TD><TD>-3.03</TD><TD>negative regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010629</TD><TD>1508</TD><TD>7</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2,ZIC2,FGF9,MSX1,NR2F2,PPARG,NR2F1</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>cellular protein complex localization</TD><TD>biological process</TD><TD>GO:0034629</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>regulation of histone deacetylation</TD><TD>biological process</TD><TD>GO:0031063</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>CAMK2D</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>positive regulation of telomerase activity</TD><TD>biological process</TD><TD>GO:0051973</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PKIB</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>regulation of hair cycle</TD><TD>biological process</TD><TD>GO:0042634</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>pyrimidine nucleoside catabolic process</TD><TD>biological process</TD><TD>GO:0046135</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>response to dietary excess</TD><TD>biological process</TD><TD>GO:0002021</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>37</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.861e-02</TD><TD>-3.02</TD><TD>basal lamina</TD><TD>cellular component</TD><TD>GO:0005605</TD><TD>23</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>LAMA4</TD></TR>
<TR><TD>4.864e-02</TD><TD>-3.02</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>161</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CAMK2D,PPARG</TD></TR>
<TR><TD>4.864e-02</TD><TD>-3.02</TD><TD>CAIRO_LIVER_DEVELOPMENT_UP</TD><TD>MSigDB lists</TD><TD>CAIRO_LIVER_DEVELOPMENT_UP</TD><TD>161</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>EFNB2,NR2F1</TD></TR>
<TR><TD>4.866e-02</TD><TD>-3.02</TD><TD>skin-neck-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma</TD><TD>1256</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,MMP16,PDE10A,TANK,PDE3A</TD></TR>
<TR><TD>4.869e-02</TD><TD>-3.02</TD><TD>TGACATY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGACATY_UNKNOWN</TD><TD>631</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CSMD3,NEBL,NR2F2,SLK</TD></TR>
<TR><TD>4.869e-02</TD><TD>-3.02</TD><TD>G alpha (s) signalling events</TD><TD>REACTOME pathways</TD><TD>R-HSA-418555</TD><TD>127</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>PDE10A,PDE3A</TD></TR>
<TR><TD>4.873e-02</TD><TD>-3.02</TD><TD>TATAAA_V$TATA_01</TD><TD>MSigDB lists</TD><TD>TATAAA_V$TATA_01</TD><TD>1222</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>RNF43,NR2F2,PPARG,ANGPTL4,TANK,NR2F1</TD></TR>
<TR><TD>4.874e-02</TD><TD>-3.02</TD><TD>Oocyte meiosis</TD><TD>KEGG pathways</TD><TD>ko04114</TD><TD>112</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,SLK</TD></TR>
<TR><TD>4.874e-02</TD><TD>-3.02</TD><TD>Oocyte meiosis</TD><TD>KEGG pathways</TD><TD>hsa04114</TD><TD>112</TD><TD>2</TD><TD>6908</TD><TD>22</TD>
<TD>CAMK2D,SLK</TD></TR>
<TR><TD>4.893e-02</TD><TD>-3.02</TD><TD>GGGYGTGNY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GGGYGTGNY_UNKNOWN</TD><TD>632</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>VIM,ITGB4,CD44,PDLIM5</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>WDR3 (WD repeat domain 3)</TD><TD>protein interactions</TD><TD>10885</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDE10A</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>WDR92 (WD repeat domain 92)</TD><TD>protein interactions</TD><TD>116143</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>PECAM1 (platelet/endothelial cell adhesion molecule 1)</TD><TD>protein interactions</TD><TD>5175</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>EFNB2</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>KCTD13 (potassium channel tetramerization domain containing 13)</TD><TD>protein interactions</TD><TD>253980</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>ZBTB3 (zinc finger and BTB domain containing 3)</TD><TD>protein interactions</TD><TD>79842</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>NUTM1 (NUT midline carcinoma, family member 1)</TD><TD>protein interactions</TD><TD>256646</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NEBL</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>SYNJ2BP (synaptojanin 2 binding protein)</TD><TD>protein interactions</TD><TD>55333</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>UBAP2 (ubiquitin associated protein 2)</TD><TD>protein interactions</TD><TD>55833</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>S100A10</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>PAX3 (paired box 3)</TD><TD>protein interactions</TD><TD>5077</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>MSX1</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>PDE12 (phosphodiesterase 12)</TD><TD>protein interactions</TD><TD>201626</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PDLIM5</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>ASB18 (ankyrin repeat and SOCS box containing 18)</TD><TD>protein interactions</TD><TD>401036</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>PRPS1</TD></TR>
<TR><TD>4.905e-02</TD><TD>-3.02</TD><TD>DPYSL3 (dihydropyrimidinase-like 3)</TD><TD>protein interactions</TD><TD>1809</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>35</TD>
<TD>TNIK</TD></TR>
<TR><TD>4.909e-02</TD><TD>-3.01</TD><TD>regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046328</TD><TD>158</TD><TD>2</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,WNT16</TD></TR>
<TR><TD>4.912e-02</TD><TD>-3.01</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>376</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LAMA4,STXBP6,NR2F1</TD></TR>
<TR><TD>4.919e-02</TD><TD>-3.01</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_DN</TD><TD>162</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>RHOU,FGF9</TD></TR>
<TR><TD>4.921e-02</TD><TD>-3.01</TD><TD>Type 2 diabetes(PMID:17463249)</TD><TD>GWAS genes</TD><TD>Type 2 diabetes(PMID:17463249)</TD><TD>8</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>PPARG</TD></TR>
<TR><TD>4.921e-02</TD><TD>-3.01</TD><TD>White blood cell types(PMID:21738478)</TD><TD>GWAS genes</TD><TD>White blood cell types(PMID:21738478)</TD><TD>8</TD><TD>1</TD><TD>2389</TD><TD>15</TD>
<TD>STXBP6</TD></TR>
<TR><TD>4.928e-02</TD><TD>-3.01</TD><TD>positive regulation of kinase activity</TD><TD>biological process</TD><TD>GO:0033674</TD><TD>619</TD><TD>4</TD><TD>16441</TD><TD>37</TD>
<TD>TNIK,CAMK2D,FGF9,SLK</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>SHC-mediated cascade:FGFR3</TD><TD>REACTOME pathways</TD><TD>R-HSA-5654704</TD><TD>18</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF9</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon</TD><TD>REACTOME pathways</TD><TD>R-HSA-936964</TD><TD>18</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>TANK</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>INTERMEDIATE_FILAMENT</TD><TD>MSigDB lists</TD><TD>INTERMEDIATE_FILAMENT</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>INTERMEDIATE_FILAMENT_CYTOSKELETON</TD><TD>MSigDB lists</TD><TD>INTERMEDIATE_FILAMENT_CYTOSKELETON</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>VIM</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>VIETOR_IFRD1_TARGETS</TD><TD>MSigDB lists</TD><TD>VIETOR_IFRD1_TARGETS</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MSX2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>WANG_RESPONSE_TO_FORSKOLIN_UP</TD><TD>MSigDB lists</TD><TD>WANG_RESPONSE_TO_FORSKOLIN_UP</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MMP16</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>REACTOME_PYRIMIDINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_PYRIMIDINE_METABOLISM</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NT5E</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>OSADA_ASCL1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>OSADA_ASCL1_TARGETS_DN</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD44</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>GSE25087_FETAL_VS_ADULT_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE25087_FETAL_VS_ADULT_TREG_DN</TD><TD>163</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,S100A10</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>GSE6269_FLU_VS_STREP_PNEUMO_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_FLU_VS_STREP_PNEUMO_INF_PBMC_DN</TD><TD>163</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD44,NR2F1</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>GSE13738_RESTING_VS_BYSTANDER_ACTIVATED_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE13738_RESTING_VS_BYSTANDER_ACTIVATED_CD4_TCELL_UP</TD><TD>163</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF9,SLC40A1</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>neck</TD><TD>COSMIC cancer mutations</TD><TD>neck</TD><TD>1264</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CLSTN2,CSMD3,MMP16,PDE10A,TANK,PDE3A</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>Fibrinogen_a/b/g_C_2</TD><TD>interpro domains</TD><TD>IPR014715</TD><TD>24</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ANGPTL4</TD></TR>
</TABLE>
</BODY></HTML>
